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Introduction                   
Headache is the most common complaint of civilized human species world wide. It has the 
dubious distinction of being the earliest recognized symptom of a wide spectrum of diseases. 
Headache has been referred to in many ancient literatures. The earliest reference dates back 
to a papyrus (ancient medical text book) as old as 3500 BC in the tomb of Thebes  that 
mentions the king in the tomb had sufferred all his life of a sickness of half head. A poem 
recovered from a Babylonian ruin written in Sumeria in 3000BC roughly translates as 
The sick eyed says not…….
I am sick eyed…..
The sick headed not …….
I am sick headed…
Hippocrates (460-377BC) wrote a description of a disease of the hemicrania that relieved on 
vomiting. This work of dissertation has been done with an aim at documenting the different 
types of headache, their clinical presentations, diagnostic modalities and responses to 
prophylaxis, who presented to the Headache clinic of Institute of Neurology, Government 
General Hospital, Chennai during a one year period. 
Aims and Objectives             
This study is aimed to 
1. To Classify and Study the incidence of various types of Primary Headache
2. Study the Clinical Profiles of each type of Primary Headache
3. Study the Neuro-physiological patterns in Migraine
4. Study the various patterns of responses to prophylaxis in Migraine. 
Review of Literature
Headache or Cephalalgia is a symptom of a number of different conditions of the head and 
neck, caused by benign or at times a medical emergency that ranks among the most common 
pain complaints. One in three persons suffers a severe headache at some point in life and in 
US, headache causes on an average 112 million bed ridden days per year and morbidity 
driven economic losses of $13 billion / year. 
History
The  earliest  references  date  back  to  a  papyrus  (3500  BC)  in  the  tomb  of  Thebes  that 
mentions  about  the  king  in  the  tomb suffering  of  half  head.  Headache  with  neuralgia is 
referred to by Egyptians (1200 BC).  Hippocrates (460-377BC) described the visual  aura in 
migraine  and  its  relief  through  vomiting[1].  Aretaeus  of  Cappadocia (2nd century  AD) 
described a unilateral headache associated with vomiting, with headache-free intervals, and 
is  credited  as  the  "discoverer"  of  migraines.[2]  Galenus of  Pergamon used  the  term 
"hemicrania" (half-head) and thought there was a connection between the stomach and the 
brain, as nausea and vomiting often accompanied an attack.[2] In the Medieval Ages migraine 
was treated with hot irons, blood letting and even witchcraft.  Bibliotheca Anatomica, Medic,  
Chirurgica, published in  London (1712), describes five major types of headaches, including 
"Megrim",  recognized  later  as  classic  migraine.[2].  Harold  Wolffe  (1950)  developed  the 
experimental  approach  to  the  study  of  headache  and  elaborated  the  vascular  theory  of 
migraine.[2].  Harold  Wolffe  (1950),  enunciated  a  list  of  pain  sensitive  structures, both 
intracranial and extracranial namely: Intracranial - Circle of Willis & first few centimeters of its 
branches, meningeal (dural) arteries, large veins and dural venous sinuses and portions of 
dura near blood vessels;  Extracranial – external carotid artery and its branches, scalp and 
neck muscles, skin and cutaneous nerves, cervical nerves and nerve roots, sinus, and teeth 
(via the V VII IX and X Cranial Nerves to CNS)[3][4]  
The first recorded system that resembles the modern one was published by Thomas Willis, in 
De Cephalagia in 1672[4]. In 1787 Christian Baur classified headaches into idiopathic 
(primary headaches) and symptomatic (secondary headaches) and defined 84 categories. 
NIH developed a classification system in 1962 [5]. Presently headaches are classified by the 
International Headache Society's International Classification of Headache Disorders (ICHD), 
first edition published in 1988 and a second edition published in 2004 [6] and accepted by 
WHO. 
The International Classification of Headache Disorders 
The  International  Headache  Society Classification  with  the  diagnostic  criteria for  most 
headache  disorders  (ICHD-2)  was  published  in  2004.[6]  The  classification  uses  numeric 
codes with one-digit  diagnostic levels for 14 headache groups, the first  four of which are 
labelled as primary headaches, while the group 5-12 are secondary headaches.[6] 
I. Primary Headaches
1. Migraine  
2. Tension-type headache   (TTH)
3. Cluster headache   and other trigeminal autonomic cephalalgias (TAC)
4. Other primary headaches
II. Secondary Headaches
5. Headache attributed to head and/or neck trauma - Head injury
6. Headache attributed to cranial or cervical vascular disorder including:
i. Intracerebral hemorrhage  
ii. Subarachnoid hemorrhage  
iii. Giant cell arteritis  
7. Headache attributed to non-vascular intracranial disorder including:
i. Idiopathic intracranial hypertension  
ii. Post dural puncture headaches  
iii. Ictal headache  
8. Headache attributed to a substance or its withdrawal   including:
i. Medication overuse headaches  
ii. Medication or drug withdrawal headaches  
iii. Hang overs  
9. Headache attributed to infection including: Meningitis
10.Headache attributed to disorder of homoeostasis
11.Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, nose, 
sinuses, teeth, mouth or other facial or cranial structures
12.Headache attributed to psychiatric disorder
13.Cranial Neuralgias and Central Causes of facial pain
14.Others
Epidemiology of Headache Disorders 
The Tension type headache is considered the most common form of headache in the general 
population with a prevalence of for nearly 80% while the prevalence of migraine is pegged at 
16% in various international studies. In contrast, migraine is a more common form of 
headache reported in clinical practice. This variance is attributed to self treatment of tension 
type headaches by the general population.[7] A substantial group of patients, conform to the 
diagnostic criteria of more than one type of headache – these cases have been grouped 
under mixed headaches. The tension migraine or tension vascular headache is one common 
example.[7].
General Population Hospital Referrals
Others 
78%
Other 
Tension-type 
Headache
Migraine
16% 76%
6%
Mixed 18%
3%
1. Migraine
Migraine is a common disabling primary headache disorder with a high prevalence, socio-
economic and personal impacts, that is ranked by the World Health Organization as number 
19 among all diseases world-wide causing disability.[8]
International Headache Society Classification of Migraine
1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Typical aura with migraine headache
1.2.2 Typical aura with non-migraine headache
1.2.3 Typical aura without headache
1.2.4 Familial hemiplegic migraine (FHM)
1.2.5 Sporadic hemiplegic migraine
1.2.6 Basilar-type migraine
1.3 Childhood periodic syndromes that are commonly precursors of 
migraine
1.3.1 Cyclical vomiting
1.3.2 Abdominal migraine
1.3.3 Benign paroxysmal vertigo of childhood
1.4 Retinal migraine
1.5 Complications of migraine
1.5.1 Chronic migraine
1.5.2 Status migrainosus
1.5.3 Persistent aura without infarction
1.5.4 Migrainous infarction
1.5.5 Migraine-triggered seizures
1.6 Probable migraine
1.6.1 Probable migraine without aura
1.6.2 Probable migraine with aura
1.6.5 Probable chronic migraine
International Headache Society Diagnosis Criteria for Migraine
1.1 Migraine without aura: This is a clinical syndrome characterised by headache with 
specific features and associated symptoms previously termed as common migraine and 
hemicrania simplex. This is characterised by recurrent headache disorder manifesting in 
attacks lasting 4-72 hours, with typical headache of unilateral location, pulsating quality, 
moderate or severe intensity, aggravation by routine physical activity and association with 
nausea and/or photophobia and phonophobia. The diagnostic criteria include: (A) At least 5 
attacks fulfilling criteria B-D; (B) Headache attacks lasting 4-72 hours (untreated or 
unsuccessfully treated); (C) Headache has at least two of the following characteristics: 1. 
unilateral location, 2. pulsating quality, 3. moderate or severe pain intensity, 4. aggravation by 
or causing avoidance of routine physical activity (eg, walking or climbing stairs); (D) During 
headache at least one of the following: 1. nausea and/or vomiting, 2. photophobia and 
phonophobia; and (E) Not attributed to another disorder
1.2 Migraine  with  aura: This  entity  previously  termed  classic  or  classical  migraine, 
ophthalmic,  hemiparaesthetic,  hemiplegic  or  aphasic  migraine,  migraine  accompagnée, 
complicated migraine etc, is a recurrent disorder of reversible focal neurological symptoms 
that develops gradually over 5-20 minutes and last for less than 60 minutes,. Headache with 
features of migraine without aura usually follows the aura symptoms, and less commonly, 
headache  lacks  migrainous  features  or  is  completely  absent.  The  aura  is  a  complex  of 
neurological symptoms that occurs just before or at the onset of migraine headache. Most 
patients  with  migraine  have  exclusively  attacks  without  aura.  Many  patients  who  have 
frequent attacks with aura may also have attacks without aura. Diagnostic criteria include [A] 
At least 2 attacks fulfilling criterion B [B] Migraine aura fulfilling criteria B and C for one of the 
subforms 1.2.1-1.2.6 & [C] Not attributed to another disorder.  Premonitory symptoms occur 
hours to a day or two before a migraine attack (with or without aura), that include various 
combinations of fatigue, difficulty in concentrating, neck stiffness, sensitivity to light or sound, 
nausea, blurred vision, yawning and pallor. Auras with similar feature are also described in 
other well-defined headache types like cluster headache. The relationship between aura and 
headache is not fully understood. Studies have demonstrated that patients with visual auras 
occasionally have symptoms in the extremities. Conversely patients with symptoms in the 
extremities virtually always also suffer visual aura symptoms. A distinction between migraine 
with visual aura and hemiparaesthetic migraine is hence not recognised in the present IHS 
classification [6]. 
1.2.1 Migraine with typical aura: Typical aura consists of visual and/or sensory 
and/or speech symptoms. Gradual development, duration no longer than one hour, a mix of 
positive and negative features and complete reversibility characterise the aura which is 
associated with a headache fulfilling criteria for Migraine without aura. Diagnostic criteria 
include (A) At least 2 attacks fulfilling criteria B–D; (B) Aura consisting of at least one of the 
following, but no motor weakness: 1. fully reversible visual symptoms including positive 
features (eg, flickering lights, spots or lines) and/or negative features (ie, loss of vision), 2. 
fully reversible sensory symptoms including positive features (ie, pins and needles) and/or 
negative features (ie, numbness), 3. fully reversible dysphasic speech disturbance; (C) At 
least two of the following: 1. homonymous visual symptoms and/or unilateral sensory 
symptoms 2. at least one aura symptom develops gradually over ≥5 minutes and/or different 
aura symptoms occur in succession over ≥5 minutes, 3. each symptom lasts ≥5 and ≤60 
minutes; (D) Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the 
aura or follows aura within 60 minutes; (E) Not attributed to another disorder. This is the most 
common migraine syndrome associated with aura, the diagnosis of which is evident with 
careful history alone, but rarely carotid dissection, AV malformation and seizure may mimic 
this condition. Aura include visual aura, the most common type that often presents as a 
fortification spectrum or scotoma without positive phenomena; sensory aura, that presents as 
pins and needles moving slowly from the point of origin or numbness and speech 
disturbances like dysphasia. Symptoms usually follow one another in succession beginning 
with visual, then sensory symptoms and dysphasia. 
1.2.2 : Typical aura with non-migraine headache: Typical aura consisting of 
visual and/or sensory and/or speech symptoms with gradual development, duration no longer 
than one hour, a mix of positive and negative features and complete reversibility characterise 
the aura which is associated with a headache that does not fulfil  criteria for 1.1 Migraine 
without aura. Diagnostic criteria includes all patterns as for Migraine with typical aura from A – 
C and a Headache that does not fulfil the criteria B-D set for 1.1 Migraine without aura, that 
begins during the aura or follows aura within 60 minutes. In the absence of headache fulfilling 
the criteria for 1.1  Migraine without aura, precise diagnosis of aura and its distinction from 
more serious diseases like transient ischemic attack becomes more important.
1.2.3: Typical aura without headache: Typical aura consisting of visual and/or sensory 
symptoms with or without speech symptoms. Gradual development, duration no longer than 
one hour, a mix of positive and negative features and complete reversibility characterise the 
aura which is not associated with headache. A small number of patients have typical aura 
without headache are commonly patients with Typical aura with migraine who on becoming 
older have lost migraine characteristics, even though auras continue. Diagnostic criteria 
includes all patterns as for Migraine with typical aura from A – C without Headache during the 
aura or following aura within 60 minutes. 
1.2.4: Familial hemiplegic migraine (FHM): Migraine with aura including motor 
weakness and at least one first- or second-degree relative has migraine aura including motor 
weakness. Specific genetic subtypes of FHM have been identified: (1) FHM1 - mutations in 
CACNA1A gene on chromosome 19 (2) FHM2 - mutations in the ATP1A2 gene on 
chromosome1, of these FHM1 very often has basilar-type symptoms in addition to the typical 
aura while headache is virtually always present. During FHM1 attacks, disturbances of 
consciousness (sometimes including coma), fever, CSF pleocytosis and confusion can occur. 
FHM1 attacks can be triggered by (mild) head trauma. In approximately 50% of FHM1 
families, chronic progressive cerebellar ataxia occurs independently of the migraine attacks. 
FHM2 is very often mistaken for epilepsy, and (unsuccessfully) treated as such. 
1.2.5 Sporadic hemiplegic migraine: Migraine with aura including motor weakness 
without first or second-degree relative having an aura including motor weakness. 
Epidemiological studies have shown that sporadic cases occur with approximately the same 
prevalence as familial cases. The attacks have the same clinical characteristics as those in 
FHM. Sporadic cases always require neuroimaging and other tests to rule out other cause. A 
lumbar puncture is also necessary to rule out pseudomigraine with temporary neurological 
symptoms and lymphocytic pleocytosis. This condition is  more prevalent in males and often 
associated with transient hemiparesis and aphasia.
1.2.6 Basilar-type migraine:  Previously termed as Basilar artery migraine or basilar 
migraine, this entity is migraine with aura symptoms clearly originating from the brainstem 
and/or from both hemispheres simultaneously affected, but no motor weakness. Diagnostic 
criteria include: A. At least 2 attacks fulfilling criteria B-D; B. Aura consisting of at least two of 
the following fully reversible symptoms, but no motor weakness: [1]  dysarthria [2] vertigo [3] 
tinnitus [4] hypacusia [5] diplopia [6] visual symptoms simultaneously in both temporal and 
nasal fields of both eyes [7] ataxia [8] decreased level of consciousness [9] simultaneously 
bilateral  paraesthesias;  C.  At  least  one  of  the  following:  [1]  at  least  one  aura  symptom 
develops gradually over ≥5 minutes and/or different aura symptoms occur in succession over 
≥5 minutes [2] each aura symptom lasts ≥5 and ≤60 minutes; D.Headache fulfilling criteria B-
D for 1.1 Migraine without aura begins during the aura or follows aura within 60 minutes; E.
Not  attributed  to  another  disorder.  Basilar-type  attacks  are  mostly  seen  in  young 
adults, many patients of whom report attacks with typical aura. In such case the code for both 
disorders need to be given. Patients with 1.2.4 FHM have basilar-type symptoms in 60% of 
cases.  Therefore,  1.2.6  Basilar-type  migraine should  be  diagnosed  only  when  no  motor 
weakness  occurs.  Many  of  the  symptoms  listed  under  criterion  B  are  subject  to 
misinterpretation as they may occur with anxiety and hyperventilation. Originally the terms 
basilar artery migraine or  basilar migraine were used but, since involvement of the basilar 
artery territory is uncertain the term basilar-type migraine is preferred.
1.3 Childhood periodic syndromes that are commonly precursors of migraine. 
1.3.1 Cyclical  vomiting:  Recurrent  episodic  attacks,  usually  stereotypical  in  the 
individual patient,  of  vomiting and intense nausea. Attacks are associated with pallor and 
lethargy. There is complete resolution of symptoms between attacks.  Cyclical vomiting is a 
self-limiting  episodic  condition  of  childhood,  with  periods  of  complete  normality  between 
episodes. The clinical features of this syndrome resemble those found in association with 
migraine headaches, and multiple threads of research over the last years have suggested 
that cyclical vomiting is a condition related to migraine. 
1.3.2 Abdominal migraine: An idiopathic recurrent disorder seen mainly in children 
and characterised by episodic  midline abdominal  pain  manifesting in  attacks lasting 1-72 
hours with  normality between episodes.  The pain is  of  moderate to  severe intensity and 
associated  with  vasomotor  symptoms,  nausea  and  vomiting.  Pain  is  severe  enough  to 
interfere with normal daily activities. Children may find it difficult to distinguish anorexia from 
nausea. The pallor is often accompanied by dark shadows under the eyes. In a few patients 
flushing is the predominant vasomotor phenomenon. Most children with abdominal migraine 
will develop migraine headache later in life. 
1.3.3 Benign  paroxysmal  vertigo  of  childhood: This  probably  heterogeneous 
disorder  is  characterised  by  recurrent  brief  episodic  attacks  of  vertigo  occurring  without 
warning and resolving spontaneously in otherwise healthy children. 
1.4 Retinal  migraine: Repeated  attacks  of  monocular  visual  disturbance,  including 
scintillations, scotomata or blindness, associated with migraine headache. 
1.5 Complications of migraine
1.5.1 Chronic migraine: Migraine headache occurring on 15 or more days per month 
for more than 3 months in the absence of medication overuse. Diagnostic criteria: [A] 
Headache fulfilling criteria C and D for 1.1 Migraine without aura on ≥15 days/month for >3 
months. [B] Not attributed to another disorder. Most cases of chronic migraine start as 1.1 
Migraine without aura and therefore, may be regarded as a complication of episodic migraine. 
As chronicity develops, headache tends to lose its attack-wise (episodic) presentation 
although it has not been clearly demonstrated that this is always so. Therefore, the default 
rule is to code such patients according to the antecedent migraine subtype plus probable 
chronic migraine plus probable medication-overuse headache. 
1.5.2 Status migrainosus: A debilitating migraine attack lasting for more than 72 
hours. Diagnostic criteria: [A] The present attack in a patient with 1.1 Migraine without aura is 
typical of previous attacks except for its duration [B] Headache has both of the following 
features: (1) unremitting for >72 hours (2) severe intensity [C] Not attributed to another 
disorder. 
1.5.3 Persistent aura without infarction: Aura symptoms persist for more than 1 
week without radiographic evidence of infarction. Diagnostic criteria: [A].The present attack in 
a patient with 1.2 Migraine with aura is typical of previous attacks except that one or more 
aura symptoms persists for >1 week [B]. Not attributed to another disorder. Persisting aura 
symptoms are rare but well documented. They are often bilateral and may last for months or 
years. Reliably effective treatment is not known though acetazolamide and valproic acid have 
helped in a few cases. It is important to exclude posterior leukoencephalopathy by diffusion 
MRI and Migrainous infarction. 
1.5.4 Migrainous infarction: One or more migrainous aura symptoms associated 
with an ischaemic brain lesion in appropriate territory demonstrated by neuroimaging. 
Diagnostic criteria: [A] The present attack in a patient with 1.2 Migraine with aura is typical of 
previous attacks except that one or more aura symptoms persists for >60 minutes [B] 
Neuroimaging demonstrates ischaemic infarction in a relevant area. [C] Not attributed to 
another disorder. Ischaemic stroke in a migraine sufferer may be categorised as cerebral 
infarction of other cause coexisting with migraine, cerebral infarction of other cause 
presenting with symptoms resembling migraine with aura, or cerebral infarction occurring 
during the course of a typical migraine with aura attack. Only the last fulfils criteria for 1.5.4 
Migrainous infarction. Increased risk for stroke in migraine patients has been demonstrated in 
women under age 45 in several studies. Evidence for an association between migraine and 
stroke in older women and in men is inconsistent. 
1.5.5 Migraine-triggered seizure: A seizure triggered by a migraine aura. Diagnostic 
criteria: [A] Migraine fulfilling criteria for 1.2 Migraine with aura [B] A seizure fulfilling 
diagnostic criteria for one type of epileptic attack occurs during or within 1 hour after a 
migraine aura. Migraine and epilepsy are highly comorbid conditions probably sharing the 
same pathophysiology, but the nature of their association is unclear. Migralepsy is the term 
used when a seizure occurs during or within 1 hour of a typical migraine aura 
attack. Reversible brain MRI abnormalities have been reported in a patient with migraine-
triggered seizure, possibly due to supratentorial focal cerebral edema. Electroencephalogram 
(EEG) findings are usually normal interictal, although various abnormalities, mainly diffuse 
slowing, have been reported in migraineurs. [23]
Symptom Migraine Epilepsy
Duration of aura 15–60 min Brief, often <1 min
Automatisms Unusual Frequent for complex 
partial seizures
Gastrointestinal aura Abdominal pain (rare) 
Nausea (common)
‘‘Butterflies’’—rising 
epigastric sensation
Visual disturbances Positive/negative Complex visual 
phenomenon
Paresthesias Common (5–60 min) Common (seconds to 
minutes)
Altered 
consciousness 
Usually responsive Often unresponsive
Olfactory Very uncommon More common
Aphasia Uncommon Common
D_ej_a vu Rare Common
Migraine–epilepsy syndromes include (1) Benign epilepsy of childhood with occipital 
paroxysms (BOEP) - BOEP is a clinical syndrome characterized by visual symptoms 
followed by a partial seizure and postictal migraine. The EEG reveals occipital spikes. A rare 
syndrome of childhood (mean age of onset 7.5 years), it accounts for less than 5% of epilepsy 
in children.[24] BOEP has features common to both epilepsy and migraine. The seizures 
usually begin with visual symptoms, including amaurosis, elementary visual hallucinations 
(phosphenes) and complex visual hallucinations, or visual illusions, including micropsia, 
metamorphopsia, or palinopsia. The visual symptoms are often followed by hemiclonic 
complex partial seizures or generalized tonic–clonic seizures. Following the seizure, 
approximately 25 to 40% of the patients develop migraine-like headaches. The interictal EEG 
is characterized by normal background activity and distinct occipital discharges. The occipital 
spikes typically have a high voltage (200–300 lV), diphasic morphology, and a unilateral or 
bilateral occipital and posterotemporal distribution. The spikes disappear with eye opening 
and reappear 1 to 20 seconds after eye closure. Occipital spikes are not specific for BOEP. 
They have been reported in persons with migraine, and in children under 4, they may not be 
associated with epilepsy or any other defined disorder. Occipital spikes can also be seen in 
other disorders, including myoclonic, absence, and photosensitive epilepsies as well as in 
coeliac disease. (2) Benign rolandic epilepsy: Benign rolandic epilepsy is characterized by 
unilateral somatosensory or motor seizures and centrotemporal spikes. An association with 
migraine has been reported in some, but not all, studies.[25] Migraine prevalence in male 
controls (11.1%) was much higher than one would expect in boys between the ages of 6 and 
15 years. Giroud and colleagues, in a controlled study, found that epilepsy with rolandic 
paroxysms and migraine were associated. Migraine incidence was studied in four groups of 
patients: patients with centrotemporal epilepsy, patients with absence epilepsy, patients with 
partial epilepsy, and nonepileptic patients with a history of cranial trauma. Migraine was 
present in 62% of the patients with centrotemporal epilepsy, 34% of the patients with absence 
epilepsy, 8% of the patients with partial epilepsy, and 6% of the patients with cranial trauma.
1.6  Probable  migraine:  Previously  termed  as  a  migrainous  disorder,  attacks  and/or 
headache missing one of the features needed to fulfil  the criteria for  the disorders coded 
above.
Demographics & Etiology
Epidemiology: According to IHS, migraine constitutes 16% of primary headaches. Migraine afflicts 
10-20% of  the  general  population.  World  -  15-20% of  women  and  10-15% of  men  suffer  from 
migraine. In India, 15-20% of people suffer from migraine with an adult female: male ratio of 2:1.[8]
[9] In childhood migraine, boys and girls are affected equally until puberty. In individuals older than 12 
years, the prevalence increases in both males and females, and the incidence declines in individuals 
older than 40 years, except for women in perimenopause. The overall prevalence is higher in females 
than in males. The female-to-male ratio increases from 
2.5:1 at puberty to 3.5:1 at age 40 years, after which it 
declines. The incidence of migraine with aura peaks in 
boys at around age 5 years and in girls at around age 
12-13  years.  The  incidence  of  migraine  without  aura 
peaks  in  boys  at  age  10-11 years  and in  girls  at  age 
14-17 years.  The  incidence of  migraine  in  females  of 
reproductive age has increased over the last  20 years, 
probably due to more awareness of the condition. In the 
United States, white women have the highest incidence 
of migraine, whereas Asian women have the lowest incidence. Moreover, low socioeconomic status is 
associated with migraine. Currently, 1 of 6 American women has migraine headaches.[10]. 
Age-Gender Incidence: Migraine is an extremely common condition which will affect 12–
28% of people at some point in their lives. However this lifetime prevalence does not provide 
for how many patients there are with active migraine at any one time. The burden of migraine 
in a population is assessed by looking at the one-year prevalence The third figure, which 
helps to clarify the picture, is the incidence that relates to the number of first attacks occurring 
at any given age and helps understanding of how the disease grows and shrinks over time. 
The one year prevalence of migraine ranges from 6–15% in adult men and from 14–35% in 
adult women.[11] These figures vary substantially with age: approximately 4–5% of children 
aged under 12 suffer from migraine, with little apparent difference between boys and girls. In 
the United States, three very large studies assessed the epidemiology of migraine in adults. 
The American Migraine Study-1 (AMS-1), collected information from 15,000 households 
representative of the US population in 1989.10 AMS-II, used virtually identical methodology 
10 years later.11 Finally, the American Migraine Prevention and Prevalence study (AMPP) 
replicated, in its first research phase, the methods of AMS-I and AMS-II.[12] In these three 
very large studies, the prevalence of migraine was about 18% in women and 6% in men. 
There is then a rapid growth in incidence amongst girls occurring after puberty, [9][11] which 
continues throughout early adult life. By early middle age, around 25% of women experience 
a migraine at least once a year, compared with fewer than 10% of men.[After menopause, 
attacks in women tend to decline dramatically, so that in the over 70s there are approximately 
equal numbers of male and female sufferers, with prevalence returning to around 5%. At all 
ages, migraine without aura is more common than migraine with aura, with a ratio of between 
1.5:1 and 2:1.[13] Incidence figures show that the excess of migraine seen in women of 
reproductive age is mainly due to migraine without aura.[13]
Thus in pre-pubertal and post-menopausal populations, migraine with aura is somewhat more 
common than amongst 15–50 year olds. There is a strong relationship between age, gender 
and type of migraine. The incidence of migraine is related to the incidence of epilepsy in 
families, with migraine twice as prevalent in family members of epilepsy sufferers, and more 
common in epilepsy sufferers themselves[14]. 
Pathophysiology of Migraine
There are many schools of thought on the pathophysiology of migraine. The older vascular 
theory;  is now considered secondary to brain dysfunction and  has fallen out of favour and 
been replaced by newer theories. 
Vascular theory: Migraines  can  begin  when  blood  vessels in  the  brain  contract  and 
expand inappropriately.  This  may start  in  the  occipital  lobe,  in  the  back of  the  brain,  as 
arteries undergo spasm. The reduced flow of blood from the occipital lobe triggers the visual 
aura.[15],[16] When the constriction stops and the  blood vessels dilate, the blood vessels 
become permeable and some fluid leaks out. This leakage is recognized by pain receptors in 
the  blood  vessels of  surrounding  tissue.  In  response,  the  body  supplies  the  area  with 
chemicals  which  cause  inflammation.  With  each  heart  beat,  blood  passes  through  this 
sensitive area causing a throb of pain.  Ray Wolffe et al (1940)[3] believed that intracranial 
vasoconstriction  is  responsible  for  the  aura  of  migraine  and  that  subsequent  rebound 
vasodilatation and activation of perivascular nociceptive nerves resulted in headache, based 
on the observations that (1) extracranial vessels become distended and pulsatile during a 
migraine attack, (2) stimulation of intracranial vessels in an awake person induces headache, 
and  (3)  vasoconstrictors  (eg,  ergots)  improve  the  headache,  whereas  vasodilators  (eg, 
nitroglycerin) provoke an attack.[17]
Depolarization theory: A  phenomenon  known  as  cortical  spreading  depression can 
cause migraines.[18] In cortical spreading depression, neurological activity is depressed 
over an area of the cortex of the brain. This situation results in the release of inflammatory 
mediators leading to irritation of cranial nerve roots, most particularly the trigeminal nerve, 
which  conveys the sensory information for  the  face  and much of  the  head.  This  view is 
supported by  neuroimaging techniques, which appear to show that migraine is primarily a 
disorder  of  the  brain  (neurological),  not  of  the  blood  vessels  (vascular).  A  spreading 
depolarization (electrical change) may begin 24 hours before the attack, with onset of the 
headache occurring around the time when the largest area of the brain is depolarized. A 
French  study  in  2007,  using  the  PET  technique  identified  the  hypothalamus as  being 
critically involved in the early stages.[19] 
Serotonin theory: Serotonin,  a  neurotransmitter,  helps  to  control  mood,  pain  sensation, 
sexual  behaviour,  sleep,  as  well  as  dilation  and  constriction  of  the  blood  vessels.  Low 
serotonin levels in the brain may lead to a process of constriction and dilation of the blood 
vessels which trigger a migraine.  Triptans activate serotonin receptors to stop a migraine 
attack.[18] 
Neural  theory:  When an area in  the brain  stem become irritated,  a  migraine begins.  In 
response to the irritation, the body releases chemicals which cause inflammation of the blood 
vessels. These chemicals cause further irritation of the nerves and blood vessels and results 
in  pain.  Substance  P is  one  of  the  substances  released  with  first  irritation.  Pain  then 
increases because substance P aids in sending pain signals to the brain.[18] 
Unifying theory: The theory encompasses both vascular and neural influences associated 
with stress that triggers changes in the brain, changes caused by serotonin release, blood 
vessels constriction, chemicals like substance P that irritate nerves and blood vessels causing 
pain.[18]
Cortical spreading depression:In  1944,  Leao  proposed  this  theory  to  explain  the 
mechanism of migraine with aura. A migraine aura is due to well-defined wave of neuronal 
excitation in the cortical  gray matter that spreads from its site of origin at the rate of 2-6 
mm/min; followed by a wave of neuronal suppression in a similar fashion. The blood vessels 
in the area simultaneously dilate and constrict. Hence, migraine aura is considered a cortical 
event with definite and well-defined neuroelectrical  basis. The neurochemical  basis of the 
CSD is the release of potassium or the excitatory amino acid glutamate from neural tissue. 
This release depolarizes the adjacent tissue, which, in turn, releases more neurotransmitters, 
propagating  the  spreading  depression.  Positron  emission  tomography  (PET)  scanning 
demonstrates  that  blood  flow  is  moderately  reduced  during  a  migrainous  aura,  but  the 
spreading  oligemia  does  not  correspond  to  vascular  territories.  The  oligemia  itself  is 
insufficient to impair function. The reason why these neurons are more excitable at a cellular 
level in certain patients is not entirely clear. Specific groups of patients with migraine have a 
genetic defect leading to a lowered threshold for CSD, and this is called familial hemiplegic 
migraine (FHM). However, for the vast majority of patients, a clear metabolic or genetic defect 
that easily explains this neuronal excitability cannot be determined.[18],[19],[20]
Brainstem activation: PET  scanning  in  patients  having  an  acute  migraine  headache 
demonstrates  activation  of  the  contralateral  pons,  even after  medications  abort  the  pain. 
Weiler et al proposed that brainstem activation may be the initiating factor of migraine. Once 
the CSD occurs on the surface of the brain,  H+ and K+ ions diffuse to the pia mater and 
activate C-fiber meningeal nociceptors, which releases proinflammatory neurochemicals (eg, 
calcitonin  gene–related  peptide)  and  plasma  extravasation  occurs.  Therefore,  a  sterile, 
neurogenic inflammation of  the trigeminovascular complex is present.  Once the trigeminal 
system is activated, it stimulates the cranial vessels to dilate. The final common pathway to 
the throbbing headache is the dilatation of blood vessels.[19],[21][22]
Cutaneous allodynia: Burstein et al 2000 [23][24] described the phenomenon of cutaneous 
allodynia,  in  which  secondary  pain  pathways  of  the  trigeminothalamic  system  become 
sensitized  during  a  migrainous  episode. This  observation  further  demonstrates  that 
sensitization of central pathways in the brain mediates the pain of migraine, in addition to the 
previously described neurovascular events.
Dopamine Pathway: Some authors have proposed a dopaminergic basis  for  migraine. In 
1977, Sicuteri postulated that a state of dopaminergic hypersensitivity is present in patients 
with migraine. Interest in this theory has recently been renewed [18]. A variety of prodromal 
symptoms  (eg,  yawning,  irritability,  nausea,  vomiting)  can  be  attributed  to  relative 
dopaminergic  stimulation.  Dopamine  antagonists,  such  as  prochlorperazine,  completely 
relieve almost 75% of acute migraine attacks.
Magnesium Deficiency: Another theory proposes that deficiency of magnesium in the brain 
triggers a chain of events, starting with platelet aggregation and glutamate release and finally 
resulting in the release of 5-hydroxytryptamine, which is a vasoconstrictor.[18]
Clinical Features: Diagnosis, description, and triggers 
The diagnosis of migraine is clinical in nature, based on criteria established by the IHS. The 
signs and symptoms of migraine vary among patients. Therefore, what a patient experiences 
before, during and after an attack cannot be defined exactly. The four phases of a migraine 
attack listed below are common but not necessarily experienced by all  migraine sufferers. 
Additionally, the phases experienced and the symptoms experienced during them can vary 
from one migraine attack to another in the same migraineur:
1. The prodrome, which occurs hours or days before the headache.
2. The aura, which immediately precedes the headache.
3. The pain phase, also known as headache phase.
4. The postdrome.
Prodrome phase: Prodromal  symptoms  occur  in  40–60%  of  migraineurs  (migraine 
sufferers).  This  phase  may consist  of  altered  mood,  irritability,  depression or  euphoria, 
fatigue,  yawning,  excessive  sleepiness,  craving  for  certain  food  (e.g.  chocolate),  stiff 
muscles  (especially in  the  neck),  constipation  or  diarrhea,  increased urination,  and other 
visceral  symptoms[25][26]  These  symptoms  usually  precede  the  headache  phase  of  the 
migraine attack by several hours or days, and experience teaches the patient or observant 
family how to detect that a migraine attack is near.
Aura phase:For the 20–30% of individuals who suffer migraine with aura, this aura comprises 
focal neurological phenomena that precede or accompany the attack. They appear gradually 
over 5 to 20 minutes and generally last fewer than 60 minutes. The headache phase of the 
migraine attack  usually begins  within  60  minutes of  the  end of  the  aura  phase,  but  it  is 
sometimes delayed up to several hours, and it can be missing entirely. Symptoms of migraine 
aura can be visual, sensory, or motor in nature.[27],[28]. Visual aura is the most common of 
the  neurological  events.  There  is  a  disturbance  of  vision  consisting  usually  of  unformed 
flashes of white and/or black or rarely of  multicolored lights  (photopsia)  or  formations of 
dazzling zigzag lines (scintillating scotoma; often arranged like the battlements of a castle, 
hence the alternative terms "fortification spectra" or "teichopsia". Some patients complain of 
blurred or shimmering or cloudy vision, as though they were looking through thick or smoked 
glass,  or,  in  some cases,  tunnel  vision and  hemianopsia.  The somatosensory aura  of 
migraine consists of digitolingual or cheiro-oral  paresthesias, a feeling of pins-and-needles 
experienced in the hand and arm as well as in the nose-mouth area on the same side. [29]
[30] Paresthesia migrates up the arm and then extends to involve the face, lips and tongue. 
Other symptoms of the aura phase can include auditory or olfactory hallucinations, temporary 
dysphasia, vertigo, tingling or numbness of the face and extremities, and hypersensitivity to 
touch.[31][32]
Pain phase: The typical migraine headache is unilateral, throbbing, moderate to severe and 
can be aggravated by physical activity. Not all of these features are necessary. The pain may 
be bilateral at the onset or start on one side and become generalized, and usually alternates 
sides from one attack to the next. The onset is usually gradual. The pain peaks and then 
subsides, and usually lasts between 4 and 72 hours in adults and 1 and 48 hours in children. 
The frequency of attacks is extremely variable, from a few in a lifetime to several times a 
week, and the average migraineur experiences from one to three headaches a month. The 
head pain varies greatly in intensity.[27],[28] The pain of migraine is invariably accompanied 
by other features. Nausea occurs in almost 90 percent of patients, while vomiting occurs in 
about one third of patients. Many patients experience sensory hyperexcitability manifested by 
photophobia,  phonophobia and  seek  a  dark  and  quiet  room.  Blurred  vision,  nasal 
stuffiness, diarrhea, polyuria, pallor or sweating may be noted during the headache phase. 
There may be localized edema of the scalp or face, scalp tenderness, prominence of a vein 
or artery in the temple, or stiffness and tenderness of the neck. Impairment of concentration 
and mood are common. Lightheadedness, rather than true vertigo and a feeling of faintness 
may occur. The extremities tend to be cold and moist.[32]
Postdrome phase: The  patient  may  feel  tired,  have  head  pain,  cognitive  difficulties, 
"hungover", gastrointestinal symptoms, mood changes and weakness.[33] Some people feel 
unusually  refreshed  or  euphoric  after  an  attack,  whereas  others  note  depression  and 
malaise. Often, some of the minor headache phase symptoms may continue, such as loss of 
appetite,  photophobia,  and  lightheadedness.  For  some patients,  a  5  to  6  hour  nap  may 
reduce the pain, but slight headaches may still occur when standing or sitting quickly. 
Defining Pain Severity: The IHS defines the intensity of pain with a verbal, four-point scale.
[34]
Number Name Annotations
0 no pain
1 mild pain does not interfere with usual activities
2 moderate pain inhibits, but does not wholly prevent usual activities
3 severe pain prevents all activities
Triggers: A migraine trigger is any factor that, on exposure or withdrawal, leads to the 
development of  an acute migraine headache. Triggers may be categorized as behavioral, 
environmental, infectious, dietary, chemical, or hormonal. Migraine attacks may be triggered 
by allergic reactions, bright lights, loud noises, and certain odours or perfumes, head trauma, 
physical  or  emotional  stress,  changes in  sleep patterns,  smoking or  exposure  to  smoke, 
skipping meals, alcohol, menstrual cycle fluctuations, birth control pills, hormone fluctuations 
during the menopause transition, foods containing tyramine (red wine, aged cheese, smoked 
fish, chicken livers, figs, and some beans),  monosodium glutamate (MSG) or  nitrates (like 
bacon, hot dogs, and salami), other foods such as chocolate, nuts, peanut butter, avocado, 
banana,  citrus,  onions,  dairy products,  and fermented or  pickled foods.,  medications (eg, 
nitroglycerin,  histamine,  reserpine,  hydralazine,  ranitidine,  estrogen).[35]  Sometimes  the 
migraine occurs with  no  apparent  "cause".  The trigger  theory supposes that  exposure to 
various environmental factors precipitates, or triggers, individual migraine episodes. Migraine 
patients have long been advised to try to identify personal headache triggers by looking for 
associations between their headaches and various suspected trigger factors. Several studies 
have found some migraines are triggered by changes in weather. One study noted 62% of the 
subjects thought weather was a factor but only 51% were sensitive to weather changes.[35] 
Most likely to trigger a migraine were, temperature, high humidity, and changes in barometric 
pressure. One study found that for some migraineurs in India, washing hair in a bath was a 
migraine trigger. The triggering effect was probably due to delayed drying of the wet hair. [36] 
Comorbidities  of  migraine:  Migraine  is  associated with  epilepsy (eg,  benign  rolandic 
epilepsy,  benign  childhood  epilepsy),  familial  dyslipoproteinemias,  hereditary  hemorrhagic 
telangiectasia, Tourette  syndrome,  hereditary essential  tremor,  hereditary cerebral  amyloid 
angiopathy, ischemic  stroke (migraine  with  aura  is  a  risk  factor,  with  an  odds  ratio  of 
6), depression and anxiety, asthma, patent foramen ovale, and stroke. Epilepsy increases the 
relative risk of migraine by 2.4. The risk of posterior circulation strokes, especially cerebellar, 
is increased in migraineurs with aura. Female migraineurs,  with or without aura, have an 
increased risk of deep white matter brain lesions. Several studies are currently investigating 
patent foramen ovale, which is seen in 18-21% of migraine patients[37]
Diagnostic Procedures 
Neuroimaging is indicated for any of the following: [A] First or worst headache of the patient's 
life [B] Change in frequency, severity, or clinical features of the headache [C] Abnormal 
neurological examination [D] Progressive or new daily, persistent headache [E] Neurological 
symptoms that do not meet the criteria for migraine with typical aura or that themselves 
warrant investigation [E] Persistent neurologic deficit [F] Hemicrania that is always on the 
same side and associated with contralateral neurological symptoms [G] Inadequate response 
to routine therapy [H] Atypical clinical presentation. Neuroimaging studies that may be 
appropriate include CT scan and MRI. Other studies such as angiography, MRA, and MRV 
also may be indicated.[19] Agarwal et al [2008],[16] have described reversible MRI brain 
white matter abnormalities in a patient with migraine. Frishberg reviewed four CT scan 
studies, four MRI scan studies, and one combined MRI and CT scan study of 897 scans of 
patients who had migraine. These findings are combined with more recent reports of one CT 
scan study of 284 patients 36 and six studies of MRI scans of 444 patients for a total of 1625 
scans of patients who had various types of migraine. Other than WMA, the studies showed no 
significant pathology except for four brain tumors (three of which were incidental findings) and 
one AVM (in a patient who had migraine and a seizure disorder). Sempere found a similarly 
low yield of 0.4%.
Electrophysiology: The electroencephalogram (EEG) was a standard test for evaluation of 
headaches in the pre-CT scan era. Gronseth and Greenberg [38] reviewed the literature from 
1941 to 1994 on the usefulness of EEG in the evaluation of patients who had headache. Most 
of the articles had serious methodologic flaws. The only significant abnormality reported in 
studies with a relatively nonflawed design was prominent driving in response to photic 
stimulation (the H-response) in migraineurs who had a sensitivity ranging from 26%17 to 
100%18 and a specificity from 80%19 to 91%.18 This finding, although interesting, is not 
necessary for the clinical diagnosis of migraine. Electrophysiological studies in migraine: a 
comprehensive review of their interest and limitations by A Ambrosini et al [2003] is indicated 
herein.[39] 
Autonomic Function Tests: The rationale to study functions of the ANS in headache is 
primarily based on clinical observations. Changes of ANS functions are obvious in cluster 
headache with autonomic symptoms (so-called trigeminal autonomic cephalgias [TACs]) [40],
[41],[42] and have been extensively investigated for these pains in the last 20 years. Changes 
of ANS function are suspected to be important in migraine but are less obvious in this 
headache. Kruszewski et al [2000][43] have extensively discussed the literature on headache 
with autonomic symptoms. In most studies small samples of patients have been investigated. 
Usually patients have been classified according to the diagnostic criteria of the International 
Headache Society and groups of patients were paralleled by healthy sex- and agematched 
control groups. Test–retest reliability has seldom been studied adequately and blinding has 
not been used. Most published studies focus on group differences in order to understand 
more about headache pathogenesis. The group differences have seldom been large, and it is 
generally not proven that ANS tests can help in diagnosing the headache disorder. Sensitivity 
and specificity is almost never discussed although some exceptions occur [44]. 
Autonomic Function Tests in Migraine:  Based on a literature review and an extensive 
investigation of patients with migraine, Thomsen, Olesen and coworkers conclude that ‘Clear 
dysfunction of the sympathetic nervous system remains to be
shown. Mild parasympathetic hypofunction with denervation supersensitivity may be present 
in migraine’ [45],[46]. Results are variable, however. Boiardi et al. [44] reported for instance 
that the diastolic blood pressure response to sustained handgrip was impaired in 61% of 
migraine patients. In a recent study, no heart-rate variability differences between migraine 
patients and control subjects were found [47]. Micieli et al. [48] found increased basal 
pupillary diameter as well as increased light reflex contraction and dilatation velocities in 
migraineurs. Increased pupillary dilatation to phenylephrine eyedrops has also been found in 
migraine[49],[50]. Recently it has been proposed that activation parasympathetic neurones in 
the pterygopalatine and otic ganglia leads to vasodilation of cranial blood vessels, release of 
inflammatory mediators and activation and/or sensitization of trigeminovascular afferents [51],
[52]. Consistent with this idea appears to be that intranasal application of lidocaine may 
relieve migraine attacks[53],[54]. It is suggested that this treatment blocks impulse 
transmission in the pterygopalatine ganglion. However, this idea of involvement of the efferent 
parasympathetic neurones in (direct or indirect) activation or sensitization of 
trigeminovascular afferents needs better experimental verification. Furthermore, relief of 
migraine attacks by intranasal lidocaine requires a doubleblind, placebo-controlled approach. 
Finally, the latter results could probably also be explained by blockade of activity in 
trigeminovascular afferents passing through the pterygopalatine ganglion. 
Procedures: Indications for LP include the following: [A] First or worst headache of a patient's 
life  [B]  Severe,  rapid-onset,  recurrent  headache  [C]  Progressive  headache  [D]  Atypical 
chronic intractable headache
Treatment
Conventional  treatment  focuses  on  three  areas:  trigger  avoidance,  abortive  therapy,  and 
prophylaxis.  Drug  therapy is  considered  effective to  reduce  the  frequency or  severity  of 
migraine attacks by 50%.[55] Children and adolescents, are often first given drug treatment, 
but the value of diet modification should not be overlooked. 
I. Abortive Therapy: The abortive treatment of migraine is divided into (1) Symptomatic 
treatment (2) Specific Anti-migraine drugs. 
Non Specific Treatment of Migraine: There is a large group of disparate nonspecific 
acute medications for migraine, that include nonsteroidal anti-inflammatory drugs (NSAIDs), 
aspirin (ASA), acetaminophen (APAP), analgesic combinations with or without caffeine, 
opioids, butalbital, isometheptene, also often in combinations, and medication classes 
including antihistamines, antinauseants, antiepilepsy drugs, and muscle relaxants. Aspirin-
acetaminophen-caffeine (AAC) mixtures are Food and Drug Administration approved for 
migraine based on a randomized controlled trial (RCT) in which preselected patients who 
were usually incapacitated (ie, required bed rest for their attacks) or who experienced 
vomiting 20% or more of the time were excluded. NSAIDs, such as naproxen, diclofenac and 
solubilized ibuprofen, also are superior to placebo in RCTs. Evidence for opioid use in acute 
migraine generally is negative. Jakubowski and colleagues found that even intermittent use of 
opioids interfered with successful therapeutic reversal of central sensitization and pain-free 
response in patients who had status migrainosus. Butalbital use had no specific evidence of 
efficacy and had an excessive risk for habituation and dependence. Prevention population-
based study suggested that episodic use of butalbital was linked to transformation into 
chronic daily headache and medication overuse headache. It is wise to never prescribe 
butalbital for migraine. [56][58]
Specific Anti Migraine Treatment: (1) Triptans are serotonin -1B/D (5HT1B/D) 
agonists that work via the serotonin-1D receptors to inhibit CGRP and inflammatory peptide 
release in the meninges and prevent the pain signal from returning from the periphery to the 
trigeminal nucleus caudalis. They work via the 5HT1B receptor to constrict vessels dilated by 
CGRP. Because there are some 5HT1B receptors in coronary and other arteries, triptans are 
contraindicated in patients who have vascular disease. Triptans are classified into Group I 
and II. Group-I triptans are fast acting with response rates of two hours of medication eg- 
Sumatriptan, Zolmitriptan, Rizatriptan, Almotriptan and Eletriptan. While group II triptans have 
a minimally slower rate of activity at 4 hours eg: Naratriptan and Frovatriptan. Selecting the 
triptan necessitates determining how fast a migraine worsens. If onset is quick, a group I 
triptan is necessary. If emesis is common, a non oral formulation like sumatriptan SC or 
Zolimitriptan Nasal spray are preferred. Some evidence suggests a triptan-NSAID 
combination can reduce headache recurrence[57]. (2) Ergots: Until the introduction of 
sumatriptan in 1991, ergot derivatives were the primary oral drugs available to abort a 
migraine once it is established. Ergot drugs can be used either as a preventive or abortive 
therapy, though their relative expense and cumulative side effects suggest reserving them as 
an abortive rescue medicine. However, ergotamine tartrate tablets (usually with caffeine), 
though highly effective, and long lasting (unlike triptans), have fallen out of favour due to the 
problem of ergotism.[57] Both ergot and triptans have the same risk for vasoconstriction DHE 
is tolerated far better, is useful as an acute treatment of long migraines because of low 
recurrence, and can be used repetitively for status migrainosus and in detoxification from 
rebound. According to AAN guidelines, maximum dosing for DHE is 3 mg per day, up to 21 
mg per week. Intranasal DHE dosing requires one spray (0.5 mg) into each nostril (without 
sniffing) at the first sign of migraine, followed 15 minutes later by an additional spray into 
each[58]  Other agents: Steroids: Based on a recent meta analysis a single dose of IV 
dexamethasone, when added to standard treatment, is associated with a 26% decrease in 
headache recurrence.[59] Amidrine, Duadrin, and Midrin is a combination of acetaminophen, 
dichloralphenazone, and isometheptene often prescribed for migraine headaches. Some 
studies have recently shown that these drugs may work better than sumatriptan for treating 
migraines.[9][57] Recently it has been found that calcitonin gene related peptides (CGRPs) 
play a role in the pathogenesis of the pain associated with migraine as triptans also decrease 
its release and action. CGRP receptor antagonists such as olcegepant and telcagepant are 
being investigated both in vitro and in clinical studies for the treatment of migraine. 
II. Prophylactic Therapy
US evidence-based guidelines for preventive treatment of migraine include the following: 
1. Recurring migraine that significantly interferes with the patient’s daily routine despite 
acute treatment (eg, two or more attacks a month that produce disability that lasts 3 or 
more days, headache attacks that are infrequent but produce profound disability 
2. Failure of, contraindication to, or troublesome side effects from acute medications 
3. Overuse of acute medications 
4. Special circumstances, such as hemiplegic migraine or attacks with a risk for 
permanent neurologic injury. 
5. Frequent headaches (more than two a week) or a pattern of increasing attacks over 
time, with the risk for developing medication overuse headache. 
6. Patient preference, that is, the desire to have as few acute attacks as possible 
Only 13% of all migraineurs currently use preventive therapy to control their attacks. The 
principles of preventive prophylaxis are 
1. Start the chosen drug at a low dose, and increase it slowly until therapeutic effects 
develop, the ceiling dose for the chosen drug is reached, or adverse events (AEs) 
become intolerable. Give each treatment an adequate trial. The full benefit of the drug 
may not be realized until 6 months have elapsed.
2. Set realistic goals. Success is defined as a 50% reduction in attack frequency, a 
significant decrease in attack duration, or an improved response to acute medication.
3. Set realistic expectations regarding AEs. The risk and extent of AEs vary greatly from 
patient to patient, and we presently have no way of predicting the presence or severity 
of AEs for an individual patient. Most AEs are self-limited and dose dependent, and 
patients should be encouraged to tolerate the early AEs that may develop when a new 
medication is started.
4. Avoid acute headache medication overuse and drugs that are contraindicated because 
of coexistent or comorbid illnesses.
5. Re-evaluate therapy, and, if possible, taper or discontinue the drug after a sustained 
period of remission (6–9 months).
6. Be sure that a woman of childbearing potential is aware of any potential risks, and 
choose the medication that has the least potential for AE on a fetus.
7. To maximize compliance, involve patients in their own care. Take patient preferences 
into account when deciding between drugs of relatively equivalent efficacy and 
tolerability.
8. Consider comorbidity, which is the presence of two or more disorders whose 
association is more likely than chance. 
The major medication groups for preventive migraine treatment include 
1. Anticonvulsants 
2. Antidepressants
3. Beta-adrenergic blockers
4. Calcium channel antagonists
5. Serotonin antagonists
6. Botulinum neurotoxins
7. Nonsteroidal anti-inflammatory drugs
8. Others - Riboflavin, Magnesium. 
If preventive medication is indicated, the agent should be chosen from one of the first-line 
categories based on the drug’s relative efficacy in double-blind placebo-controlled trials, its 
side effect profile, and the patient’s preference, in addition to coexistent and comorbid 
conditions. Preventive treatment is often recommended for only 6 to 9 months; however, to 
date, no randomized placebo-controlled trials have been performed to investigate migraine 
frequency after the preventive treatment has been discontinued. Diener and colleagues12 
assessed 818 patients who had migraine and were treated with topiramate for 6 months to 
see the effects of topiramate discontinuation. Although the number of migraine days did 
increase. These findings suggest that patients should be treated for 6 months, with the option 
to continue to 12 months. 
Beta-Adrenergic Blockers: Beta—blockers, the most widely used class of drugs in 
prophylactic migraine treatment, are approximately 50% effective in producing a greater than 
50% reduction in attack frequency. Evidence has consistently demonstrated that non 
selective beta-blocker propranolol is significantly effective, selective b1-blockers metoprolol, 
atenolol, bisoprolol, nadolol, and timolol are also effective, while beta-blockers with intrinsic 
sympathomimetic activity (eg, acebutolol, alprenolol, oxprenolol, pindolol) are not effective for 
migraine prevention. Propranolol is effective for migraine prevention at a daily dose of 120 to 
240 mg, but no correlation has been found between its dose and its clinical efficacy. [58] The 
action of beta—blockers is probably central and could be mediated by (1) inhibiting central b-
receptors that interfere with the vigilance-enhancing adrenergic pathways, (2) interaction with 
5—HT receptors (but not all effective beta—blockers bind to the 5—HT receptors), and (3) 
cross-modulation of the serotonin system. Propranolol inhibits nitric oxide (NO) production by 
blocking inducible NO synthase. Propranolol also inhibits kainate-induced currents and is 
synergistic with N-methyl- D-aspartate blockers, which reduce neuronal activity and have 
membrane-stabilizing properties. Contraindications to the use of beta-blockers include 
asthma and chronic obstructive lung disease, congestive heart failure, atrioventricular 
conduction defects, Raynaud’s disease, peripheral vascular disease, and brittle diabetes.[59]
Antidepressants: Antidepressants consist of several different drug classes with 
different mechanisms of action. Only one member of the class of tricyclic anti-depressants 
(TCAs), (amitriptyline) has proved efficacy in migraine. Although the mechanism by which 
antidepressants work to prevent migraine headache is uncertain, it does not result from 
treating masked depression. Antidepressants are useful in treating many chronic pain states, 
including headache, independent of the presence of depression, and the response occurs 
sooner than the expected antidepressant effect. The antidepressants that are clinically 
effective in headache prevention inhibit noradrenaline and 5—HT reuptake or are antagonists 
at the 5—HT2 receptors. The TCA dose range is wide and must be individualized. Most TCAs 
are sedating. Start with a low dose of the chosen TCA at bedtime, except when using 
protriptyline, which should be administered in the morning. If the TCA is too sedating, switch 
from a tertiary TCA (eg, amitriptyline, doxepin) to a secondary TCA (eg, nortriptyline, 
protriptyline). [60] AEs are common with TCA use. Antimuscarinic AEs include dry mouth, a 
metallic taste, epigastric distress, constipation, dizziness, mental confusion, tachycardia, 
palpitations, blurred vision, and urinary retention, conduction abnormalities, especially in the 
elderly, and these patients should be carefully monitored or other agents should be 
considered.  Start at a dose of 10 to 25 mg at bedtime. The usual effective dose for migraine 
ranges from 25 to 200 mg. Nortriptyline, a major metabolite of amitriptyline, is a secondary
amine that is less sedating than amitriptyline. Start at a dose of 10 to 25 mg at bedtime. The 
dosage ranges from 10 to 150 mg/d. Protriptyline is a secondary amine that is similar to 
nortriptyline. Start at a dose of 5 mg in the morning. The dosage ranges from 5 to 60 mg/d as 
a single or split dose. [61]
Calcium Channel Antagonists: Two types of calcium channels exist: calcium entry 
channels, which allow extracellular calcium to enter the cell, and calcium release channels, 
which allow intracellular calcium (in storage sites in organelles) to enter the cytoplasm. 
Calcium entry channel subtypes include voltage-gated, opened by depolarization; ligand 
gated, opened by chemical messengers, such as glutamate; and capacitative, activated by 
depletion of intracellular calcium stores. The mechanism of action of the calcium channel 
antagonists in migraine prevention is uncertain, but possibilities include inhibition of 5—HT 
release, neurovascular inflammation, or the initiation and propagation of cortical spreading 
depression. Flunarizine, a nonselective calcium channel antagonist with antidopaminergic 
properties, was superior to placebo in six of seven randomized clinical trials.[61] The dose is 
5 to 10 mg given at night, women seem to need lower doses than men. The most prominent 
AEs include weight gain, somnolence, dry mouth, dizziness, hypotension, occasional 
extrapyramidal reactions, and exacerbation of depression. Because of its side effects, 
flunarizine should be considered as a second-line drug for migraine prevention, after beta-
blockers. Verapamil was more effective than placebo in two of three trials, but both positive 
trials were small and dropout rates were high, rendering the findings uncertain. Rigorous 
randomized controlled trial evidence does not exist to support the use of verapamil for 
migraine. Nimodipine, nicardipine, diltiazem, and cyclandelate, other nonselective calcium 
channel antagonists, cannot be recommended for migraine prophylaxis.[61]
Anticonvulsants: Anticonvulsants are increasingly recommended for migraine prevention 
because of well-conducted placebo-controlled trials. With the exception of valproic acid, 
topiramate, and zonisamide, anticonvulsants may substantially interfere with the efficacy of 
oral contraceptives. Carbamazepine 600 to 1200 mg/d, may be effective in preventive 
migraine treatment but it is rarely used in clinical practice for this purpose.[61] Gabapentin 
(1800–2400 mg) showed efficacy in a placebo-controlled double-blind trial, the attack 
frequency was reduced by 50% in approximately one third of patients. The most common AEs 
were dizziness or giddiness and drowsiness. [61]Valproic Acid is a simple 8-carbon, 2-chain 
fatty acid. Divalproex sodium is a combination of valproic acid and sodium valproate. Both are 
effective as is an extended-release form of divalproex sodium. In 1992, Hering and Kuritzky 
evaluated the efficacy of sodium valproate in migraine treatment in a double-blind, 
randomized, crossover study. Sodium valproate was effective in preventing migraine or 
reducing the frequency, severity, and duration of attacks in 86.2% of 29 patients, whose 
attacks were reduced from 15.6 to 8.8 a month. Nausea, vomiting, and gastrointestinal 
distress are the AEs that occur most commonly; their incidence decreases, however, 
particularly after 6 months. Later,
tremor and alopecia can occur. Valproate has little effect on cognitive functions and rarely 
causes sedation. Valproate is teratogenic.[61] Topiramate: Two large, pivotal, multicenter, 
randomized, double-blind, placebo-controlled clinical trials assessed the efficacy and safety of 
topiramate (50, 100, and 200 mg/d) in migraine prevention. In the first trial, the responder rate 
(patients withR50%reduction in monthly migraine frequency) was 52% with topiramate, 200 
mg/d (P<.001); 54% with topiramate, 100 mg/d (P<.001); and 36% with topiramate, 50 mg/d 
(P 5 .039), compared with 23% with placebo.The 200-mg dose was not significantly more 
effective than the 100-mg dose. The second pivotal trial54 had significantly more patients who 
exhibited at least a 50% reduction in mean monthly migraines in the groups treated with 
topiramate at a dosage of 50 mg/d (39%; P 5 .009), 100 mg/d (49%; P 5 .001), and 200 mg/d 
(47%; P 5 .001). The most common AE of topiramate is paresthesia; other common AEs are 
fatigue, decreased appetite, nausea, diarrhea, weight decrease, taste perversion, 
hypoesthesia, and abdominal pain. In the migraine trials, body weight was reduced an 
average of 2.3% in the 50-mg group, 3.2% in the 100-mg group, and 3.8% in the 200-mg 
group. The most common central nervous system AEs were somnolence, insomnia, mood 
problems, anxiety, difficulty with memory, language problems, and difficulty with 
concentration. Renal calculi can occur with topiramate use.[62] Lamotrigine: blocks voltage-
sensitive sodium channels, leading to inhibition of neuronal glutamate release of glutamate. 
Chen and colleagues reported on two patients who had migraine with persistent aura-like 
visual phenomena for months to years. After 2 weeks of lamotrigine treatment, both had 
resolution of the visual symptoms. Although open-label studies have suggested that 
lamotrigine may have a select role in the treatment of patients with frequent or prolonged 
aura, results from a placebo-controlled study in migraine were negative. Steiner and 
colleagues59 compared the safety and efficacy of lamotrigine (200 mg/d) and placebo in 
migraine prophylaxis in a double-blind, randomized, parallel-group trial. Improvements were 
greater on placebo, and these changes, which were not statistically significant, indicate that 
lamotrigine was ineffective for migraine prophylaxis. [62]Other Drugs include AngiotensinS-
Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists, Botulinum Toxin Type 
A, Medicinal Herbs and Vitamins Feverfew (Tanacetum parthenium) is a medicinal herb 
whose effectiveness has not been totally established.[62]
2. Tension-type headache (TTH)
Tension  headaches,  renamed tension-type  headaches by  the International  Headache 
Society in 1988, are the most common type of primary headaches. Tension-type headaches 
account for nearly 90% of all headaches. Approximately 3% of the population suffers from 
chronic-tension  type  headache.[2] The International  Headache Society  (IHS)  classification 
system of 1988, included  tension-type headache as a category,  further defined as either 
episodic or chronic.  Whilst this type of headache was previously considered to be primarily 
psychogenic,  a  number  of  studies  have appeared after  the  first  edition of  the  ICHS  that 
strongly suggest a neurobiological basis, at least for the more severe subtypes of tension-
type  headache.[6] Tension  headaches  were  previously  termed  as  -  muscle  contraction 
headache,  psychomyogenic  headache,  stress  headache,  ordinary  headache,  essential 
headache, idiopathic headache and psychogenic headache. The division into  episodic and 
chronic subtypes  that  was  introduced  in  the  first  edition  of  the  classification  has  proved 
extremely useful. The chronic subtype is a serious disease causing greatly decreased quality 
of life and high disability. The exact mechanisms of tension-type headache are not known. 
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IHS DIAGNOSTIC CRITERIA FOR TENSION TYPE HEADACHES
2.1 Infrequent episodic tension-type headache: 
Infrequent episodes of headache lasting minutes to days, the pain being typically bilateral, 
pressing or tightening in quality and of mild to moderate intensity, which does not worsen with 
routine physical activity, without nausea but photophobia or phonophobia may be present. 
Diagnostic criteria include (A) At least 10 episodes occurring on <1 day per month on average 
(<12 days per year) and fulfilling criteria B-D (B) Headache lasting from 30 minutes to 7 days 
(C) Headache has at least two of the following characteristics: (1) bilateral location (2) 
pressing/tightening (non-pulsating) quality (3) mild or moderate intensity (4) not aggravated by 
routine physical activity such as walking or climbing stairs (D) Both of the following: (1) 
no nausea or vomiting (anorexia may occur) (2) no more than one of photophobia or 
phonophobia (E) Not attributed to another disorder. [6]
2.1.1 Infrequent episodic tension-type headache associated with pericranial 
tenderness: Diagnostic criteria includes (A) Episodes fulfilling criteria A-E for 2.1 Infrequent 
episodic tension-type headache (B) Increased pericranial tenderness on manual palpation 
2.1.2 Infrequent episodic tension-type headache not associated with pericranial 
tenderness: Diagnostic criteria includes: (A) Episodes fulfilling criteria A-E for 2.1 Infrequent 
episodic tension-type headache (B) No increased pericranial tenderness. Increased 
pericranial tenderness recorded by manual palpation is the most significant abnormal finding 
in patients with tension-type headache. The tenderness increases with the intensity and 
frequency of headache and is further increased during actual headache. The diagnostic value 
of EMG and pressure algometry is limited Palpation is a useful guide for the treatment 
strategy. It also adds value and credibility to the explanations given to the patient.
2.2 Frequent episodic tension-type headache: 
Frequent episodes of headache lasting minutes to days. The pain is typically bilateral, 
pressing or tightening in quality and of mild to moderate intensity, and it does not worsen with 
routine physical activity. There is no nausea but photophobia or phonophobia may be present. 
Diagnostic criteria include (A) At least 10 episodes occurring on ≥1 but <15 days per month 
for at least 3 months (≥12 and <180 days per year) and fulfilling criteria B-D (B) Headache 
lasting from 30 minutes to 7 days, (C) Headache has at least two of the following 
characteristics: 1. bilateral location, 2. pressing/tightening (non-pulsating) quality, 3. mild or 
moderate intensity, 4. not aggravated by routine physical activity such as walking or climbing 
stairs, (D) Both of the following: 1. no nausea or vomiting (anorexia may occur), 2. no more 
than one of photophobia or phonophobia, (E) Not attributed to another disorder. Frequent 
tension-type headache often coexists with migraine without aura. Coexisting tension-type 
headache in migraineurs should preferably be identified by a diagnostic headache diary. The 
treatment of migraine differs considerably from that of tension-type headache and it is 
important to educate patients to differentiate between these types of headaches in order to 
select the right treatment and to prevent medication-overuse headache.
2.2.1 Frequent episodic tension-type headache associated with pericranial 
tenderness: Diagnostic criteria include: (A) Episodes fulfilling criteria A-E for 2.2 Frequent 
episodic tension-type headache (B) Increased pericranial tenderness on manual palpation 
2.2.2 Frequent episodic tension-type headache not associated with pericranial 
tenderness: Diagnostic criteria include: (A) Episodes fulfilling criteria A-E for 2.2 Frequent 
episodic tension-type headache (B) No increased pericranial tenderness
2.3 Chronic tension-type headache
This is a disorder evolving from episodic tension-type headache, with daily or very frequent 
episodes of headache lasting minutes to days. The pain is typically bilateral, pressing or 
tightening in quality and of mild to moderate intensity, and it does not worsen with routine 
physical activity. There may be mild nausea, photophobia or phonophobia. Diagnostic criteria: 
(A) Headache occurring on ≥15 days per month on average for >3 months (≥180 days per 
year)1 and fulfilling criteria B-D (B) Headache lasts hours or may be continuous (C) 
Headache has at least two of the following characteristics: 1. bilateral location, 2. 
pressing/tightening (non-pulsating) quality, 3. mild or moderate intensity 4. not aggravated by 
routine physical activity such as walking or climbing stairs (D) Both of the following: 1. no 
more than one of photophobia, phonophobia or mild nausea, 2. neither moderate or severe 
nausea nor vomiting, (E) Not attributed to another disorder
When it is uncertain how many attacks fulfil one or other set of criteria it is strongly 
recommended to use a diagnostic headache diary prospectively. In many uncertain cases 
there is overuse of medication. When this fulfils criterion B for any of the subforms of 8.2 
Medication-overuse headache, the default rule is to code for 2.4.3 Probable chronic tension-
type headache plus 8.2.8 Probable medication-overuse headache. When these criteria are 
still fulfilled 2 months after medication overuse has ceased, 2.3 Chronic tension-type 
headache should be diagnosed and 8.2.8 Probable medication-overuse headache discarded. 
It should be remembered that some patients with chronic tension-type headache develop 
migraine-like features if they have severe pain and , conversely, some migraine patients 
develop increasingly frequent tension-type-like interval headaches, the nature of which 
remains unclear.
2.3.1 Chronic tension-type headache associated with pericranial tenderness: 
Diagnostic criteria: (A) Headache fulfilling criteria A-E for 2.3 Chronic tension-type headache 
(B) Increased pericranial tenderness on manual palpation
2.3.2 Chronic tension-type headache not associated with pericranial tenderness: 
Diagnostic criteria: (A) Headache fulfilling criteria A-E for 2.3 Chronic tension-type headache 
(B) No increased pericranial tenderness
2.4 Probable tension-type headache
Patients meeting one of these sets of criteria may also meet the criteria for one of the 
subforms of 1.6 Probable migraine. 
2.4.1 Probable infrequent episodic tension-type headache: Diagnostic criteria: (A) 
Episodes fulfilling all but one of criteria A-D for 2.1 Infrequent episodic tension-type headache 
(B) Episodes do not fulfil criteria for 1.1 Migraine without aura (C) Not attributed to another 
disorder.
2.4.2 Probable frequent episodic tension-type headache: Diagnostic criteria: (A) 
Episodes fulfilling all but one of criteria A-D for 2.2 Frequent episodic tension-type headache 
(B) Episodes do not fulfil criteria for 1.1 Migraine without aura (C) Not attributed to another 
disorder. 
2.4.3 Probable chronic tension-type headache: Diagnostic criteria: (A) Headache 
occurring on ≥15 days per month on average for >3 months (≥180 days per year) and fulfilling 
criteria B-D, (B) Headache lasts hours or may be continuous (C) Headache has at least two of 
the following characteristics: 1. bilateral location, 2. pressing/tightening (non-pulsating) 
quality,  3. mild or moderate intensity, 4.not aggravated by routine physical activity such as 
walking or climbing stairs. (D) Both of the following: 1. no more than one of photophobia, 
phonophobia or mild nausea
2. neither moderate or severe nausea nor vomiting (E) Not attributed to another disorder but 
there is, or has been within the last 2 months, medication overuse fulfilling criterion B for any 
of the subforms of 8.2 Medication-overuse headache
Pathophysiology
Various precipitating factors may cause TTH in susceptible individuals [2]. One half of 
patients with TTH identify stress or hunger as a precipitating factor that include - Stress - 
Usually occurs in the afternoon after long stressful work hours, Sleep deprivation & Eyestrain, 
Uncomfortable stressful position and/or bad posture, Irregular meal time (hunger), and 
Caffeine withdrawal. Until recently it was believed that tension headaches were caused 
by muscle tension around the head and neck. Recent research has shown that tension 
headache patients do not have increased muscle tension.[63] Another theory is that the pain 
may be caused by a malfunctioning pain filter which is located in the brain stem. The view is 
that the brain misinterprets information, for example from the temporal muscle or other 
muscles, and interprets this signal as pain. One of the main neurotransmitters which is 
probably involved is serotonin.[64]. Recent studies of nitric oxide (NO) mechanisms suggest 
that NO may play a key role in the pathophysiology of CTTH.[64] The sensitization of pain 
pathways may be caused by or associated with activation of nitric oxide synthase (NOS) and 
the generation of NO. Patients with chronic tension-type headache have increased muscle 
and skin pain sensitivity, demonstrated by low mechanical, thermal and electrical pain 
thresholds. Hyperexcitability of centralnociceptive neurons (in trigeminal spinal 
nucleus, thalamus, and cerebral cortex) is believed to be involved in the pathophysiology of 
chronic tension-type headache.[64] Recent evidence for generalized increased pain 
sensitivity or hyperalgesia in CTTH strongly suggests that pain processing in the central 
nervous system is abnormal in this primary headache disorder. Moreover, a dysfunction in 
pain inhibitory systems may also play a role in the pathophysiology of chronic tension-type 
headache.[65]
Frequency: Tension-type  headaches  can  be episodic or chronic[6] Episodic  tension-type 
headaches are defined as tension-type headaches occurring fewer than 15 days a month, 
whereas chronic tension headaches occur 15 days or more a month for at least 6 months. 
Tension-type headaches can last  from minutes to days,  months or even years,  though a 
typical tension headache lasts 4–6 hours
Epidemiology
Headaches account for 1-4% of all emergency department (ED) visits and are the ninth most 
common reason for a patient to consult a physician. Physicians classify 90% of headaches 
reported to them as muscle contraction or migraine headaches. No literature suggests that 
headache frequency is different in other regions of the world. A female preponderance exists, 
14-17%, compared with 5-6% in males. All ages are susceptible, but most patients are young 
adults.[65]
• Approximately 60% of headache onset occurs in those older than 20 years.
• Headache onset is unusual in those older than 50 years.
Clinical Features
Pain onset in tension-type headache can have a throbbing quality and is usually more gradual 
than onset in migraines. Compared with migraines, tension-type headaches are more variable 
in duration, more constant in quality, and less severe.[6]
• IHS diagnostic criteria for tension-type headaches states that 2 of the following 
characteristics must be present:
o Pressing or tightening (nonpulsatile quality)
o Frontal-occipital location
o Bilateral - Mild/moderate intensity
o Not aggravated by physical activity
• Tension-type headache history is as follows:
o Duration of 30 minutes to 7 days
o No nausea or vomiting (anorexia may occur)
o Photophobia and/or phonophobia
o Minimum of 10 previous headache episodes; fewer than 180 days per year with 
headache to be considered "infrequent"
o Bilateral and occipitonuchal or bifrontal pain - Pain described as "fullness, 
tightness/squeezing, pressure," or "bandlike/viselike"
o May occur acutely under emotional distress or intense worry & Insomnia, often 
present upon rising or shortly thereafter
o Muscular tightness or stiffness in neck, occipital, and frontal regions
o Duration of more than 5 years in 75% of patients with chronic headaches
o Difficulty concentrating
o No prodrome
Physical examination serves mainly to exclude the possibility of other headache causes.
• Vital signs should be normal.
• Normal neurologic examination
• Tenderness may be elicited in the scalp or neck, but no other positive physical exam 
findings should be noted.
• Pain should not be elicited over temporal arteries or positive trigger zones.
• Some patients with occipital tension headaches may be very tender when upper 
cervical muscles are palpated.
• Pain associated with neck flexion and stretching of paracervical muscles must be 
distinguished from nuchal rigidity associated with meningeal irritation.[66][67][68]
Laboratory Studies
Laboratory work should be unremarkable in cases of tension-type headache. Specific tests 
should  be  obtained  if  the  history  or  physical  examination  suggests  another  diagnostic 
possibility. Head CT scan or MRI is necessary only when the headache pattern has changed 
recently,  the  headache  cannot  be  clearly  defined  by  the  clinician  as  a common  primary 
headache disorder (that is not a cluster, migraine, or tension-type of headache), or neurologic 
examination reveals abnormal findings.[67]
Treatment
Nonsteroidal  anti-inflammatory  drugs  (NSAIDs): These  agents  may  alleviate 
headache pain by inhibiting prostaglandin synthesis, reducing serotonin release, and blocking 
platelet aggregation. Although the effects of NSAIDs in the treatment of headache pain tend 
to be patient specific, ibuprofen is usually the DOC for initial therapy. Other options include 
naproxen, ketoprofen, and ketorolac.[66]
Follow-Up
Physical therapy for patients with headache includes warm and cold packs, ultrasound, and 
electrical stimulation. Regular exercise, stretching, balanced meals, and adequate sleep is 
part of a headache prevention program. Trigger point injections, occipital nerve blocks, or 
changes that improve posture may be used.
Deterrence/Prevention: Deterrence and prevention of headache may include the following: 
Physical therapy, Biofeedback and relaxation therapy, Cervical traction and Injection of trigger 
points. 
Complications: Complications of headache may include the following: Undue reliance on 
nonprescription  caffeine-containing  analgesics,  Dependence  on/addiction  to  narcotic 
analgesics, GI bleed from use of NSAIDs, Risk of epilepsy 4 times greater than that of the 
general population 
Prognosis: Headache may become chronic if life stressors are not changed. Most cases are 
intermittent and do not interfere with work or normal life span.
3. Trigeminal autonomic cephalalgias
Cluster headache, nicknamed "suicide headache", is a neurological disease that involves, 
as its most prominent feature, an immense degree of pain. "Cluster" refers to the tendency of 
these headaches to  occur  periodically,  with  active  periods  interrupted  by  spontaneous 
remissions.[6]. The first complete description of cluster headache was given by the London 
neurologist Wilfred Harris in 1926. He named the disease Migrainous neuralgia [72]. Cluster 
headaches have been called by several other names in the past including Erythroprosopalgia 
of Bing, Ciliary neuralgia, Erythromelagia of the head, Horton's headache (named afterBayard 
T.  Horton,  an  American  neurologist),  Histaminic  cephalalgia,  Petrosal  neuralgia, 
sphenopalatine  neuralgia,  Vidian  neuralgia,  Sluder's  neuralgia,  and  Hemicrania 
angioparalyticia.[73].  It  affects  approximately  0.1% of  the  population,  and  men  are  more 
commonly affected than women. The trigeminal  autonomic cephalalgias share the clinical 
features  of  headache  and  prominent  cranial  parasympathetic  autonomic  features. 
Experimental and human functional imaging suggests that these syndromes activate a normal 
human trigeminal-parasympathetic reflex with clinical signs of cranial sympathetic dysfunction 
being secondary.
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IHS DIAGNOSTIC CRITERIA
3.1 Cluster headache
This entity presents with attacks of severe, strictly unilateral pain which is orbital, supraorbital, 
temporal or in any combination, lasting 15-180 minutes, occurring from once every other day 
to 8 times a day. The attacks are associated with one or more of the following, all of which are 
ipsilateral: conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, forehead and 
facial sweating, miosis, ptosis, eyelid oedema. Most patients are restless or agitated during 
an attack. Diagnostic criteria:
A. At least 5 attacks fulfilling criteria B-D
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain 
lasting 15-180 minutes if untreated
C. Headache is accompanied by at least one of the following: 
1) ipsilateral conjunctival injection and/or lacrimation, 2) ipsilateral nasal congestion 
and/or rhinorrhoea, 3) ipsilateral eyelid oedema, 4) ipsilateral forehead and facial 
sweating, 5) ipsilateral miosis and/or ptosis, 6) a sense of restlessness or agitation
D. Attacks have a frequency from one every other day to 8 per day
E. Not attributed to another disorder
Acute attacks involve activation of the posterior hypothalamic grey matter. Cluster headache 
may be inherited (autosomal dominant) in about 5% of cases. Attacks usually occur in series 
(cluster periods) lasting for weeks or months separated by remission periods usually lasting 
months or years. However, about 10-15% of patients have chronic symptoms without 
remissions. In a large series with good follow-up, 27% of patients had only a single cluster 
period. These should be coded as 3.1Cluster headache. During a cluster period, and in the 
chronic subtype, attacks occur regularly and may be provoked by alcohol, histamine or 
nitroglycerine. Pain is maximal orbital, supraorbital, temporal or in any combination of these 
sites, but may spread to other regions of the head. Pain almost invariably recurs on the same 
side during an individual cluster period. During the worst attacks, the intensity of pain is 
excruciating. Patients are usually unable to lie down and characteristically pace the floor. Age 
at onset is usually 20-40 years. For unknown reasons prevalence is 3-4 times higher in men 
than in women. Cluster headache with coexistent trigeminal neuralgia (cluster-tic syndrome): 
Some patients have been described who have both 3.1Cluster headache and 13.1Trigeminal 
neuralgia. They should receive both diagnoses. The importance of this observation is that 
both conditions must be treated for the patient to be headache free.
3.1.1 Episodic cluster headache: Cluster headache attacks occurring in periods lasting 7 
days to 1 year separated by pain-free periods lasting 1 month or longer. Diagnostic criteria: 
(A) Attacks fulfilling criteria A-E for 3.1Cluster headache. (B) At least two cluster periods 
lasting 7-365 days1 and separated by pain-free remission periods of ≥1 month. 
3.1.2 Chronic cluster headache: Cluster headache attacks occurring for more than 1 year 
without remission or with remissions lasting less than 1 month. Diagnostic criteria: (A) Attacks 
fulfilling criteria A-E for 3.1 Cluster headache, (B) Attacks recur over >1 year without 
remission periods or with remission periods lasting <1 month. Chronic cluster headache may 
arise de novo (previously referred to as primary chronic cluster headache) or evolve from the 
episodic subtype (previously referred to as secondary chronic cluster headache). Some 
patients may switch from chronic to episodic cluster headache.
3.2 Paroxysmal hemicrania: Attacks with similar characteristics of pain and associated 
symptoms and signs to those of cluster headache, but they are shorter-lasting, more frequent, 
occur more commonly in females and respond absolutely to indomethacin. Diagnostic criteria: 
(A) At least 20 attacks fulfilling criteria B-D, (B) Attacks of severe unilateral orbital, 
supraorbital or temporal pain lasting 2-30 minutes, (C) Headache is accompanied by at least 
one of the following: 1. ipsilateral conjunctival injection and/or lacrimation, 2. ipsilateral nasal 
congestion and/or rhinorrhoea, 3. ipsilateral eyelid oedema, 4. ipsilateral forehead and facial 
sweating, 5. ipsilateral miosis and/or ptosis; (D) Attacks have a frequency above 5 per day for 
more than half of the time, although periods with lower frequency may occur; (E) Attacks are 
prevented completely by therapeutic doses of indomethacin (F) Not attributed to another 
disorder. There is no male predominance. Onset is usually in adulthood, although childhood 
cases are reported. Paroxysmal hemicrania with coexistent trigeminal neuralgia (CPH-tic 
syndrome): Patients who fulfil criteria for both 3.2 Paroxysmal hemicrania and 13.1 Trigeminal 
neuralgia should receive both diagnoses. The importance of this observation is that both 
conditions require treatment. The pathophysiological significance of the association is not yet 
clear.
3.2.1 Episodic paroxysmal hemicrania: Attacks of paroxysmal hemicrania occurring in 
periods lasting 7 days to 1 year separated by pain-free periods lasting ≥1 month. Diagnostic 
criteria: (A) Attacks fulfilling criteria A-F for 3.2 Paroxysmal hemicrania (B) At least two attack 
periods lasting 7-365 days and separated by pain-free remission periods of ≥1 month 
3.2.2 Chronic paroxysmal hemicrania (CPH): Attacks of paroxysmal hemicrania occurring 
for >1 year without remission or with remissions lasting <1 month. Diagnostic criteria: (A) 
Attacks fulfilling criteria A-F for 3.2 Paroxysmal hemicrania Attacks recur over >1 year without 
remission periods or with remission periods lasting <1 month
3.3 Short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing (SUNCT): This syndrome is characterised by short-lasting attacks of 
unilateral pain that are much briefer than those seen in any other TAC and very often 
accompanied by prominent lacrimation and redness of the ipsilateral eye. Diagnostic criteria: 
(A) At least 20 attacks fulfilling criteria B-D; (B) Attacks of unilateral orbital, supraorbital or 
temporal stabbing or pulsating pain lasting 5-240 seconds; (C) Pain is accompanied by 
ipsilateral conjunctival injection and lacrimation; (D) Attacks occur with a frequency from 3 to 
200 per day; (E) Not attributed to another disorder.  This syndrome was described after the 
publication of the first edition of The International Classification of Headache Disorders and 
has become well recognised in the last decade. Patients may be seen with only one of 
conjunctival injection or tearing, or other cranial autonomic symptoms such as nasal 
congestion, rhinorrhoea or eyelid oedema may be seen. 3.3 SUNCT may be a subform of 
A3.3 Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic 
symptoms (SUNA), described in the appendix. The literature suggests that the most common 
mimics of 3.3 SUNCT are lesions in the posterior fossa or involving the pituitary gland. 
SUNCT with coexistent trigeminal neuralgia: Patients have been described in whom there is 
an overlap between 3.3 SUNCT and 13.1 Trigeminal neuralgia. Such patients should receive 
both diagnoses. This differentiation is clinically difficult.
3.4 Probable trigeminal autonomic cephalalgia
Headache attacks that are believed to be a subtype of trigeminal autonomic cephalalgia but 
which do not quite meet the diagnostic criteria for any of the subtypes described above. 
Diagnostic criteria: Attacks fulfilling all but one of the specific criteria for one of the subtypes of 
trigeminal autonomic cephalalgia. Not attributed to another disorder. Patients coded as 3.4 
Probable trigeminal autonomic cephalalgia or one of its subforms either have had an 
insufficient number of typical attacks or fail to fulfil one of the other criteria.
3.4.1 Probable cluster headache: Diagnostic criteria: (A) Attacks fulfilling all but one of 
criteria A-D for 3.1 Cluster headache (B) Not attributed to another disorder
3.4.2 Probable paroxysmal hemicrania: Diagnostic criteria: (A) Attacks fulfilling all but one 
of criteria A-E for 3.2 Paroxysmal hemicrania (B) Not attributed to another disorder
3.4.3 Probable short-lasting unilateral neuralgiform headache attacks with 
conjunctival injection and tearing Diagnostic criteria: (A) Attacks fulfilling all but one of 
criteria A-D for 3.3 Short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing (SUNCT) (B) Not attributed to another disorder
Epidemiology
Cluster headaches are diagnosed more often in men. The male-to-female ratio in cluster 
headache ranges from 4:1 to 7:1. It primarily occurs between the ages of 20 to 50 years.
[74] This gap between the sexes has narrowed over the past few decades. Limited 
epidemiological studies have suggested prevalence rates of between 56 and 326 people per 
100,000. Custer headaches, are more common away from the equator towards the poles.[75]
Pathophysiology
Cluster headaches classified as vascular headaches cause intense pain - caused by 
the dilation of blood vessels which creates pressure on the trigeminal nerve. While this 
process is the immediate cause of the pain, the etiology (underlying cause or causes) is not 
fully understood.[42]
Hypothalamic  Abnormality:  Among  the  most  widely  accepted  theories  is  that  cluster 
headaches are due to an abnormality in the hypothalamus; Dr Goadsbys’ theory explains 
why  cluster  headaches  frequently  strike  around  the  same  time  each  day,  and  during  a 
particular  season,  since  one of  the  functions  the  hypothalamus performs is  regulation  of 
the biological clock.[74]  Metabolic abnormalities have also been reported in patients. The 
hypothalamus  is  responsive  to  light  /  day  length  and  photoperiod; olfactory stimuli, 
including  phero-mones ; steroids including sex  steroids and corticosteroids;  neurally 
transmitted information arising in particular from the heart, stomach, reproductive system; 
blood borne  stimuli  including  leptin ghrelin,  angiotensin,  insulin,  pituitary hormones, 
cytokines, blood plasma concentrations of glucose and osmolarity, etc and stress.[76] 
Genetics: There is a genetic component to cluster headaches, although no single gene has 
been identified as the cause. First-degree relatives of sufferers are more likely to have the 
condition than the population at large.[77] However, genetics appears to play a much smaller 
role in cluster headache than in some other types of headaches.
Triggers: Nitroglycerin (glyceryl  trinitrate)  can sometimes induce cluster  headaches in 
sufferers  in  a  manner  similar  to  spontaneous  attacks.  Ingestion  of alcohol,  chocolate, 
exposure  to hydrocarbons (petroleum  solvents,  perfume),  heat,  napping,  nicotine  may 
trigger cluster headaches.[78] 
Neuroimaging
Functional MRI shows brain areas being activated during pain
The  above fMRI pictures  indicate  the  brain  areas  which  are  activated  during  pain  only, 
compared to the pain free periods. These pictures show brain areas which are always active 
during pain in yellow/orange colour (called "pain matrix"). The area in the centre (in all three 
views) is specifically activated during cluster headache only.  The bottom row Voxel-based 
morphometry (VBM)  pictures  show structural  brain  differences  between  cluster  headache 
patients and people without headaches; only a portion of the hypothalamus is different. [79],
[80]
Clinical Features
Cluster headaches are excruciating unilateral headaches,of extreme intensity. The duration of 
the common attack ranges from as short as 15 minutes to three hours or more. The onset of 
an attack is rapid, and most often without the preliminary signs that are characteristic of 
a migraine. However, some sufferers report preliminary sensations of pain in the general area 
of attack, often referred to as "shadows", that may warn them an attack is imminent.[74] 
Though the headaches are almost exclusively unilateral, there are many documented as 
cases of "side-shifting" between cluster periods, or, even rarer, simultaneously (within the 
same cluster period) bilateral headache. They are often initially mistaken for brain tumors 
and multiple sclerosis until patients are treated with corticosteroids and then 
imaged. Trigeminal neuralgia can also bring on headaches with similar qualities. However, 
with Trigeminal neuralgia the pain is mostly located around the "cheek" area and is described 
as being more lance-like in quality. [74]
Pain: The degree of pain involved in cluster headaches is markedly greater than in 
other headache conditions, including severe migraines, and experts believe that it may be the 
most severe pain known to medical science. It  has been described by female patients as 
being more severe than childbirth.[74] The McGill Pain Index can be used to rate levels of 
pain. The pain is lancinating or boring in quality, and is located behind the eye (periorbital) or 
in the temple, sometimes radiating to the neck or shoulder.  Analogies frequently used to 
describe the pain are a red-hot poker inserted into the eye, or a spike penetrating from the top 
of  the  head,  behind  one  eye,  radiating  down  to  the  neck,  or  sometimes  having  a  leg 
amputated without any anaesthetic.  
Cyclical recurrence and regular timing: Cluster headaches are occasionally referred 
to  as  "alarm clock  headaches",  because of  its  ability  to  wake  a  person from sleep,  and 
because of  the regularity of  its  timing in that  both the individual  attacks and the clusters 
themselves can have a metronomic regularity; attacks striking at a precise time of day each 
morning or night is typical, even precisely at the same time a week later. This has prompted 
researchers to speculate an involvement of the brain's "biological clock" or circadian rhythm. 
[6][74]
Other symptoms include ptosis,  conjunctival injection, lacrimation, rhinorrhea, facial 
blushing, swelling and sweating. These features are known autonomic symptoms. The attack 
is also associated with restlessness, aversion to bright lights and loud noise during the attack, 
nausea is comparatively rare. The neck is often stiff or tender with jaw or tooth pain[6][74]. 
Episodic or Chronic Cluster Headache: occur once or more daily, often at the same 
times each day, for a period of several weeks, followed by a headache-free period lasting 
weeks, months, or years. Cluster headaches occurring in two or more cluster periods lasting 
from 7 to 365 days with a pain-free remission of one month or longer between the clusters are 
considered episodic. If the attacks occur for more than a year without a pain-free remission of 
at least one month, the condition is considered chronic. Chronic clusters run continuously 
without any "remission" periods between cycles. The condition may change from chronic to 
episodic  and from episodic  to  chronic.  Remission  periods  lasting  for  decades before  the 
resumption of clusters are known to occur. Cluster headaches often go undiagnosed for many 
years, being confused with migraine or other causes of headache.[6][74] 
Treatment
Medications  to  treat  cluster  headaches  are  classified  as 
either abortives or prophylactics (preventatives).  In  addition,  short-term  transitional 
medications (such as steroids) may be used while prophylactic treatment is instituted and 
adjusted. With abortive treatments often only decreasing the duration of the headache and 
preventing it from reaching its peak rather than eliminating it entirely, preventive treatment is 
always indicated for cluster headaches, to be started at the first sign of a new cluster cycle.
Abortive treatment: During the onset of a cluster headache, some patients respond to rapid 
inhalation of pure oxygen (12-15 litres per minute in a non-rebreathing mask).[81][82] When 
used at the onset this can abort the attack in as little as 1 minute or as long as 10 minutes. 
Once an attack is at its peak, oxygen therapy appears to have little effect so most people 
have an oxygen provider close. Alternative first-line treatment is subcutaneous administration 
of triptan drugs,  like sumatriptan and zolmitriptan. The  injectable  form  of  sumatriptan  has 
been shown to abort a cluster headache within fifteen minutes in 96% of cases. Because of 
the  rapid  onset  of  an  attack,  the  triptan  drugs  are  usually  taken  by subcutaneous 
injection rather  than  by  mouth. Beta  blockers as  a  treatment  has  been  tried.  Recently, 
researchers have linked low testosterone as a possible cause of cluster headaches, which 
can  be  especially  troublesome  since  the  most  effective  pain  medications  for  clusters, 
like morphine,  reduce testosterone levels.  Lidocaine and other  topical  anesthetics sprayed 
into the nasal cavity may relieve or stop the pain, Vaso-constrictors such as ergot compounds 
were also used. Other abortive remedies that work include ice, hot showers, cool or lukewarm 
water  sprayed  on  the  face  around  the  sinus,  temple,  and  ear  areas,  breathing  cold  air, 
caffeine, and drinking large amounts of water in the early stages of an attack.  Hyperbaric 
oxygen therapy has been used successfully in treating cluster headaches though it was not 
shown to be more successful than surface oxygen[82]. 
Prophylactic Treatment:  A wide variety of prophylactic medicines are in use, and patient 
response  to  these  is  highly  variable.  Current  European  guidelines  suggest  the  use  of 
the calcium channel blocker verapamilate a dose of at least 240 mg daily. Steroids, such 
as prednisolone, are also effective, with a high dose given for the first five days or longer 
before  tapering  down. Methysergide, lithium and anticonvulsant topiramate are 
recommended  as  alternative  treatments.  Muscle  relaxants and  atypical anti-
psychotics have also been used. Magnesium supplements have been shown to be of some 
benefit in about 40% of patients. Melatonin has also been demonstrated to bring significant 
improvement  in  approximately half  of  episodic  patients. Other neuropathic  pain  alleviating 
agents such as the Tricyclic antidepressants including Amitriptyline and Nortriptyline can 
also be used [82]. 
Materials and Methods   
The patients registered at the Headache Clinic, Institute of Neurology, Madras Medical 
College. Chennai 600003 during a one year period between the March 2007 and February 
2008 were taken for this study. The clinical material was collected from the records of the 
headache Clinic - OPD case sheets and patient interviews with a detailed pre-prepared 
proforma [Appendix-1]. 
Inclusion Criteria
1. Patients registered at the Headache Clinic, Institute of Neurology, Madras Medical 
College. Chennai 600003 between 1st March 2007 and 28th February 2008
2. Patients in all age groups in both sexes, of any racial and socioeconomic denomination 
and profession were included
3. Patients were followed up for one year from the date of their registration and those who 
completed one year of follow up were included. All headaches were classified 
according to the International Headache Society Criteria 2004.
Exclusion Criteria
1. Patients with systemic, metabolic, traumatic disorders and or radiological findings that 
were documented to be directly or indirectly related to the causation of headache were 
excluded
2. Headache located or transmitted to the Cranium from the Maxillo / Mandibulofacial 
region, pharynx, paranasal sinuses, neck and ear were excluded.
3. Patients with incomplete clinical profiles, diagnostic & treatment records were 
excluded. 
4. Patients who did not complete the one year follow up were excluded.
Evaluation of Results
The clinical presentations, radiological features, laboratory results, neurophysiological 
patterns, treatment and its response on follow up, the progress and complications were 
documented and tabulated in a Master Chart (Appendix-2). The various parameters of the 
patients were compared, classified and analysed with specific reference to national and 
international studies. 
Results                                         
A total of 535 patients registered at the Headache Clinic, Institute of Neurology, Madras Medical 
College & GHH, Chennai between 1st March 2007 and 28th February 2008 were included in the study. 
Of the total of 535 patients, 402 (75.14%) patients had migraine, 35 (6.54%) had tension type 
headache, 11 (2.06%) Trigeminal autonomic cephalagia, 9 (1.68%) had other types of primary 
headaches and 78(14.58%) had mixed tension vascular type of headache. 
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.1 No Type of Primary Headache No of Patients
1 Migraine 402
2 Tension Type Headache 35
3 Trigeminal autonomic cephalalgia 11
4 Other Primary headaches 9
5 Mixed Tension Vascular Headache 78
 TOTAL NO CASES 535
Types of Headache
MIGRAINE 75.14%
TTH
6.54%
TAC 2.06% OTHERS 1.68%
MIXED HA 14.58%
Fig A
I. Classification of Headaches
Of the 402 case of Migraine,192 (47.68%) patients had Migraine without Aura, 38 (9.53%) patients 
had Migraine with Aura, 92(23.09%) patients had Migraine which presented with & without aura, 
70(17.37%) patients had complications of migraine and 10(2.48%) patients had probable migraine. 
Our study did not include patients with Childhood Periodic Syndromes & Retinal Migraine. The 92 
patients who had Migraine which presented with & without aura were considered as a separate group. 
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.2 No Type of Migraine IHS Code No of Patients
1 Migraine without Aura 1.1 192
2 Migraine with Aura 1.2 38
3 Migraine with and without aura                 1.1 / 1.2 92
4 Childhood Periodic Syndromes 1.3 0
5 Retinal Migraine 1.4 0
6 Complications of Migraine 1.5 70
7 Probable Migraine 1.6 10
 TOTAL 402
MIGRAINE
1
2
3
4
5
Of the patients Migraine with Aura (38 patients) the predominant subtype was Typical Aura with 
Headache (18 patients). Our study also included 5 patients of Typical Aura with Non Migraine HA, 3 
patients with Typical Aura without Headache and 12 patients with Basilar Type Migraine. Our study 
group did not include patients with Familial Hemiplegic Migraine and Sporadic Hemiplegic Migraine. 
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Fig B
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No Type of Migraine with Aura
IHS 
Code
No of Patients with 
Migraine with Aura
1 Typical Aura with Headache 1.2.1 18
2 Typical Aura with Non Migraine HA 1.2.2 5
3 Typical Aura without Headache 1.2.3 3
4 Familial Hemiplegic Migraine 1.2.4 0
5 Sporadic Hemiplegic Migraine 1.2.5 0
6 Basilar Type Migraine 1.2.6 12
 TOTAL  38
MIGRAINE WITH AURA
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Of the 70 patients with complications of migraine, 46 patients had Chronic Migraine (9 patients with 
Chronic Migraine since Onset & 37 patients with Episodic Headache converting to Migraine), 5 
patients had Migrainous Infarction (Cerebellar Infarction -3 & Right Occipital Infarction -2) and 19 
patients had Migraine Trigerred Seizures (Migraine Terminating as Seizures – 14, Migralepsy - 5). No 
patients with Status Migrainous or Persistent Aura without Infarction were included in the study.
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.4 No Type of 
Complications of 
Migraine 
IHS 
Code
Sub Types No of 
Patients
Total No 
of 
Patients
1 Chronic Migraine 1.5.1 Chronic Migraine since Onset 9
Episodic Headache converting to 
Migraine 37
46
2 Status Migrainosus 1.5.2
0
3 Persistent Aura 
without Infarction
1.5.3
0
4 Migrainous Infarction 1.5.4 Cerebellar Infarction 3
Right Occipital Infarction 2
5
5 Migraine Triggered 
Seizures
1.5.5 Migraine Terminating as Seizures 14
Migralepsy 5
19
 TOTAL  70
In our study, we came across 61 patients with Migraine & Seizures, 19 patients had Migraine 
Triggered Seizures, 20 patients had Post ictal migrainous headache and 22 patients had Migraine & 
Coexistent Seizure. Of the 19 patients who had migraine triggered seizures 14 patients had migraine 
terminating as seizures and 5 patients had Migralepsy.
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.5 No Migraine & Seizures No of Patients
1 Migraine Triggered Seizures 19
2 Post Ictal Migrainous Headache 20
3 Migraine & Coexistent Seizure 22
Our study also included 5 patients with  Ophthalmoplegic Migraine of which 4 had Abducent Nerve 
palsy and 1 patient had Oculomotor Nerve palsy.
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.6 No Migrainous Ophthalmoplegia No of Patients
1 Abducent Nerve Palsy 4
2 Oculomotor Nerve Palsy 1
Out of a total of 535 patients registered at the Headache Clinic, 35 (6.54%) had tension type 
headache, of which 5 patients had Infrequent Episodic TTH, 7 patients had Frequent Episodic TTH, 19 
patients had Chronic TTH, and 4 patients had Probable TTH. 
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.7 No Type of TTH IHS Code No of Patients
1 Infrequent Episodic TTH 2.1 5
2 Frequent Episodic TTH 2.2 7
3 Chronic TTH 2.3 19
4 Probable TTH 2.4 4
 TOTAL 35
Out of a total of 535 patients registered at the Headache Clinic 11 (2.06%) had Trigeminal autonomic 
cephalagia of which 5 patients had Cluster Headache, 4 patients had Paroxysmal hemicrania, 2 
patients had Short Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing. 
No case of Probable TAC was registered.
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No Type of Trigeminal Autonomic Cephalalgia
IHS 
Code
No of 
Patients
1 Cluster Headache 3.1 5
2 Paroxysmal hemicrania 3.2 4
3 SUNCT 3.3 2
4 Probable TAC 3.4 0
TOTAL 11
Of the 5 patients who had Cluster Headache 3 were classified as Episodic Cluster Headache and 2 as 
Chronic Cluster Headache. Of the 4 patients who had Paroxysmal Hemicrania, 2 were classified as 
Episodic Paroxysmal Hemicrania and 2 as Chronic Paroxysmal Hemicrania. 
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.9 No Type of Cluster Headache IHS Code No of Patients
1 Episodic Cluster Headache 3.1.1 3
2 Chronic Cluster Headache 3.1.2 2
TOTAL 5
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0 No Type of TAC IHS Code No of Patients
1 Episodic Paroxysmal Hemicrania 3.2.1 2
2 Chronic Paroxysmal Hemicrania 3.2.2 2
TOTAL 4
Primary headaches were few among the  registered patients at the Headache Clinic. 9(1.68%) 
patients had  primary headaches, of which 2 patients had Primary Stabbing Headache, 1 patient had 
Primary Headache associated with Sexual Activity, 1 patient had Primary hypnic Headache, and 5 
patients had New Daily Persistent Headache.
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1 No Other Primary Headaches IHS Code No of Patients
1 Primary Stabbing Headache 4.1 2
2 Primary Cough Headache 4.2 0
3 Primary Exertional Headache 4.3 0
4 Primary Headache ass with Sexual Activity 4.4 1
5 Primary Hypnic Headache 4.5 1
6 Primary Thunderclap Headache 4.6 0
7 Hemicrania Continuua 4.7 0
8 New Daily Persistent Headache 4.8 5
TOTAL 9
2. Epidemiological Data
The patients were analysed for [1] Age Distribution:
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2 No Age Group No of Patients 
with Migraine
No of Patients 
with TTH
No of Patients with 
Mixed Tension 
Vascular Headache
No of Patients 
with TAC
1 0-10yrs 9 0 0 0
2 11-20yrs 161 2 0 0
3 21-30yrs 129 8 0 2
4 31-40yrs 75 11 41 8
5 41-50yrs 17 12 29 1
6 51 + yrs 11 2 8 0
 Migraine was most common in the 2nd and 3rd decades , 290 out of 402 patients were between 
11-30years of age (11-20yrs - 161 patients, 21-30yrs – 129 patients, 31-40yrs – 75patients). Majority 
of the patients (23 out of 35 patients) with  Tension type headache were in the 4th and 5th decade of life 
(21-30yrs - 8 patients, 31-40yrs – 11 patients, 41-50yrs – 12patients).   Tension vascular type of 
headache matched the tension type headache in age distribution, being more common in 4th and 5th 
decade of life. Trigeminal Autonomic Cephalalgia was more common between 31-40years of age - 8 
patients.
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In patients with migraine triggered seizures of the total 19, 10 patients were in the age group of 
11-20years. Basilar migraine was also found to be common in the age group of 11-20years(9 out of 12 
patients). Patients with migrainous stroke were between 21-40years of age and  Chronic migraine was 
noticed in 4th and 5th decade of life predominantly. 
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3 No Age Group No of Patients 
1 0-10yrs 1
2 11-20yrs 10
3 21-30yrs 5
4 31-40yrs 3
5 41-50yrs 0
6 51 + yrs 0
[2] Gender Distribution: The patients analysed for gender distribution. Female patients dominated in 
the category of migraine 299 of the 402 patients, in tension headache 26 of the 35 patients and  in 
tension vascular headache 57 of 78 patients, while in trigeminal autonomic cephalalgia 9 of the 11 
patients were male.
Fig D
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4 No Sex Distribution Migraine TTH Mixed TVH TAC
1 Male 103 9 21 9
2 Female 299 26 57 2
 
Complications of migraine was more common in female patients as evidenced by all the five patients 
with migrainous stroke were females. Out of the 19 patients with migraine triggered seizures 12 were 
female and 7 were male. Chronic migraine was predominantly seen in females (30 out of 46 patients).
[3] Family Predilection: A detailed clinical history as recorded with the proforma in appendix -1 was 
analysed for the various clinical parameters in each case. Family history was positive in 229 patients 
(56.96%) with migraine, 11 patients (31.43%) with tension headache, 51 patients (65.38%) with 
tension vascular headache and none with TAC.    
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5 No Family 
History
Migraine TTH Mixed TVH TAC
1 Positive F.H 229 11 51 0
2 Negative. F.H 173 24 27 11
3. Clinical Presentations
A] Presentation: 
1. Migraine: Headache in patients with migraine, 313 presented with unilateral headache, of which 
208 patients experienced shift of sides while 105 patients had always  a unilateral headache. Most of 
the episodes of migrainous headache  in our patients lasted more than 12 hours [141 patients]. The 
migrainous headaches were predominantly temporal (233 patients). Most of the patients experienced 
a throbbing type of headache (271 patients).
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6 No Duration Migraine TTH Mixed TVH TAC
1 1-6 hours 56 5 0 9
2 6-12 hours 92 10 9 2
3 12-24hours 141 18 35 -
4 More than 24 hours 113 2 34 -
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7 No Location Migraine TTH TAC
1 Unilateral 313 4 9
Unilateral with shifting sides 208 - -
Same Unilateral side 105 - -
2 Bilateral 89 31 2
2. Tension Type Headache: In patients with TTH 18 presented with headache of more than 12hours 
duration, while 10 patients had duration of 6-12 hours and 5 patients had duration of 1-6hours. The 
headache was holocranial in 31 of the 35 patients while it was hemicranial in the other 4 patients. 31 
of these patients who experienced bilateral headaches had headaches confined to the frontal region. 
Most of the patients experienced aching type of headache (23 patients), while it was band like in 11 
patients and throbbing in 6 patients. In most of these patients the headache radiated to nuchal region 
and there was an associated scalp tenderness during the episodes of headache. 
3. Tension Vascular Headache: Of the 78 patients diagnosed most patients had a duration of more 
than 12 hours(69 patients). 62 patients had a earlier diagnosis of Migraine without Aura whose 
frequency of episodes increased over a period of few years to chronic migraine / transformed migraine 
(more than 15 episodes per month) which progressed to bilateral holocranial headache. The character 
of headache changed from the typical throbbing nature to diffuse aching pain at times band like pain 
with radiation to the neck. As the headache gets transformed patients experience fewer associated 
symptoms of migraine.
4. Trigeminal Autonomic Cephalalgia: In patients with Trigeminal Autonomic Cephalagia 9 
presented with headache of less than 6 hours duration, while 2 patients had a duration of 6-12 hours. 
2 of the patients experienced bilateral headaches while 9 had unilateral headaches with most (9 
patients) confined to the frontal temporal region and was aching in character.
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8 No Location Migraine TTH TAC
1 Frontal 95 19 0
2 Temporal 233 8 0
3 Occipital 47 5 0
4 Parietal 27 3 2
5 Fronto Temporal 0 0 9
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No Type of Headache Migraine
TTH Mixed 
TVH
TAC
1 Throbbing 271 6 12 2
2 Pricking 56 3 1 1
3 Aching 47 23 16 8
4 Band Like 0 11 24 0
5 Diffuse Dull Ache 13 0 25 0
6 Burning 15 0 0 0
B] Symptoms, Aggravating and Relieving Factors: 
1. Migraine: The predominant premonitary symptom was yawning (98patients), followed by fatigue, 
irritability, sense of feeling low and over eating in few patients. Associated symptoms in order 
occurrence being photophobia, phonophobia, blurring of vision, nausea, vomiting and giddiness.  Loss 
of consciousness was reported in 49 patients and ipsilateral pain in limbs in 45 patients. Autonomic 
symptoms like lacrimation, redness and transient syncope were reported in few patients. The most 
common aggravating factor in our study group was mental stress, while physical stress, head bath, 
bright sunlight, lack of sleep, travel and consumption of chocolates were also commonly reported. 
Head bath as an aggravating factor has been observed in 267 patients. The relieving factors were 
mostly rest and analgesics or topical applications and sleep. 
Temporal
Occipital Parietal Frontal
Fig E
Location of Migrainous Headaches
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0 No Premonitary Symptoms Migraine TTH TAC
1 Yawning 98 1 -
2 Fatigue 57 14 -
3 Irritability 39 19 4
4 Feeling low 20 1 -
5 Over Eating 22 0 -
2. Tension Type Headache: The predominant premonitary symptom was  feeling low. Associated 
symptoms being phonophobia (27 patients) or photophobia,  nausea or vomiting and in few patients 
paresthesia and giddiness.  The most common aggravating factor in our study group was mental 
stress, while physical stress, travel, head bath and lack of sleep were also commonly reported. The 
relieving factors were mostly rest and analgesics or topical applications, pressure and coffee / tea 
ingestion. 
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No
Associated 
Symptoms Migraine TTH MixedTVH TAC
1 Blurring of Vision 372 0 5 4
2 Photophobia 395 8 33 9
3 Phonophobia 398 27 12 9
4 Nausea 373 19 42 10
5 Vomiting 128 5 10 10
6 Giddiness 148 7 3 0
7 Lacrimation 27 1 0 11
8 Paresthesia 34 10 9 0
9 Tremulousness 38 0 0 0
10 Transient LOC 49 0 0 0
11 Confusion 19 0 0 0
12 Redness of Eyes 16 0 0 11
13 Pain ipsilateral limbs 45 0 0 0
14 Drooping of eyelids 0 0 0 7
15 Nasal Stuffiness 0 0 0 9
3.   Tension Vascular Headache: The predominant associated symptoms were nausea (42 patients), 
with photophobia (33 patients), phonophobia (12 patients), paraesthesia (9 patients), giddiness (3 
patients)  in order of occurrence.  The most common aggravating factor in our study group was mental 
stress, while physical stress, travel, head bath and lack of sleep were also commonly reported. The 
relieving factors were mostly analgesics, rest, sleep, pressure and coffee / tea ingestion. Of these 3 
patients who were on multiple analgesics prescribed, responded on withdrawal of drugs.  
4. Trigeminal Autonomic Cephalagia: The predominant associated symptom was nausea and 
vomiting (10 patients), with redness of eyes, nasal stuffiness, phonophobia, photophobia, drooping of 
eyelids and blurring of vision the other common associated symptoms in order of occurence. 
Aggravating factors were not reported in most patients in this study though alcohol intake, sunlight and 
lack of sleep were reported. The relieving factors were mostly  analgesics or topical applications, 
pressure and coffee / tea ingestion. 
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2 No Aggravating Factors Migraine TTH MixedTVH TAC
1 Head Bath 267 15 18 0
2 Physical Stress 281 22 21 0
3 Mental Stress 367 25 47 0
4 Sunlight 241 12 31 1
5 Travel 193 18 11 0
6 Lack of Sleep 235 19 22 2
7 Perfumes 53 0 0 0
8 Petrol/Diesel Smell 22 0 0 0
9 Concentrated Reading 44 4 8 0
10 Chocolates 192 0 18 0
11 Cold Food/Drink 176 0 10 0
12 Close Rooms - Theatre/Auditorium 48 8 18 0
13 Alcohol Intake 0 0 0 3
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3 No Releiving Factors Migraine TTH Mixed TVH TAC
1 Rest & Analgesics 398 37 26 0
2 Rest & Topical Applications 112 14 4 8
3 Sleep 356 11 14 1
4 Rest 65 6 9 1
6 Local Pressure 0 26 5 6
7 Coffee / Tea 2 16 7 1
8 Analgesic Abstinence 0 0 3 0
C] Aura: 
The preponderant type of aura reported in our migranous patients was visual aura in 113 patients 
while sensory aura was reported in 32 patients and both in 9 patients. The visual aura was 
predominantly in the form of flickering of lights in 67 patients, while zig-zag lines, scintillating scotomas 
and fortification spectra was noted in 22 patients, 16 patients and 8 patients respectively. The sensory 
aura seen was commonly in the form of paresthesia (27 patients). In patients with migraine triggered 
seizures of the total 19 patients, 14 patients had visual aura. 
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4 No Aura No of Patients Type of Aura
1 Visual Aura 113 Fortification Spectra 8
Scintillating Scotoma 16
Flickering Lights 67
Zig Zag Lines 22
2 Sensory Aura 32 Paresthesia 27
Numbness 5
3 Visual & Sensory aura 9
D] Migraine Triggered Seizures:
Of the 19 patients who had Migraine Triggered Seizures 14 patients had Migraine Terminating as 
Seizures and 5 patients had Migralepsy. On analysing the seizure pattern of these 19 patients,  9 
patients had GTCS, 5 patients had CPS and 5 patients presented with prolonged LOC of more tha 20 
minutes, suggesting a generalised seizure rather than an associated autonomic dysfunction.
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5 No Migraine Triggered Seizures No of Patients
1 GTCS 9
2 CPS 5
3 Prolonged LOC 5
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6 No M T Seizures & Aura No of Patients 
1 Without Aura 5
2 With Visual Aura* 14
*Aura was colourless, unformed flickering of light and scintillating scotomas of longer duration
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7 No Time between Migraine & onset of seizure No of Patients
1 2-3hrs 5
2 3-6 hrs 8
3 6-12 hrs 4
4 >12 hrs 2
E. Associated Conditions: 
1. Migraine: In our study of 402 patients with migraine the following clinical conditions were seen 
associated – namely Healed granulomatous lesions on CT, Seizures, Hypertension, Head Injury, 
Sinusitis, Psychiatric Changes and Stroke
2. Tension Type Headache: In our study of 35 patients with TTH the following clinical conditions were 
seen associated – namely healed granulomatous lesions in CT, Hypertension and Head Injury.
3. Tension Vascular Headache: In our study of 78 patients with TVH, 15 patients had associated 
mental depression.   
4. Trigeminal Autonomic Cephalagia:In our study of 11 patients with TAC, no significant clinical 
conditions were associated.
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8 No Clinical Diagnosis Migraine TTH MIxedTVH TAC
1 Seizures 61 0 0 0
2 Granulomatous Diseses 72 12 0 0
3 Stroke 9 0 0 0
4 Head Injury 23 12 0 0
5 Hypertension 32 15 0 0
6 Sinusitis 23 0 0 0
7 Transient Global Amnesia 2 0 0 0
8 Psychiatric Changes 10 3 15 0
4. Diagnostic Tests
1. Electrophysiology: 
Migraine: EEG was taken in 54 of the 402 patients with migraine. 28 of the 54 patients showed 
non specific slowing in posterior region, while 5 patients showed spikes and sharp waves in 
occipital region. Spikes not altered by eye opening. 21 of the 54 patients had no specific changes.
(b) Migraine Triggered Seizures: EEG was taken in all the 19 patients with Migraine Triggered 
Seizures. Changes were seen in 10 out of 19 pts, 6 patients had spikes in posterior head region. 
Spikes and sharp waves during visual aura showed waxing and waning separated by completely 
normal EEG activity despite the persistence of symptomsand these spikes were not altered by eye 
opening. 4 pts had non specific slowing. 
(c) Tension Type Headache: EEG was taken in 12 of the 35 patients with TTH, 2 of these patients 
showed non specific slowing in posterior region, while 10 of the patients had no specific changes
(d) Trigeminal Autonomic Cephalagia: EEG was taken in 4 of the 11 patients with TAC and none 
showed  specific changes. 
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9 No Migraine -EEG Migraine TTH
1 No Changes 21 10
2 Non Specific Slowing in Posterior Region 28 2
3 Spikes & Sharp Waves in Occipital Region 5 0
2. Autonomic Function Tests:  A case control age matched study of heart rate variability was done 
in 17 patients with migraine. The values as depicted in tables 4.30 and 4.31 for controls and patients 
respectively represent (1) Heart Rate /minute in resting state (2) Resting Systolic BP (3) Resting 
Diastolic BP (4) LF - Low Frequency Heart Rate Variation (5) High Frequency Heart Rate Variation (6) 
LF/HF ratio (7) Mean Heart Rate (8) Mean RR Interval. 
Low Frequency Heart Rate Variation (LF): A mean control value of 40.34 and a mean test value for 
migraineurs of 37.4 with a SD (5.83) p value of 0.2837. Hence concluded that there is no significance.
High Frequency Heart Rate Variation (HF): A mean control value of 59.93 and a mean test value for 
migraineurs of 62.60 with a SD (11.18), p value of 0.620. Hence concluded that there is no 
significance. 
LF/ HF Ratio: A mean control value of 0.706 and a mean test value for migraineurs of 0.709 with a SD 
(0.411), p value of 0.975. Hence concluded that there is no significance.
Mean Heart Rate: A mean control value of 74.0 and a mean test value for migraineurs of 76.20 with a 
SD (8.64), p value of 0.0327. Hence concluded that this value shows significant difference between 
the control and test.
Mean RR Interval: A mean control value of 0.813 and a mean test value for migraineurs of 0.842 with 
a SD (0.124), p value of 0.738. Hence concluded that there is no significance.
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CONTROL
S.NO. AGE GENDER
HR-/min 
RESTING
SBP-
mmHg 
RESTING
DBP-
mmHg 
RESTING LF HF LF/HF
MEAN 
HR
MEAN 
RR
C1 30 F 73 116 76 38.60 61.40 0.630 79.00 0.765
C2 42 F 81 114 68 35.70 64.30 0.560 66.00 0.912
C3 18 F 68 124 76 38.80 61.20 0.640 62.00 0.961
C4 25 F 79 110 70 35.50 64.50 0.550 66.00 0.912
C5 21 F 80 124 76 38.50 61.50 0.630 79.00 0.756
C6 15 F 78 120 80 36.20 68.30 0.682 74.00 0.812
C7 43 F 79 122 78 38.30 61.70 0.620 62.00 0.959
C8 27 F 81 124 84 35.40 64.60 0.560 70.00 0.912
C9 35 F 81 124 80 42.30 57.70 0.750 69.00 0.757
C10 19 F 78 120 76 35.80 64.20 0.560 74.00 0.813
C11 27 F 79 118 60 41.80 58.20 0.720 69.00 0.887
C12 19 F 80 120 78 38.70 61.30 0.630 62.00 0.960
C13 40 M 74 116 78 42.30 57.70 0.733 79.00 0.757
C14 25 M 82 120 84 54.90 45.10 1.220 70.00 0.890
C15 47 M 82 120 80 54.80 45.20 1.210 62.00 0.890
C16 19 M 81 124 80 42.30 57.70 0.750 69.00 0.757
C17 20 F 78 120 76 35.80 64.20 0.560 74.00 0.813
   78.47059 119.7647 76.47059 40.33529 59.92941 0.706176 69.76471 0.853706
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PATIENTS WITH MIGRAINE
S.NO. AGE GENDER
HR-/min 
RESTING
SBP
-mmHg 
RESTING
DBP
-mmHg 
RESTING LF HF LF/HF
MEAN 
HR
MEAN 
RR
P1 32 F 62 110 78 36.50 63.50 0.575 57.83 1.224
P2 45 F 95 130 90 27.90 72.10 0.387 68.33 1.130
P3 16 F 80 120 80 43.80 56.20 0.779 84.00 0.715
P4 23 M 85 120 70 15.70 84.30 0.186 73.46 0.839
P5 21 F 96 120 70 44.80 55.20 0.812 92.82 0.652
P6 13 M 72 90 70 20.60 79.40 0.259 71.01 0.859
P7 41 F 68 108 70 17.50 82.50 0.212 63.23 0.951
P8 24 F 65 100 70 39.60 60.40 0.656 75.31 0.901
P9 34 F 78 100 70 39.60 60.40 0.656 83.16 0.723
P10 16 M 80 100 70 37.90 62.10 0.610 79.51 0.759
P11 27 F 85 110 70 36.90 63.10 0.585 84.04 0.716
P12 18 F 70 90 60 17.70 82.30 0.215 68.37 0.880
P13 41 F 80 120 70 34.70 65.30 0.531 78.67 0.763
P14 24 F 92 120 80 72.00 28.00 2.571 91.72 0.655
P15 48 F 92 120 80 51.00 49.00 1.041 83.65 0.720
P16 17 F 72 90 60 49.40 50.60 0.976 66.08 0.980
P17 21 M 74 140 80 50.20 49.80 1.008 71.12 0.846
79.17647 111.0588 72.82353 37.40 62.60 0.709 76.02 0.842
3. CT Scan:  
(a) Migraine: CT scan of Brain was taken in all of the 402 patients, of whom 83 had 
changes. The most common change reported in CT scan brain was calcified granulomas in 69 
patients, gliosis in 8 patients and basal ganglia calcification in 6 patients. CT scan of the para-
nasal sinuses was performed in 53 patients of which 18 showed maxillary sinusitis while it was 
normal in 35 patients. CT scan Brain was taken in all the 19 patients with Migraine trigerred 
seizures, was found to be  normal in all patients. 
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2 No Migraine Neuro Imaging - CT Brain No of Patients
1 Normal 319
2 Abnormal 83
 Total 402
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3 No CT Brain In Migraine No of Patients
1 Calcified Granuloma 69
2 Gliosis 8
3 Basal Ganglia Calcification 6
TOTAL 83
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4 No CT Paranasal Sinues in Migraine No of Patients
1 Normal 35
2 Chronic Maxillary Sinusitis 18
TOTAL 53
(b) Tension Type Headache: CT scan of brain was taken in all of the 35 patients, of 
whom 15 had changes. The most common change reported in CT scan brain was calcified 
granulomas in 12 patients and gliosis in 3 patients.. 
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5 No CT Brain in TTH No of Patients
1 Normal 20
2 Calcified Granuloma 12
3 Gliosis 3
(c) Trigeminal Autonomic Cephalagia: CT scan of brain was taken in all of the 11 
patients with none showing abnormality.
5. Prophylaxis
1. Migraine: The patients with migraine were given prophylactic therapy with either 
Propronolal (20-160mg), or Amitryptylline(12.5-50mg), or Propronolal (20-160mg) and Amitryptylline 
(12.5-50mg), or Flunarizine(5mg), or Topiramate(50mg), or Sodium Valproate ER(500mg). 
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6 No Drugs Patients
1 Propronolal(20-160mg) 99
2 Amitryptylline(12.5-50mg) 51
3 Propronolal (20-160mg)+ Amitryptylline (12.5-50mg) 215
4 Flunarizine(5mg) 27
5 Topiramate(50mg) 5
6 Sodium Valproate ER(500mg) 5
 TOTAL 402
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7 No Migraine No of 
Patients
Disease Free period
>1 
Year
6Months-
1year
Less 
than 
6month
s
Decreased 
Intensity & 
Frequency 
of Pain
No 
Response
1 Propronolal(20-160mg) 99
15 42 18 24 -
2
Amitryptylline(12.5-50m
g) 51
9 13 10 13 6
3 Propronolal (20-160mg)
+ Amitryptylline 
(12.5-50mg)
215 37 66 68 44 -
4 Flunarizine(5mg) 27
9 8 6 4 -
5 Topiramate(50mg) 5
- - 3 2 -
6
Sodium Valproate 
ER(500mg)
5 - 2 - 2 1
2. Migraine Triggered Seizures: All patients were treated with anti migrainous prophylaxis with 
T.Propronolal (40-120mg) or T.Flunarizine (5-10mg) and analgesics during episodes of headache. T. 
Sodium valproate (600mg) was given to patients who had seizures on follow up. Follow up period was 
1 year. Of the 19 patients 16 patients had 1 year incident free period, while 3 patients had seizure 
attacks in between which were treated with Sodium valproate (600mg).
3. Tension Type Headache: All patients were treated with Amitryptiline (10-50mgms). Of the 
35 patients 3 patients responded with a disease free interval of 1year, 9 patients with a disease free 
interval of 6 months to 1 year, 9 patients with a disease free interval of less than 6months, 11 patients 
responded with decreased intensity and frequency of episodes while 3 patients did not show any 
response. 
3. Tension Vascular Headache: All 78 patients were treated with Amitryptiline (10-50mgms) 
and Propronolol (40-160mgms). Of the 78 patients 63 patients responded with decreased intensity 
and frequency of episodes while 15 patients did not show any response.
4. Trigeminal Autonomic Cephalagia: All patients who presented with acute pain were 
treated with analgesics (Naproxen 50mgms, Ibuprofen 400mgms, indomethacin 25-75mgms, or 
occasionally steroids). Prophylaxis was provided for 11patients of which 8 were given Amitryptiline 
(25-50mgms), 3 patients were given Propranolol (80-120mgms). Of the 8 patients given Amitryptiline 7 
patients responded with a disease free interval of 1year, 1 patient with a disease free interval of 6 
months to 1 year. Of the 3 patients given Propranolol all 3 patients responded with a disease free 
interval of 1year. 
Discussion                    
This study at the Headache Clinic of the Institute of Neurology, Madras Medical College & 
GGH, Chennai between 1st March 2007 and 28th February 2008, encompassed a period of 
one year. 
I DEMOGRAPHY OF PRIMARY HEADACHES:
I. INCIDENCE: Of the 535 patients of primary headaches included in this study 402 (75.14%) 
patients had migraine, 35 (6.54%) had tension type headache, 11 (2.06%) had Trigeminal 
autonomic cephalalgia, 9 (1.68%) had other types of primary headaches and 78(14.58%) had 
mixed tension vascular type of headache. This profile of headaches in our study was is in 
inverse correlation with many international studies. [Lipton et al 2002].[83] Tension type 
headaches are considered the most common form of headache in the general population with 
a prevalance of nearly 80% while the prevalance of migraine is pegged at 16% in various 
international studies. In contrast, migraine is a more common form of headache reported in 
clinical practice. This variance is attributed to self treatment of tension type headaches by the 
general population. This variation reported in our study correlates with the study of Lance and 
Curran [1964] [84]
In our study, 78 patients were observed to present with features of tension headache 
and later had features of migraine. This substantial group of patients, who conformed to the 
diagnostic criteria of more than one type of headache have been grouped under a common 
head “mixed or overlap headaches” - tension vascular headache.  This observation of ours is 
in consonance with the observations of Lance and Curran [1964].[84] 
A. Incidence of Migraine: In our study of the 402 cases of Migraine, 192 (47.68%) 
patients had Migraine without Aura, 38 (9.53%) patients had Migraine with Aura, 92(23.09%) 
patients had Migraine which presented with and without aura, 70(17.37%) patients had 
complications of migraine and 10(2.48%) patients had probable migraine. The ratio of 
Migraine without Aura and Migraine with Aura in our study is calculated approximately at 5:1 
which correlates with international studies [Allan H Ropper 2005].[85].However the ratio 
narrows down to 1.5:1 if migraine without aura is compared against migraine with and without 
aura.  Our study did not include patients with Childhood Periodic Syndromes & Retinal 
Migraine. This is attributable to the existence of independent Institutes for Children and Eye 
Diseases within close reach of our institute. In our study of the 402 cases of Migraine, 92 
(23.09%) patients had Migraine which presented with or without aura. These 92 patients were 
placed as a separate group. This group of patients have has been identified and given 
particular mention in the ICHD 2004 classification. “Many patients who have frequent attacks 
with aura also have attacks without aura (code as 1.2 Migraine with aura and 1.1 Migraine 
without aura).” [86]. Yet, the world literature lacks specific references of this group of cases, 
their epidemiological significance, clinical behaviour and therapeutic importance. Similarly the 
ICHD-2 lacks any specific guidelines about the statistical placement of this group of cases. 
Hence, in our study we have placed this group of patients as a separate sub entity within the 
entity migraine. A detailed study of the epidemiology significance, clinical and therapeutic 
behaviour of these patients is needed.
B. Incidence of Tension Type Headaches: In this study of 535 headache patients 35 
(6.54%) had tension type headache, of which 5 patients had Infrequent Episodic TTH, 7 
patients had Frequent Episodic TTH, 19 patients had Chronic TTH, and 4 patients had 
Probable TTH. The prevalence of Tension type headache was 40.5% in epidemiological 
studies by Schwartz et al (1998)[87]. This study also included 3 patients of TTH with chronic 
drug overuse who have been classified under tension vascular headache. 
C. Incidence of Trigeminal Autonomic Cephalagias: Out of a total of 535 patients 
registered at the Headache Clinic 11 (2.06%) had Trigeminal autonomic cephalalgia of which 
5 patients had Cluster Headache, 4 patients had Paroxysmal hemicrania, 2 patients had 
Short Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing. No 
case of Probable TAC was registered. 
In this study the incidence of cluster headache is 1% in contrast to the observation 
made, that cluster headache appears to be less common in India than in the west [Ambar 
Chakravarthy et al 2004][88]. The prevalence of cluster headache estimated in U.S is around 
0.1%. 
A total of 535 patients registered at the Headache Clinic 9 (1.68%) had other types of 
primary headaches of which 2 patients had Primary Stabbing Headache, 1 patient had 
Primary Headache associated with Sexual Activity, 1 patient had Primary Hypnic Headache, 
and 5 patients had New Daily Persistent Headache
II. AGE AND GENDER DISTRIBUTION - A. Age Distribution: 
(i) Migraine: Of the 402 patients having migraine most of them were between 
11-40years of age (11-20yrs - 161 patients, 21-30yrs – 129 patients, 31-40yrs – 75patients).In 
this study Migraine with aura peaked around 13-15 years of age in males(6 out of 11) and 
around 22-25 years in females(15 out of 27). The onset and peaking in both male and female 
patients in this study is 8-10 years delayed in contrast to that observed  in western population 
by  Stewart et al [1991]. According to him  the incidence of migraine with aura in females 
peaked between ages 12 and 13 (14.1/1000 person-years);  and  in males, migraine with aura 
peaked in incidence several years earlier, around 5 years of age at 6.6/1000 person-years. 
Before puberty, migraine prevalence is higher in boys than in girls. The peak incidence of 
basilar migraine in this study was around 10-15 years which correlates with the international 
literature.  As adolescence approaches, incidence and prevalence increase more rapidly in 
girls than in boys. The prevalence increases throughout childhood and early adult life until 
approximately age 40, after which it declines [Stewart WF et al 1991][89]. If the migraine 
headaches persist beyond 40 years of age there is more chance for transformation into 
chronic migraine. Transformation is proportional  is proportional to the chronicity of headache 
with early onset in teens. 
(ii) Tension Type Headache: Of the 35 patients having Tension type headache most 
of them were between 31-50years of age (23 out of 35 patients, 31-40yrs – 11 patients, 
41-50yrs – 12patients). The average age of onset of TTH is higher than in migraine in this 
study, namely 25 to 30 years. The prevalence peaks between ages 30 to 39 and decreases 
slightly with age [Rasmussen BK 1995][90]. Of the 78 patients who had features of mixed 
tension vascular type of headache 41 patients were between 31-40 years of age. 
(iii) Trigeminal Autonomic Cephalagias: Of the 11patients having cluster headache 
most of them (8 out of 11 patients) were between 31-40years, which correlates with the 
observation by Bohra et al.2002[91]
B. Gender Distribution: The patients analysed for gender distribution.  in tension headache 
26 of the 35 patients were female, while in cluster headache 9 of the 11 patients were male 
(i) Migraine:  Of the 402 patients with migraine 73% of them were females. Female 
predominance is noted in all groups including migraine with aura, migraine without aura, 
basilar migraine, migraine triggered seizures, migrainous infarction and chronic migraine. 
Menstrually related migraine was noticed in 46 patients whereas pure menstrual migraine was 
present in 3 patients. The American Migraine Study-1 (AMS-1)[10] and AMS-II, collected 
information from 15,000 households representative of the US population in 1989 and 1999. 
Finally, the American Migraine Prevention and Prevalence study (AMPP) replicated, in its first 
research phase, the methods of AMS-I and AMS-II.12 In these three very large studies, the 
prevalence of migraine was about 18% in women and 6% in men [Abu-Arefeh.I et al 1994]
[92]. 
(ii) Tension Type Headache: The female-to-male ratio of TTH in this study is 3:1, 
again showing a female preponderance. In western countries the ratio is 5:4 indicating that, 
unlike migraine, women are affected only slightly more than men Stovner L,et al 2007[93]. Of 
the 78 patients with Tension Vascular Headche 57 were female.
(iii) Trigeminal Autonomic Cephalagias: In this study male predominance is noted in 
concordance with the observation by Manzoni GC [Manzoni GC et al 1998][94]. Of the two 
female patients included under TAC, one had SUNCT and other had episodic cluster 
headache.   . 
C. Family Predilection:  Family history was positive in 229 patients (56.96%) with migraine. 
Of the 38 patients with migraine with aura 25 out of 38 patients had a first degree relative 
suffering from headache. Positive family history is also noticed in patients with basilar 
migraine and in patients with migrainous strokes. Russell MB et al [1995] has stated that first 
degree relatives of patients with migraine with aura had a three –four fold   increased risk  of 
migraine and it is two fold in first degree relatives patients with migraine with out aura[95].  11 
patients (31.43%) with tension headache in this study had a positive family history. Family 
background of some form of headache in 40% of patients with Tension Type Headache has 
been reported by Freidman A et al [1964][96], while Russell MB et al [1999][97] reported that 
parents siblings and children had a 2.1 to 3.9 fold increase risk of chronic TTH during their life 
time. 51 patients (65.38%) with tension vascular headache had a family history of  migraine in 
40 patients and of TTH in 11 patients. Our study group doesn’t have a family history  in the 
TAC group even though Kudrow L et al.[1980][98] in his study has reported a high risk of 
cluster headache by 14 times among first degree relatives of cluster headache patients
II. CLINICAL PRESENTATIONS OF PRIMARY HEADACHES
A. MIGRAINE: 
i) Location and Character: In patients with migraine 313 presented with 
unilateral headache, with 208 of these patients experiencing shift of sides. The headache was 
predominantly temporal (233 patients). Most of the patients experienced a throbbing type of 
headache (271 patients) with a maximal duration of 12-24 hours in 141 patients. The 
predominant premonitory symptom was yawning (98patients), with nausea, phonophobia, 
photophobia and blurring of vision the commonest associated symptom in order of 
occurrence.  Loss of consciousness was reported in 49 patients and ipsilateral pain in limbs in 
45 patients more commonly in upper limbs and it represents extension of allodynia. Some 
authors consider it as an aura as it precedes the headache [Guiloff RJ 1988][99]. 
ii] Aura: Among the several types of aura, visual aura was more common (113 
of 130 cases) which is in concordance with the literature. Negative visual aura was more 
common than positive symptoms and often occurred in isolation.(Kelman L et al 2004)[100] 
Typical visual aura but headache not fulfilling the criteria for migraine was seen in 5 patients. 
Three patients while on treatment for migraine headaches with aura, later had only aura alone 
without headache. The visual aura was predominantly in the form of flickering of lights in 67 
patients, while zig-zag lines, scintillating scotomas and fortification spectra was noted in 22 
patients, 16 patients and 8 patients respectively. This is in correlation with most international 
studies. When patients with typical aura with migraine headache become older, their 
headache may lose migraine characteristics or disappear completely even though auras 
continue. Sensory aura was reported in 32 patients and both in 9 patients. The sensory aura 
seen was commonly in the form of paraesthesia (27 patients). [Christopher J Boes et al 2004]
[101]  
iii] Aggravating and Relieving Factors: In our study the most common 
aggravating factors were mental stress, while physical stress and lack of sleep were also 
commonly reported. Head bath as an aggravating factor has been observed in 267 patients. A 
similar observation has been referred to by Ravishankar et al 2006[9]. Common triggers of 
migraine are well established but 'hair wash or head bath' as a trigger for migraine has so far 
not been reported. This prospective study analysed this unusual trigger link in 94 out of 1000 
Indian patients who fulfilled the International Headache Society criteria for migraine. In 11 
patients, hair wash was the only trigger; in 45 patients hair wash was one of the triggers and 
in 38 patients hair wash was a trigger concurrently and in combination with another common 
trigger. The effect of episodic and long-term prophylaxis in preventing this trigger-like 
headache has been analysed. The relieving factors were mostly rest and analgesic ingestion 
and sleep. 
iv] Associated Clinical Conditions: In our study of 402 patients with migraine 
the following clinical conditions were seen associated – namely evidence of healed 
Granulomatous diseases, Seizures, Hypertension,  Head Injury, Sinusitis, Psychiatric 
Changes and Stroke. The risk of stroke may be increased two- to threefold in migraine 
sufferers. Young adult sufferers and women using hormonal contraception appear to be at 
particular risk. The mechanism of this association though vastly unclear is attributed to 
chronic abnormalities of cerebral blood vessel tone [Etminan M et al 2005] [102].  Women 
who experience auras have been found to have twice the risk of strokes and heart attacks 
over non-aura migraine sufferers and women who do not have migraines [Kurth T et al 2006]
[103]. Similar observation was made in this study and all the patients who had migrainous 
strokes were female and all of them had migraine with aura. Migraine sufferers seem to be at 
risk for both thrombotic and hemorrhagic stroke as well as transient ischemic attacks [Becker 
C et al 2007] [104] 
v] Special Types of Migraine: Our study also included 5 cases of 
Ophthalmoplegic Migraine of which 4 had Abducent Nerve palsy and 1 patient had 
Oculomotor Nerve palsy.  This is a very rare condition in children, characterized by a migraine 
like attack Weiss AH et al [2006][105]. The oculomotor nerve is most commonly involved, with 
pupillary abnormality and ptosis, followed by the abducent, and rarely the trochlear nerve 
Ferrante E et al [2006][106]. The attack usually lasts from days to months and resolves 
spontaneously. A number of adult cases have been reported Lee TG et al [2002][107]. 
Twelve patients had basilar migraine and 10 out of 12 patients were in 1st and 
2nd decade. The symptoms experienced by majority of them were vertigo, diplopia, ataxia, 
parasthesias, hemianopias, and decreased level of consciousness. Two of these patients also 
had some attacks without basilar features. These observations are in correlation with most 
international studies. Basilar migraine is common is adolescent age groups and more in 
males  With increasing maturity of the nervous system attacks of basilar migraine become 
less common and generally are replaced by migraine without aura [Peatfield RC et al 2000]
[108].
vi] Complication of Migraine: (a)Chronic Migraine: In our study of the 402 
case of Migraine, 70(17.37%) patients had complications of migraine. Of these 70 patients, 46 
patients had Chronic Migraine (9 patients of Chronic Migraine since Onset & 37 patients of 
Episodic Headache converting to Migraine), 5 patients had Migrainous Infarction (Cerebellar 
Infarction -3 & Right Occipital Infarction -2) and 19 patients had Migraine Trigerred Seizures 
(Migraine Terminating as Seizures – 14, Migralepsy - 5). No patients with Status Migrainous 
or Persistent Aura without Infarction were included in the study. In our study, the most 
common complication observed in patients with migraine was transformation of migraine to 
chronic migraine or chronic daily headache. As the chronicity develops migraine headache 
lose its episodic presentation. Most of these patients with transformed migraine are patients 
with migraine without aura which is concordant with the studies of Siberstein SD et al 
2001[109].  Five patients were diagnosed to have migrainous infarction in our study. All the 
five patients were females in the age group of 20-35 years. All the infarctions occurred in 
patients with migraine with aura and were in the posterior cerebral artery territory (3occipital 
infarcts & 2cerebellar infarcts). Women who experience auras have been found to have twice 
the risk of strokes and heart attacks over non-aura migraine sufferers and women who do not 
have migraines [Kurth T et al 2006][103].This observation in our study is also concordant with 
observation by Peter Goadsby P.J [2002][110]. Three patients had only migraine and no other 
risk factors. Two of these patients tested positive for anti-phospholipid antibodies. The 
incidence of stroke in this study is 0.9% as against 10-15% in the literature. This increased 
risk of stroke parallels the chronicity of migraine. 
(b) Migraine Trigerred Seizures: In our study, we came across 61 instances of Migraine 
associated with Seizures, 19 patients had Migraine Triggered Seizures, 20 patients had Post 
Ictal Migrainous Headache and 22 patients had Migraine & Coexistent Seizure. Of the 19 
patients who had Migraine Triggered Seizures, 14 patients had Migraine Terminating as 
Seizures and 5 patients had Migralepsy. Analysis of the 19 patients showed that 9 patients 
had GTCS, 5 patients had CPS and 5 patients presented with prolonged LOC. Migralepsy as 
defined in literature are seizures occurring during or within an hour of migrainous aura 
[Lennox WG et al 1960][111]. In our study of these 19 patients who had migraine which 
terminated as seizures, 14 patients differed from the classical description of migralepsy in 
their duration of headache with a window period of more than three hours well outside the 
defined window period of 1 hour.. This group of 14 patients presented with both migraine with 
aura and migraine without aura. 12 of the 14 patients responded to anti-migrainous 
prophylaxis alone with a 1year episode free period, while 2 patients responded to anti-
migrainous prophylaxis alone with a 3 & 6 month episode free period. Hence these patients 
were grouped as Migraine triggered seizures. These observations in our study correlate with 
observations of Anderman F et al (1987) [112].The timing and features of headache in 
patients with epilepsy were explored by various studies. Marks and Ehernberg et al [1993]
[113] evaluated and established the relationship between catamenial epilepsy and patients 
with migraine with aura, showing an increased risk for an association between seizures and 
migraine. Lenaerts et al [1999][114] evaluated the degree of co-morbidity and established the 
pattern of temporal relationship between migraine and epilepsy in 202 patients in tertiary care 
clinics, which outlines that Migraine attacks equally precede or follow seizures, but migraine 
aura more often preceded the seizure. This correlated with the observations in our study. In 
analyzing our group of patients, migraine preceeded the seizures in 19 of 56 patients (14 
migraine with aura), and followed it in 20 of 56 patients. Of the 19 patients, 5 patients had 
migralepsy and 14 patients had migraine which terminated as seizures. Relationship between 
duration of headache and terminations as seizures was analysed. In our patients, all had a 
prolonged duration of migraine ranging from 2->12hrs duration. This observation in our study 
is in contrast to the observation of Young et al [1983][115] in their epilepsy unit, where their 
patients had a brief duration of headache lasting for upto 20 minutes, which was of hemi-
cranial throbbing pain, except for 2 patients who had a prolonged duration of headaches. 
Headache can also be the sole or most predominant manifestation of epileptic seizures, this 
is a relatively rare situation [Laplante P et al 1983][116] 
(c) Migraine and Loss of Consciousness: Relation ship between Migraine & LOC was also 
analysed in our study group of migraine triggered seizures. In our study group 5 patients had 
loss of consciousness. Episodes of impairment of consciousness have been reported in 
10-20% of migraineurs in various series mainly in the young and the mechanisms is not clear. 
Sicuteri et al., found a marked hypersensitivity to bromocriptine in patients with presumptive 
migraine syncope. The drug caused marked hypotension in these patients, which was 
reversed by domperidone, suggesting dopamine receptor hypersensitivity. LOC in basilar 
migraine which is attributed to constriction of basilar artery can range from few minutes to 30 
minutes. Stupurous periods in migraine (Migraine stupor and coma) vary from 12 hrs to 5 
days during attacks of migraine. Measurement of cerebral blood flow during an episode of 
migraine stupor demonstrated a severe, global reduction in cerebral blood flow Bickerstaff ER 
et al 2005.[117].
B. TENSION TYPE HEADACHE In patients with TTH 18 presented with headache of 
more than 12hours duration, while 10 patients had a duration of 6-12 hours and 5 patients 
had a duration of 1-6hours. 31 of these patients experienced bilateral headaches with most 
(19 patients) confined to the frontal region. Bendtsen L et al [2006][118] evaluated and 
compiled the features of tension type headache. TTH is characterized by a bilateral, pressing, 
tightening pain of mild to moderate intensity, occurring in short episodes of variable duration 
(episodic forms) or continuously (chronic form). The headache is not associated with the 
typical migraine features, such as vomiting, severe photophobia, and phonophobia. In the 
chronic form, only one of these accompanying symptoms is allowed and only mild nausea is 
accepted. Because of lack of accompanying symptoms and milder pain intensity, patients 
rarely are severely incapacitated by their pain. TTH is the most featureless of the primary 
headaches and, because many secondary headaches may mimic TTH, a diagnosis of TTH 
requires exclusion of other organic disorders. A general and neurologic examination and 
prospective follow-up using diagnostic headache diaries6 with registration of all consumed 
drugs are, therefore, of utmost importance to reach a diagnosis. There are no reliable specific 
paraclinical tests that are useful in differential diagnosis. Manual palpation of the pericranial 
muscles and their insertions should be done to demonstrate a possible muscular factor for 
patients and to plan treatment strategy, where physical training and relaxation therapy are 
important components. [Jensen R 1999][119].
The headache was holocranial in 31 of the 35 patients while it was hemicranial in the 
other 4 patients. Most of the patients experienced a aching type of headache (23 patients), 
while it was band like in 11 patients and throbbing in 6 patients. The predominant premonitary 
symptom was phonophobia (30 patients), with nausea, paraesthesia, giddiness and 
photophobia other common associated symptoms in order of occurrence.  The most common 
aggravating factor in our study group was mental stress, while physical stress, travel, head 
bath and lack of sleep were also commonly reported. The relieving factors were mostly 
pressure and analgesics and coffee / tea ingestion. As TTH was commonly associated with 
depression and is aggravated by mental stress, previously was thought to be psychogenic 
now a neurological basis was established. Other common aggravating factors include poor 
self related health, inability to relax after work and sleeping few hours per night (Bendsten L 
etal 2000)[120]. In our study of 35 patients with TTH the following clinical conditions were 
seen associated – namely evidence of healed Granulomatous Diseases, Hypertension and 
Head Injury. 
C. TENSION VASCULAR HEADACHE: Of the 78 patients diagnosed most patients 
had durations of more than 12 hours. 62 patients had an earlier diagnosis of Migraine without 
Aura whose frequency of episodes increased over a period of few years to chronic migraine / 
transformed migraine (more than 15 episodes per month) which progressed to bilateral 
holocranial headache with scalp tenderness in most patient. The episodic nature of migraine 
headache was lost and character of the headache changed, pattern shifting  from typical 
throbbing pain to diffuse aching and band like pain with radiation to the neck. The 
predominant accompanying symptoms like nausea, photophobia and phonophobia were less 
frequent and less intense in this group than compared to typical migraine. 15 patients of this 
group presented  initially with episodic tension type headache later transforming to the mixed 
entity.   The most common aggravating factor in our study group was mental stress and 
physical stress, travel, head bath and lack of sleep. The relieving factors were mostly 
analgesics, rest, and sleep. Of these 3 patients who were on multiple analgesics prescribed, 
medication overuse headache, responded after withdrawing them from drugs. In our study of 
78 patients with TVH, 15 patients had associated mental depression. Majority of patients in 
this group required two drugs one antimigrainous prophylaxis and an added antidepressant 
for prevention or for reducing the intensity and severity of their headaches. This terminology 
has been used in our study as a separate entity, as these patients shared features of both 
migraine and Tension type headache. But Dodick et al 2006 [71] has considered the term 
Tension Vascular Headache antiquated. 
  D. TRIGEMINAL AUTONOMIC CEPHALAGIAS: In patients with TAC 9 presented 
with headache of less than 6 hours duration, while 2 patients had a duration of 6-12 hours. 2 
of the patients experienced bilateral headaches while 9 had unilateral headaches with most (9 
patients) confined to the frontal temporal region. Most of the patients experienced an aching 
type of headache (8 patients), while it was throbbing in 2 patients and pricking in 1 patient. 
The predominant premonitary symptom was nausea and vomiting (10 patients), with redness 
of eyes, nasal stuffiness, phonophobia, photophobia, drooping of eyelids and blurring of vision 
the other common associated symptoms in order of occurance.  Aggravating factors were not 
reported in most patients in our study alcohol intake, sunlight and lack of sleep were reported. 
The releiving factors were mostly analgesics, pressure and coffee / tea ingestion. In 
consonance with our observations Rozen TD et al [1999][75] described the features of typical 
cluster headache. Typical cluster headache location is retro-orbital, periorbital, and 
occipitonuchal. Maximum pain is normally retro-orbital in more than 70% of patients. Pain 
quality is described as boring, stabbing, burning, or squeezing. Cluster headache intensity is 
always severe and never mild, although headache pain intensity may be less at the beginning 
and end of cluster periods. The duration of individual cluster headaches is between 15 
minutes and 180 minutes, with more than 75% attacks lasting less than 60 minutes. Attack 
frequency is between one and three attacks per day, with most patients experiencing two or 
fewer headaches in a day. Cluster headache is marked by its associated autonomic 
symptoms that typically occur on the same side as the head pain but can be bilateral. 
Lacrimation is the most common associated symptom, occurring in 73% of patients, followed 
by conjunctival injection in 60%, nasal congestion in 42%, nasal rhinorrhea in 22%, and a 
partial Horner’s syndrome in 16% to 84%. 
III DIAGNOSTIC STUDIES 
A. Electrophysiology: 
(i) Migraine: EEG Sharp waves and spikes in posterior occipital region mainly occipital 
region, more during the period of aura and was normal during the interval period between 
attacks of migraine. This correlates with a large multicenter study - incidence of spikes and 
paroxysmal events was 12.5% compared to 0.7% in normal adult volunteers. The percentage 
goes still high up in patients with seizures. Monomorphic or polymorphic slow waves, seen 
bilaterally. Few cases also showed slowing in posterior head region [Beaumanoir A et al 
1987][121]. EEG was taken in 54 of the 402 patients with  migraine 28 of the 54 patients 
showed Non Specific Slowing in Posterior Region, while 5 patients showed Spikes & Sharp 
Waves in Occipital Region while 21 of the patients had no specific changes 
(ii) TTH EEG was taken in 12 of the 35 patients with TTH, 2 of these patients showed 
Non Specific Slowing in Posterior Region, while 10 of the patients had no specific changes
(iii) TAC EEG was taken in 4 of the 11 patients with CH & TAC, all 4 patients showed 
no specific changes. 
B. Autonomic Function Tests: 
Based on a literature review and an extensive investigation of patients with migraine, 
Thomsen, Olesen and coworkers conclude that ‘Clear dysfunction of the sympathetic nervous 
system remains to be shown. Mild parasympathetic hypofunction with denervation 
supersensitivity may be present in migraine’ Results are variable. Boiardi et al.[1988][44] 
reported for instance that the diastolic blood pressure response to sustained handgrip was 
impaired in 61% of migraine patients. In our study (1) Low Frequency Heart Rate Variation 
(LF) with a mean control value of 40.34 and mean test value for migraineurs of 37.4 and a p 
value of 0.2837 was found not significant. The LF is mediated by sympathetic and 
parasympathetic contributions and is believed to reflect the vasomotor reflex (2) High 
Frequency Heart Rate Variation (HF) with a mean control value of 59.93 and a mean test 
value of 62.60 and p value of 0.620 was found not significant. The HF is mediated by 
parasympathetic nervous control and is related to respiratory sinus arrhythmia. Akselrod S  et 
al [1981][122]. These parameters can be influenced by posture. (3) LF/ HF Ratio with a mean 
control value of 0.706 and a mean test value of 0.709 and p value of 0.975 was found not 
significant. Therefore, the LF/HF ratio reportedly represents sympathetic nervous control. 
However, Eckberg DL [1997][123] critically reviewed the simplified interpretation of the LF/HF 
ratio as an index of sympathovagal balance. Furlan et al [1999][124] observed significantly 
decreased LF power, increased HF power, and a decreased LF/HF ratio between midnight 
and 6 AM in ambulatory subjects (3) Mean Heart Rate with a mean control value of 74.0 and 
a mean test value of 76.20 and p value of 0.0327 was found significant. It is concluded that 
this value shows significant difference between the control and test. In a recent study by 
Pierangeli G et al [1997][47] no heart-rate variability differences between migraine patients 
and control subjects were found (4) Mean RR Interval with a mean control value of 0.813 and 
a mean test value of 0.842 and p value of 0.738 was found not significant. Havanka-
Kanniainen et al [1986][125] and Thomsen et al [1995][45] reported decreased R-R variations 
in subjects with migraine, which indicated parasympathetic hypofunction. Mikamo et al[1989]
[126] and Pogacnik et al [1993][127] reported that there was no significant difference in R-R 
variability between migraineurs and controls. The findings of Masako T et al [2000][128] 
suggest that patients with migraine have cardiac parasympathetic hypofunction and abnormal 
rhythm generation. 
B. Imaging Studies: (i) Migraine: CT scan of brain was taken in all of the 402 patients, of 
whom 83 had changes. The most common change reported in CT scan brain was calcified 
granulomas in 69 patients, gliosis in 8 patients and basal ganglia calcification in 6 patients. 
CT scan of the para-nasal sinuses was performed in 53 patients of which 18 showed 
maxillary sinusitis while it was normal in 35 patients. Frishberg BM et al  1994 [129] reviewed 
four CT scan studies, four MRI scan studies, and one combined MRI and CT scan study of 
897 scans of patients who had migraine. These findings are combined with more recent 
reports of one CT scan study of 284 patients and six studies of MRI scans of 444 patients for 
a total of 1625 scans of patients who had various types of migraine. Other than white matter 
abnormalities, the studies showed no significant pathology except for four brain tumours 
(three of which were incidental findings) and one AVM (in a patient who had migraine and a 
seizure disorder). Sempere found a similarly low yield of 0.4%.
V. PROPHYLAXIS 
A. MIGRAINE: The patients with migraine were given prophylactic therapy with either 
Propronolal  (20-160mg) or Amitryptylline (12.5-50mg) or Propronolal (20-160mg) and 
Amitryptylline (12.5-50mg) or Flunarizine (5mg) or Topiramate (50mg) or Sodium Valproate 
ER(500mg). Patients with migraine with and without aura responded well to beta blocker at 
lower dosages with headache free interval of more than six months in majority. This is in 
correlation with meta analysis from many studies where beta blockers was associated with 
reduction in migraine activity and more than 100 clinical trials clearly established the benefits 
of propronolol. Patients with mixed tension vascular headache responded well to 
amitryptylline and a combination of beta blocker and amitryptylline than propronolol as 
evidenced in studies by Mathew NT et al [1991][130]. Flunarizine in doses of 5-10mg used in 
this study mainly adolescents and in patients with basilar features provided a good reduction 
in headache frequency and was well tolerated
B. TENSION TYPE HEADACHE: All patients in our study were treated with 
Amitryptiline (10-50mgms). Of the 35 patients 3 patients responded with a disease free 
interval of 1year, 9 patients with a disease free interval of 6 months to 1 year, 9 patients with 
a disease free interval of less than 6months, 11 patients responded with decreased intensity 
and frequency of episodes while 3 patients did not show any response. This is in 
concordance with various studies. Prophylactic pharmacotherapy include tricyclic 
antidepressant, amitriptyline, is the only drug proved effective in several controlled trials in 
TTH. Bendtsen L et al [2005][131]. The two most recent studies reported that amitriptyline (75 
mg per day) reduced headache index (duration _ intensity) by 30% compared with placebo. 
The effect is long lasting (at least 6 months)55 and not related to the presence of depression. 
Bendtsen L et al [1996][132]. If patients do not respond to amitriptyline, mirtazapine could be 
attempted. Venlafaxine or SSRIs could be considered in patients who have concomitant 
depression, if tricyclics or mirtazapine are not tolerated. 
C. TENSION VASCULAR HEADACHE: All 78 patients were treated with Amitryptiline 
(10-50mgms) and Propronolol (40-160mgms). Of the 78 patients 63 patients responded with 
decreased intensity and frequency of episodes while 15 patients did not show any response.
D. TRIGEMINAL AUTONOMIC CEPHALALGIAS: Two patients with SUNCT were on 
prophylaxis with sodium valproate with moderate response. Four patients with paroxysmal 
hemicrania responded well to Indomethacin during acute phases and were given prophylaxis 
with Amitrptiline with good response. All 4 patients had a disease free interval of six months. 
Prophylaxis was provided for 5 patients with cluster headache of which 3 were given 
Amitryptiline (25-50mgms), 2 patients were given Propranolol (80-120mgms). Of the 3 
patients given Amitryptiline 2 patients responded with a disease free interval of 1year, 1 
patient with a disease free interval of 6 months to 1 year. Of the 2 patients given Propranolol, 
both of them  responded with a disease free interval of 1year. These drug therapies are at 
variance to usual protocols. But these patients showed marked responses indicating that 
these were probable Cluster Headache Migraine overlap syndromes. Solomon S et al [1986]
[133] has referred to a similar clinical situation were the patients had clinical features of both 
types of headaches. But the criteria enunciated by him were considered imprecise. Graham et 
al [1975][134] referring to combined syndromes has described migraine headaches in 
recurrent bouts resembling cluster headache responding to migraine prophylaxis. 
  
Summary                            
The observations of this study are here with summarised 
1. Migraine is the commonest type of headache comprising of about 75%. Migraine 
without aura [48%] was more common than migraine with aura [32%]. Female 
preponderance was noticed in all subtypes of migraine, age of onset being in 2nd 
and 3rd decade for majority of the subgroups of migraine, except for basilar migraine 
which was common in 1st and 2nd decade.
2.  Chronic migraine, Migraine triggered seizures and Migrainous infarction were the 
complications of migraine encountered in this study in the order of frequency of 
occurrence. Transformation to Chronic migraine was more common from episodic 
forms and in patients with onset of migraine in teens or twenties. Migrainous 
infarction was seen only in female patients who had exclusively migraine with aura 
and all the five patients had posterior circulation strokes.
3. 14 patients were grouped as migraine triggered seizures. These patients differed 
from the classical description of migralepsy in their duration of headache, with a 
window period of more than three hours prior to the seizure. This group of patients 
presented with both migraine with aura and migraine without aura and responded to 
anti-migrainous prophylaxis alone with a 1 year episode free period.
4. Mean Heart Rate shows difference between the control and migraine patients but is 
within physiological range and no variation was observed in power spectral 
analysis.
5. Patients with migraine with and without aura responded well to beta blocker at 
lower dosages with headache free interval of more than six months in majority. 
Patients with basilar migraine benefited from either propronolal or flunarizine, but 
patients with chronic migraine responded predominantly to combination 
prophylaxis.
6. Patients with tension type headache responded to amitriptyline and those patients 
with tension vascular headache i.e. patients with features of tension type headache 
and of migraine responded well to a combination of beta blocker and amitryptyline.
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                                           PROFORMA  FOR  HEADACHE
Name:                                                    Age:                                                      Sex:
Residential address:
Occupation:
MIN No:                                                                         Headache clinic No:
Details about headache:    How long-  
                                           Age of onset-
                                           Headache free period if any-
Duration in hours-
Location-  Unilateral-                        Bilateral-
Temporal-                   Frontal -                  Occipital -                   Holocranial-
Radiation to neck-                       Retro orbital region-            Limbs ( UL & LL) –
Character-  Throbbing-                   Tight sensation-                  Shock like-
                    Pricking-                       Aching-                               Jarring-
Frequency-    Episodes/week-                  Episodes/month-
Recent change in frequency-
Frequency with prophylactic drugs-
Associated features-   Photophobia and phonophobia-
                                    Nausea and vomiting-
                                    Yawning-
                                     Drowsiness-
                                    Giddiness/ vertigo-
                                     LOC-
                                     Redness of eyes-
                                     Lacrimation-             
                                     Diplopia-                               
                                     Parasthesias-
Aura-  Visual-   Positive visual phenomena:  Small bright dots-
                                                                         White spots/ flashes of light (photopsias)-
                                                                           Fortification spectra (teichopsia)-
                                                                            Other zig zag lines-
                                                                              Coloured spots of light-
                                                                                
                          Negative visual phenomena:  Blind spots (scotomas)-
                                                                           Black dots/ spots-
                                                                           Hemianopias- 
                          Disturbances of visual perception- blurred vision-
                                                                                     Micropsia/ macropsia/teleopsia-
                                                                                      Tunnel vision-
Triggering factors-      Physical stress/ mental stress-                      Sunlight-
                                     Sleep alteration-                                            Travel-
                                      Headbath-                                                      Perfumes/fumes-
                                       Cold items-                                                    Position of neck-
                                        Others-
Relieving factors-         Pressure-                                                         Coffee/ tea-
                                       Analgesics                                                       Rest-.
Relationship to menstrual cycles-
 
Family history-
On Examination-     BP-                                    Temporal artery-                       Sinuses-
                                 
                                 Palpabrel fissure-               Refraction-                               Fundii-
                                  Cranial nerves-
                                    Long tract signs-
Associated conditions-    Seizures-                          HT-                          Stroke-
                             
                                          Granulomatous diseases-                 Psychiatric diseases-
Investigation-       CT scan Brain-
                             EEG (where required)
Diagnosis-             Primary-                                        Secondary-
                               Migraine  /  Tension type headache  /  Short lasting headache  /  
           
                                Cluster headache  /  Paroxysmal hemicrania
Medications-           Propranolol                                              Topiramate
                                 Amitryptyline                                           Flunarizine
Follow up-
Appendix                                     2  
                                         Master Charts 
A. Migraine
B. Tension Type Headache
C. Cluster Headache
D. Tension Vascular Headache
APPENDIX 2 – A : MASTER CHART – MIGRAINE 
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ABBREVIATIONS
25 F 7 Temporal Throbbing 6 Visual Yes MWA prop DFI-12M
31 F 14 Temporal Throbbing 20 CM amt + prop DFI-6M+
17 M 15 Temporal Pricking 4 Sensory&Visual Yes MWA prop DFI-6M+
23 F 30 Temporal Throbbing 3 Calcif Granuloma MWOA Amit DIF
8 F 3 Occipital Aching 12 Yes MWOA Flunarazine DFI-6M
50 F 24 Frontal Throbbing 16 CM amt + prop DFI-6M+
25 F 8 Temporal Throbbing 4 Visual Yes MWA-BM prop DFI-6M+
27 M 7 Temporal Throbbing 6 Sensory Yes MWWOA amt + prop DFI-6M+
22 M 14 Temporal Burning 5 Calcif Granuloma MWOA prop DFI-6M+
18 F 4 Parietal Throbbing 8 MWOA prop DFI-6M+
13 F 2 Occipital Throbbing 4 Sensory & Visual Yes MWA-BM Flunarazine DFI-6M
15 M 8 Temporal Pricking 2 Yes MWOA Amit DIF
32 F 9 Parietal Diffuse 6 MWOA amt + prop DFI-6M+
18 F 8 Frontal Throbbing 2 Visual Yes GTCS MTS prop DFI-6M+
44 F 14 Frontal Throbbing 20 CM amt + prop DFI-6M+
23 M 20 Temporal Throbbing 8 Visual Calcif Granuloma MWWOA amt + prop DFI-6M
25 F 4 Parietal Throbbing 6 Visual Yes MWA prop DFI-6M+
14 F 8 Temporal Aching 4 Yes MWOA Amit DIF
25 F 15 Temporal Aching 2 Sensory MWWOA amt + prop DFI-6M+
10 F 5 Temporal Throbbing 6 Yes Calcif Granuloma MWOA Flunarazine DFI-12M
42 F 8 Frontal Throbbing 18 CM amt + prop DFI-6M+
33 F 14 Temporal Throbbing 8 Visual Yes MWWOA amt + prop DFI-6M
22 M 5 Temporal Pricking 2 MWOA prop DFI-6M+
29 M 8 Temporal Pricking 4 Yes Calcif Granuloma MWOA prop DFI-6M
28 M 24 Temporal Throbbing 6 Visual MWWOA amt + prop DFI-6M+
15 F 4 Temporal Aching 6 Yes MWOA prop DFI-6M+
32 F 8 Frontal Throbbing 2 Visual Gliosis MWWOA amt + prop DFI-6M
40 F 10 Frontal Pricking 3 Yes MWOA prop DFI-6M+
22 F 24 Temporal Throbbing 4 Visual MWA prop DFI-12M
25 F 5 Parietal Throbbing 5 Yes MWOA Amit DIF
20 F 12 Temporal Throbbing 2 Visual Yes CPS MTS Sod Valp DIF
18 M 7 Temporal Throbbing 6 Visual Yes LOC MTS prop DFI-12M
20 F 8 Temporal Throbbing 8 Visual Yes Calcif Granuloma MWA amt + prop DFI-6M+
27 M 24 Temporal Pricking 10 Yes MWOA amt + prop DFI-6M+
31 F 30 Frontal Aching 12 Yes MWOA amt + prop DFI-6M
MWA – MIGRAINE 
WITH AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
MWWOA
MIGRAINE WITH 
OR WITHOUT 
AURA
CM – CHRONIC 
MIGRAINE
PM – PROBABLE 
MIGRAINE
MTS –MIGRAINE 
TRIGERRED 
SEIZURES
MIGSTR
MIGRAINOUS 
STROKE 
BM – BASILLAR 
MIGRAINE
DFI-6M+
FREE INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - DISEASE 
FREE INTERVAL 
LESS THAN 
6MONTHS
DFI-12M
FREE INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
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ABBREVIATIONS
22 F 7 Frontal Throbbing 4 Visual Yes MWA prop DFI-12M
24 F 14 Temporal Throbbing 2 Yes Calcif Granuloma MWOA Amit DIF
8 F 8 Occipital Aching 2 Visual Yes LOC MTS Flunarazine DFI-6M
36 F 15 Frontal Throbbing 22 CM amt + prop DFI-6M+
14 F 9 Temporal Pricking 4 sensory Yes MWWOA amt + prop DFI-6M+
27 M 24 Temporal Diffuse 8 Calcif Granuloma MWOA Amit DIF
35 F 14 Temporal Throbbing 5 MWOA prop DFI-6M+
12 M 12 Temporal Throbbing 4 Sensory & Visual Yes
MWA-
BM prop DFI-6M+
18 M 24 Frontal Diffuse 11 Calcif Granuloma MWOA prop DFI-6M+
36 F 15 Temporal Throbbing 12 MWOA Amit DIF
13 M 7 Occipital Throbbing 3 Visual Yes
MWA-
BM Flunarazine DFI-12M
29 F 12 Temporal Throbbing 6 Visual Gliosis Stroke MWA amt + prop DFI-6M+
14 M 14 Frontal Throbbing 7 MWOA amt + prop DFI-6M
12 M 4 Temporal Throbbing 2 sensory MWWOA amt + prop DFI-6M+
38 F 7 Temporal Throbbing 3 Yes GTCS MTS prop DFI-12M
16 F 3 Parietal Pricking 5 Yes MWOA Amit DFI-6M
40 F 12 Temporal Throbbing 19 Yes CM amt + prop DFI-6M
25 F 15 Temporal Aching 7 Yes Calcif Granuloma MWOA amt + prop DFI-6M+
18 M 13 Frontal Throbbing 5 Visual Yes MWWOA amt + prop DFI-6M+
22 M 24 Frontal Throbbing 4 MWOA prop DFI-6M+
38 F 12 Temporal Aching 10 Yes MWOA Topiramate DIF
12 M 14 Frontal Throbbing 8 Basal Gang Calc MWOA Amit DIF
40 F 24 Temporal Throbbing 3 Visual Yes MWWOA amt + prop DFI-6M+
24 F 5 Temporal Pricking 4 MWOA amt + prop DFI-6M
18 F 14 Temporal Throbbing 2 Visual Yes
MWA-
BM prop DFI-6M+
27 M 15 Frontal Throbbing 3 Yes GTCS MTS Sod Valp DFI-6M+
45 F 24 Temporal Throbbing 19 Yes Calcif Granuloma CM amt + prop DFI-6M+
16 F 6 Parietal Aching 5 Yes MWOA Amit DIF
15 F 12 Temporal Throbbing 8 Visual Yes MWWOA amt + prop DFI-6M+
28 F 14 Temporal Throbbing 11 Yes MWOA prop DFI-6M+
14 M 7 Frontal Aching 2 Visual LOC MTS prop DIF
15 F 15 Frontal Throbbing 3 Visual Yes MTS prop DFI-12M
38 M 24 Temporal Aching 20 Yes CM amt + prop DFI-6M+
53 F 12 Temporal Throbbing 18 Yes Calcif Granuloma CM amt + prop DFI-6M
26 M 8 Frontal Throbbing 3 Yes MWOA Amit NR
MWA – 
MIGRAINE WITH 
AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
MWWOA – 
MIGRAINE WITH 
OR WITHOUT 
AURA
CM – CHRONIC 
MIGRAINE
PM – PROBABLE 
MIGRAINE
MTS –MIGRAINE 
TRIGERRED 
SEIZURES
MIGSTR– 
MIGRAINOUS 
STROKE 
BM – BASILLAR 
MIGRAINE
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
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MORETHAN 12 
MONTHS
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24 F 5 Frontal Throbbing 8 Yes Calcif Granuloma MWOA prop DFI-6M+
32 F 24 Temporal Pricking 2 Yes MWOA Amit DIF
18 F 14 Temporal Throbbing 4 Visual Yes MWA prop DFI-6M+
36 M 24 Temporal Throbbing 15 Calcif Granuloma CM amt + prop DFI-6M+
14 M 24 Temporal Throbbing 3 MWOA amt + prop DFI-6M
17 F 4 Parietal Burning 5 Yes MWOA amt + prop DFI-6M+
14 M 5 Temporal Throbbing 11 Sensory Yes CPS MTS prop DFI-6M
18 F 16 Frontal Throbbing 4 Yes MWOA prop DFI-6M+
9 M 4 Occipital Aching 2 Visual Yes
MWA-
BM Flunarazine DFI-6M
42 F 14 Temporal Throbbing 20 CM amt + prop DFI-6M+
26 F 12 Temporal Throbbing 2 Visual Yes MWA prop DFI-6M
34 M 24 Temporal Pricking 4 Yes Calcif Granuloma MWOA Amit DIF
24 F 12 Frontal Throbbing 8 MWOA prop DFI-6M+
22 M 15 Temporal Throbbing 6 Sensory & Visual Yes Gliosis PM amt + prop DFI-6M
32 F 12 Temporal Throbbing 5 MWOA prop DFI-6M+
14 F 8 Occipital Aching 3 Visual Yes
MWA-
BM Flunarazine DFI-12M
45 F 24 Temporal Throbbing 20 Calcif Granuloma CM amt + prop DFI-6M+
28 M 12 Temporal Pricking 8 Sensory Yes MWWOA amt + prop DFI-6M
24 M 12 Frontal Throbbing 6 Yes MWOA amt + prop DFI-6M+
26 F 24 Temporal Throbbing 4 Visual Yes MWWOA Topiramate DIF
15 F 6 Temporal Throbbing 2 MWOA amt + prop DFI-6M+
13 F 8 Occipital Throbbing 5 Visual Yes
MWA-
BM prop DFI-6M
53 F 24 Temporal Diffuse 18 Yes CM amt + prop DFI-6M+
18 F 14 Temporal Throbbing 3 Yes Calcif Granuloma MWOA amt + prop DFI-6M+
38 M 12 Frontal Throbbing 5 Yes MWOA Amit DFI-6M
22 F 12 Temporal Throbbing 2 Visual Yes MWA prop DFI-6M+
20 F 6 Occipital Aching 1 Yes MWOA Flunarazine DFI-12M
28 M 6 Temporal Throbbing 8 MWOA amt + prop DFI-6M
36 F 3 Temporal Throbbing 20 Visual Yes CM amt + prop DFI-6M+
34 M 12 Frontal Throbbing 7 Visual MWWOA Amit DFI-6M+
16 F 14 Frontal Throbbing 4 Yes MWOA prop DFI-6M+
18 F 8 Temporal Pricking 8 Visual Yes Calcif Granuloma MWWOA amt + prop DFI-6M
22 M 5 Temporal Throbbing 5 GTCS MTS prop DFI-6M+
20 F 8 Temporal Pricking 3 Visual Yes Basal Gang Calc MWWOA amt + prop DFI-6M+
19 F 10 Frontal Throbbing 2 Visual Yes MWOA Amit DFI-6M
MWA – 
MIGRAINE WITH 
AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
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MIGRAINE WITH 
OR WITHOUT 
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ABBREVIATIONS
18 F 5 Temporal Throbbing 4 Visual Yes MWOA amt + prop DFI-6M+
24 M 5 Temporal Throbbing 2 Visual Calcif Granuloma
MWA-
BM prop DFI-6M
16 F 12 Temporal Throbbing 5 Yes MWOA amt + prop DFI-6M
42 F 12 Frontal Throbbing 15 Yes Calcif Granuloma CM amt + prop DFI-6M+
36 M 24 Temporal Pricking 3 Yes MWOA amt + prop DFI-6M+
15 F 5 Temporal Throbbing 5 Yes MWOA prop DFI-6M
24 F 7 Occipital Throbbing 2 Visual Yes MWWOA amt + prop DFI-6M+
28 F 12 Temporal Throbbing 4 Yes Calcif Granuloma MWOA Amit DFI-6M+
32 M 6 Temporal Throbbing 9 MWOA prop DFI-6M
19 F 4 Frontal Throbbing 12 Visual Yes MWWOA amt + prop DFI-6M+
14 F 2 Temporal Pricking 4 MWOA amt + prop DFI-6M+
12 M 5 Frontal Throbbing 4 Yes Basal Gang Calc MWOA amt + prop DFI-6M+
25 F 6 Temporal Throbbing 6 Sensory & Visual Yes MWWOA prop DFI-6M
18 F 12 Temporal Throbbing 5 MWA Amit DFI-12M
20 M 3 Temporal Pricking 4 Yes MWOA amt + prop DFI-6M+
22 F 14 Parietal Throbbing 2 Visual Yes MWA amt + prop DFI-6M
44 F 24 Temporal Throbbing 20 Yes CM amt + prop DFI-6M+
18 F 9 Frontal Throbbing 5 Calcif Granuloma MWOA prop DFI-6M
16 M 5 Temporal Throbbing 3 Visual Yes MWWOA amt + prop DFI-6M+
22 M 12 Temporal Throbbing 5 Visual Yes MWWOA amt + prop DFI-6M+
24 M 12 Temporal Throbbing 8 Yes MWOA Amit DFI-6M
8 F 2 Temporal Throbbing 12 Yes MWOA amt + prop DIF
29 F 4 Occipital Aching 7 Visual Yes MWA Flunarazine DFI-6M
19 F 24 Temporal Throbbing 4 Yes Calcif Granuloma MWOA amt + prop DFI-6M+
17 F 12 Temporal Throbbing 8 MWOA amt + prop DFI-6M+
14 M 12 Frontal Throbbing 5 Visual Yes CPS MTS prop DFI-6M+
25 F 12 Temporal Pricking 3 Visual MWWOA amt + prop DIF
33 F 24 Parietal Throbbing 2 Yes MWOA amt + prop DFI-6M+
39 M 24 Temporal Throbbing 4 Yes MWOA prop DFI-6M+
43 F 6 Temporal Throbbing 2 MWOA amt + prop DIF
18 M 24 Temporal Throbbing 20 Yes MWOA amt + prop DFI-6M+
20 F 12 Temporal Throbbing 5 Visual Yes Gliosis Stroke CM amt + prop DIF
26 F 4 Occipital Aching 4 Visual Yes MWWOA amt + prop DFI-6M+
23 F 3 Temporal Burning 8 Yes MWOA prop DFI-6M
40 F 12 Frontal Throbbing 5 Yes MWOA prop DFI-6M
MWA – 
MIGRAINE WITH 
AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
MWWOA – 
MIGRAINE WITH 
OR WITHOUT 
AURA
CM – CHRONIC 
MIGRAINE
PM – PROBABLE 
MIGRAINE
MTS –MIGRAINE 
TRIGERRED 
SEIZURES
MIGSTR– 
MIGRAINOUS 
STROKE 
BM – BASILLAR 
MIGRAINE
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
AG
E
SE
X
D
U
R
AT
IO
N
 IN
 H
R
S
LO
C
AT
IO
N
C
H
AR
AC
TE
R
FR
EQ
U
EN
C
Y 
/ 
M
O
N
TH
AU
R
A
FA
M
 H
C
TS
C
AN
 - 
BR
AI
N
C
O
M
PL
IC
AT
IO
N
S
D
IA
G
N
O
SI
S
PR
O
PH
YL
AX
R
ES
PO
N
SE
ABBREVIATIONS
22 M 24 Temporal Throbbing 3 Visual Calcif Granuloma MWA amt + prop DIF
14 M 4 Temporal Pricking 12 Visual Yes MWA prop DFI-6M
18 F 2 Temporal Throbbing 7 MWOA amt + prop DFI-6M+
32 F 3 Temporal Throbbing 14 Sensory Yes MWWOA amt + prop DFI-6M+
20 F 8 Frontal Throbbing 12 Yes MWOA prop DFI-6M+
45 F 5 Temporal Throbbing 7 Visual Yes Calcif Granuloma MWA amt + prop DIF
26 M 15 Temporal Throbbing 24 Yes CM amt + prop DIF
14 F 6 Temporal Pricking 3 Yes MWOA Topiramate DFI-6M
18 F 2 Occipital Aching 4 Visual Yes
MWA-
BM Flunarazine DFI-6M
52 F 2 Temporal Throbbing 12 Visual Yes Calcif Granuloma MWWOA amt + prop DFI-6M+
19 M 20 Temporal Throbbing 12 Visual MWWOA amt + prop DFI-6M+
27 F 3 Occipital Diffuse 16 Yes CM amt + prop DFI-6M
35 F 5 Temporal Throbbing 12 MWOA Amit DFI-12M
14 F 6 Frontal Throbbing 12 Yes MWOA prop DFI-6M+
42 M 21 Temporal Throbbing 24 Yes Gliosis CM amt + prop DFI-6M+
18 F 3 Temporal Throbbing 8 Visual MWWOA Sod Valp DFI-6M+
20 F 3 Temporal Pricking 12 Yes Calcif Granuloma MWOA amt + prop DFI-12M
38 M 5 Temporal Throbbing 12 Yes MWOA amt + prop DIF
25 M 8 Parietal Throbbing 24 Yes MWOA Amit DIF
19 F 11 Temporal Pricking 8 Yes MWOA amt + prop DFI-6M+
12 F 5 Occipital Throbbing 5 Sensory & Visual Yes
MWA-
BM prop DFI-6M+
18 F 4 Temporal Throbbing 12 Calcif Granuloma MWOA amt + prop DFI-12M
42 M 18 Frontal Pricking 24 Yes CM amt + prop DFI-6M+
20 F 3 Temporal Burning 8 Visual GTCS MTS prop DFI-6M
36 M 2 Temporal Throbbing 14 Visual Yes Calcif Granuloma MWWOA amt + prop DIF
24 F 3 Temporal Throbbing 12 Visual Yes Calcif Granuloma MWWOA amt + prop DFI-6M+
26 F 4 Frontal Throbbing 12 MWOA prop DFI-6M
30 F 5 Temporal Pricking 24 Yes MWOA Amit DFI-6M+
34 F 3 Frontal Throbbing 12 Yes MWOA amt + prop DFI-6M+
22 F 4 Frontal Throbbing 12 Visual Yes MWA prop DFI-12M
18 M 8 Temporal Throbbing 6 Yes MWOA amt + prop DIF
15 F 11 Occipital Pricking 4 Yes MWOA Flunarazine DFI-12M
18 F 2 Temporal Throbbing 14 Visual MWWOA amt + prop DFI-6M+
36 M 8 Temporal Pricking 24 Yes MWOA Sod Valp DFI-6M+
29 M 6 Frontal Throbbing 12 Basal Gang Calc MWOA prop DFI-6M
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ABBREVIATIONS
14 F 5 Temporal Burning 24 Visual Yes MWA prop DFI-6M+
18 M 12 Occipital Diffuse 3 Yes MWOA amt + prop DFI-6M+
22 F 14 Temporal Throbbing 3 Visual Yes Calcif Granuloma MWA amt + prop DIF
34 F 12 Frontal Throbbing 5 Visual Yes MWWOA amt + prop DFI-6M+
19 M 24 Temporal Aching 8 Yes MWWOA prop DFI-6M+
43 F 24 Temporal Pricking 12 CM amt + prop DFI-12M
52 F 7 Occipital Throbbing 7 Yes MWOA Amit DFI-6M+
38 F 12 Temporal Throbbing 4 MWOA amt + prop DFI-12M
24 M 8 Frontal Throbbing 8 Yes Calcif Granuloma CM amt + prop DFI-6M+
22 F 14 Temporal Throbbing 5 Visual Yes MWWOA amt + prop DFI-6M+
19 F 12 Frontal Aching 3 MWOA Amit DFI-12M
17 F 24 Temporal Throbbing 2 Yes MWOA amt + prop DFI-6M+
29 F 12 Parietal Throbbing 4 Yes MWOA amt + prop DFI-12M
51 M 7 Temporal Throbbing 2 Visual Yes Calcif Granuloma MWWOA amt + prop DIF
36 F 12 Parietal Throbbing 20 Yes CM amt + prop DFI-12M
18 M 8 Temporal Diffuse 5 Yes MWOA prop DFI-6M+
26 M 24 Frontal Throbbing 4 Visual MWWOA amt + prop DIF
22 F 5 Occipital Throbbing 8 Yes MWOA Amit DIF
21 F 12 Temporal Throbbing 5 MWOA Topiramate DFI-6M
19 M 7 Temporal Aching 3 Yes MWOA amt + prop DIF
24 F 12 Frontal Throbbing 12 Calcif Granuloma MWOA amt + prop DIF
35 M 24 Temporal Pricking 7 Visual Yes MWWOA amt + prop DFI-6M+
16 F 24 Temporal Throbbing 14 Calcif Granuloma MWOA prop DFI-6M+
17 F 6 Occipital Pricking 1 Visual Yes MWWOA Flunarazine DFI-12M
14 M 12 Temporal Throbbing 3 MWOA amt + prop DFI-6M+
50 M 12 Temporal Throbbing 16 Yes CM amt + prop DIF
39 M 8 Frontal Throbbing 20 CM amt + prop DIF
14 F 24 Frontal Throbbing 3 Sensory MWA prop DFI-6M+
11 F 14 Temporal Throbbing 22 Yes MWOA Amit DFI-12M
26 F 7 Temporal Throbbing 20 Visual Yes Gliosis Stroke CM amt + prop DFI-6M
32 F 24 Occipital Burning 2 Sensory Yes MWWOA Flunarazine DIF
28 M 24 Frontal Throbbing 8 Yes MWOA amt + prop DFI-6M+
17 F 24 Temporal Burning 6 Visual Yes GTCS MTS prop DFI-6M+
15 F 8 Temporal Throbbing 2 MWOA amt + prop DFI-6M+
32 F 9 Parietal Throbbing 4 Visual Yes MWA prop DFI-6M
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21 M 12 Temporal Diffuse 4 Visual Yes MWWOA amt + prop DFI-6M+
17 F 12 Frontal Throbbing 8 Yes Calcif Granuloma MWOA prop DFI-6M
8 F 24 Temporal Aching 5 Visual Calcif Granuloma MWA prop DFI-6M
13 F 6 Occipital Throbbing 3 Yes MWOA prop DFI-6M
8 F 12 Occipital Diffuse 2 Sensory Yes MWWOA Flunarazine DFI-6M+
15 F 6 Temporal Throbbing 4 Yes MWOA amt + prop DFI-12M
29 F 24 Temporal Throbbing 2 Yes MWOA prop DIF
31 F 24 Frontal Throbbing 24 Visual Yes CM amt + prop DFI-6M+
29 M 12 Frontal Throbbing 3 Visual Yes MWWOA amt + prop DFI-12M
15 F 24 Temporal Pricking 2 Calcif Granuloma MWOA amt + prop DFI-6M+
18 M 6 Temporal Burning 4 Yes MWOA amt + prop DFI-6M
44 F 6 Parietal Throbbing 2 MWOA prop DFI-6M+
20 F 6 Parietal Throbbing 5 Yes MWOA amt + prop DFI-6M
24 M 24 Temporal Throbbing 15 Yes CM amt + prop DFI-6M
15 F 12 Occipital Pricking 4 MWOA Amit NR
51 M 12 Temporal Throbbing 2 Yes MWOA amt + prop DFI-6M
26 F 12 Temporal Aching 5 Visual Yes LOC MTS prop DFI-12M
25 F 24 Occipital Throbbing 3 Yes MWOA prop DFI-6M+
30 F 12 Temporal Throbbing 2 Visual Yes MWWOA amt + prop DFI-6M
32 F 24 Frontal Throbbing 18 Yes CM amt + prop DFI-12M
18 F 12 Temporal Pricking 8 MWOA amt + prop DFI-6M
47 M 12 Temporal Throbbing 6 Yes Calcif Granuloma MWOA amt + prop DFI-6M
22 M 14 Frontal Throbbing 2 Visual MWWOA amt + prop DFI-12M
34 F 6 Temporal Throbbing 4 Visual Yes CPS MTS prop DFI-6M+
37 F 24 Temporal Aching 15 Yes CM amt + prop DFI-6M
12 F 6 Temporal Throbbing 8 Yes MWOA Amit DFI-6M
21 F 12 Frontal Throbbing 6 Yes MWOA amt + prop DFI-12M
25 F 6 Frontal Throbbing 8 Visual Yes Calcif Granuloma MWWOA amt + prop DFI-6M
29 F 6 Occipital Aching 6 Yes MWOA Flunarazine DFI-12M
15 F 24 Temporal Throbbing 2 Visual Yes Gliosis Stroke MIGSTR prop DFI-6M+
19 F 12 Frontal Throbbing 4 MWOA amt + prop DFI-6M
38 F 24 Temporal Throbbing 3 Yes MWOA Amit DFI-6M+
22 M 6 Temporal Throbbing 2 Sensory MWWOA Topiramate DFI-6M
18 M 6 Temporal Pricking 4 Yes Basal Gang Calc MWOA prop DFI-6M+
35 F 12 Parietal Throbbing 2 Visual Yes MWOA Amit NR
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ABBREVIATIONS
34 M 24 Temporal Diffuse 2 Yes MWOA prop DFI-6M
24 F 12 Temporal Pricking 5 Visual MWA amt + prop DFI-6M
35 F 24 Frontal Throbbing 20 Visual Yes CM amt + prop DFI-12M
9 F 12 Frontal Throbbing 6 Yes Calcif Granuloma MWOA amt + prop DFI-6M
16 M 6 Temporal Throbbing 2 Yes MWOA amt + prop DFI-12M
28 F 6 Temporal Pricking 6 MWOA amt + prop DFI-6M
18 F 12 Occipital Aching 6 Visual Yes MWWOA amt + prop DFI-6M
22 M 12 Temporal Throbbing 2 Visual Yes MWWOA amt + prop DFI-6M
20 F 6 Frontal Throbbing 6 Yes MWOA amt + prop DIF
32 F 12 Parietal Throbbing 2 Yes GTCS MTS Sod Valp DFI-6M
25 M 6 Temporal Aching 4 Visual Yes MWWOA Amit DFI-12M
17 M 24 Temporal Throbbing 3 Yes MWOA amt + prop DFI-6M
35 M 6 Parietal Throbbing 15 Calcif Granuloma CM amt + prop DFI-6M
17 F 6 Temporal Throbbing 2 Sensory Yes Calcif Granuloma MWWOA prop DIF
19 F 6 Temporal Throbbing 6 MWOA Flunarazine DIF
25 F 24 Occipital Aching 6 Yes MWOA amt + prop DFI-12M
42 F 12 Frontal Throbbing 2 Yes MWOA amt + prop DFI-6M
29 F 12 Temporal Throbbing 6 Visual MWWOA prop DFI-12M
12 F 24 Temporal Throbbing 2 Yes MWOA amt + prop DFI-6M
44 F 126 Frontal Throbbing 18 Yes Calcif Granuloma CM prop DIF
17 M 24 Temporal Burning 2 Sensory & Visual Yes MWWOA Flunarazine DFI-6M+
22 M 6 Occipital Throbbing 3 Yes MWOA amt + prop DFI-12M
28 F 6 Frontal Throbbing 15 Yes MWOA amt + prop DFI-6M
36 F 12 Temporal Pricking 5 Visual MWWOA Amit NR
19 F 24 Occipital Throbbing 3 Yes Calcif Granuloma MWOA amt + prop DFI-12M
24 F 6 Temporal Throbbing 2 MWOA amt + prop DFI-6M
20 M 12 Frontal Throbbing 5 Yes MWOA Flunarazine DIF
28 F 12 Temporal Aching 5 Visual Yes CM amt + prop DFI-6M
22 F 24 Temporal Pricking 3 Yes MWOA amt + prop DFI-12M
18 M 12 Occipital Throbbing 2 Yes MWOA amt + prop DFI-6M
18 F 24 Temporal Throbbing 20 Visual Yes MWWOA amt + prop DIF
17 M 6 Temporal Aching 5 Yes LOC MTS prop DFI-6M
21 F 24 Frontal Throbbing 3 Yes MWOA amt + prop DFI-12M
17 M 12 Parietal Throbbing 5 Visual Calcif Granuloma MWA prop DIF
32 F 12 Temporal Pricking 3 Yes MWOA Amit DFI-6M+
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34 F 6 Temporal Pricking 2 MWOA Amit DFI-6M
7 F 12 Temporal Pricking 6 Visual MWA prop DIF
18 F 12 Frontal Throbbing 15 Yes Calcif Granuloma CM amt + prop DFI-12M
24 F 24 Temporal Throbbing 2 Visual Yes MWWOA amt + prop DFI-6M
44 F 6 Occipital Aching 6 Visual Yes MWWOA Flunarazine DFI-12M
15 M 6 Temporal Throbbing 3 Yes MTS prop DIF
36 F 12 Frontal Throbbing 2 Yes MWOA amt + prop DFI-6M
29 F 24 Frontal Throbbing 18 Yes CM amt + prop DFI-6M
27 M 6 Occipital Diffuse 6 Visual Yes MWWOA prop DIF
32 M 12 Temporal Throbbing 5 MWOA Amit DFI-12M
18 F 6 Parietal Throbbing 6 Yes Basal Gang Calc MWOA amt + prop DFI-6M
50 F 6 Temporal Throbbing 6 VS MWA prop DIF
15 M 24 Temporal Aching 3 Yes MWOA amt + prop DFI-12M
17 F 6 Frontal Throbbing 6 Yes MWOA amt + prop DFI-6M
38 M 24 Frontal Throbbing 20 Yes Calcif Granuloma CM amt + prop DFI-6M
22 M 6 Occipital Throbbing 4 Sensory MWWOA amt + prop DFI-12M
24 F 12 Temporal Pricking 6 Yes MWOA amt + prop DFI-6M
36 F 24 Temporal Throbbing 2 Visual Yes MWWOA Amit NR
52 F 12 Temporal Throbbing 11 Sensory Yes Calcif Granuloma MWWOA amt + prop DFI-6M
32 F 12 Temporal Throbbing 6 Visual Gliosis Stroke MIGSTR prop DIF
28 F 24 Frontal Aching 8 Yes Calcif Granuloma MWOA amt + prop DFI-6M
18 M 12 Temporal Throbbing 2 Yes MWOA amt + prop DFI-6M
35 F 12 Temporal Pricking 18 Yes CM amt + prop DFI-6M
28 M 6 Temporal Throbbing 1 Visual Yes MWWOA amt + prop DFI-6M
19 F 6 Temporal Burning 4 Yes MWOA prop DFI-12M
15 F 24 Frontal Throbbing 3 Yes Calcif Granuloma MWOA Amit DFI-6M
53 F 12 Occipital Throbbing 6 Visual MWWOA Amit DFI-6M
27 M 24 Temporal Throbbing 3 Yes MWOA prop DIF
15 F 24 Frontal Throbbing 4 MWOA amt + prop DFI-6M
33 F 24 Temporal Throbbing 22 Visual Yes CM amt + prop DFI-12M
16 M 12 Temporal Throbbing 6 Yes MWOA Amit DFI-6M+
19 F 6 Occipital Aching 4 Visual Calcif Granuloma GTCS MTS prop DIF
26 F 24 Parietal Throbbing 5 Visual Yes MWWOA amt + prop DFI-12M
18 F 6 Temporal Pricking 2 Yes MWOA amt + prop DFI-6M
18 M 24 Temporal Aching 6 Visual Yes Calcif Granuloma MWA prop DIF
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10 F 12 Temporal Throbbing 4 Yes MWOA Amit DFI-6M+
36 F 6 Temporal Aching 3 Visual Yes Calcif Granuloma MWA prop DIF
35 M 24 Frontal Aching 15 Yes CM amt + prop DFI-12M
18 F 6 Occipital Throbbing 2 Visual Yes MWWOA Flunarazine DFI-6M+
42 F 24 Frontal Throbbing 5 MWOA amt + prop DIF
16 F 12 Temporal Pricking 3 Yes Calcif Granuloma MWOA Amit DFI-12M
30 M 6 Temporal Throbbing 2 Sensory & Visual Calcif Granuloma MWA amt + prop DFI-6M
20 M 24 Frontal Aching 8 Yes MWOA amt + prop DFI-12M
52 F 6 Temporal Throbbing 6 Sensory Yes MWWOA amt + prop DFI-6M
18 F 12 Parietal Throbbing 4 Yes MWOA prop DIF
16 F 24 Temporal Pricking 8 Visual MWWOA Amit DFI-6M
24 M 24 Frontal Throbbing 18 Yes Calcif Granuloma CM amt + prop DFI-12M
40 F 6 Parietal Throbbing 10 Yes MWOA amt + prop DFI-6M
25 M 6 Temporal Throbbing 4 Visual Yes MWWOA amt + prop DFI-6M
30 F 12 Temporal Aching 2 Visual MWA prop DIF
26 M 12 Frontal Throbbing 4 Yes Calcif Granuloma MWOA amt + prop DFI-12M
51 F 5 Frontal Throbbing 20 Yes CM amt + prop DFI-6M
20 F 12 Temporal Throbbing 2 Yes MWOA prop DIF
22 F 24 Temporal Aching 3 Visual Yes CPS MTS prop DIF
18 F 24 Occipital Diffuse 2 Yes MWOA Amit DFI-6M+
12 M 6 Temporal Throbbing 1 Yes MWOA prop DFI-12M
19 M 12 Temporal Throbbing 4 MWOA amt + prop DFI-6M
26 F 12 Temporal Throbbing 2 Visual Yes MWWOA amt + prop DIF
33 F 24 Frontal Throbbing 15 CM amt + prop DIF
15 F 6 Occipital Pricking 2 Yes MWOA Flunarazine DFI-6M+
27 M 6 Occipital Throbbing 3 Visual Yes Calcif Granuloma MWWOA amt + prop DIF
35 F 12 Temporal Burning 4 Sensory MWWOA amt + prop DIF
40 M 24 Occipital Throbbing 4 Yes MWOA amt + prop DFI-6M 
18 F 24 Temporal Throbbing 6 Yes MWOA prop DIF
25 F 12 Temporal Pricking 8 Visual Yes MWOA Amit DFI-6M+
23 M 12 Frontal Aching 16 Yes CM amt + prop DFI-6M
35 F 24 Temporal Throbbing 8 Yes MWOA amt + prop DFI-12M
26 F 12 Frontal Throbbing 8 Yes MWOA Amit DFI-6M
22 F 6 Frontal Aching 4 Yes Calcif Granuloma MWA prop DIF
25 F 24 Parietal Throbbing 3 Visual Yes Calcif Granuloma MWWOA amt + prop DIF
MWA – 
MIGRAINE WITH 
AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
MWWOA – 
MIGRAINE WITH 
OR WITHOUT 
AURA
CM – CHRONIC 
MIGRAINE
PM – PROBABLE 
MIGRAINE
MTS –MIGRAINE 
TRIGERRED 
SEIZURES
MIGSTR– 
MIGRAINOUS 
STROKE 
BM – BASILLAR 
MIGRAINE
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
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ABBREVIATIONS
17 F 6 Temporal Pricking 2 Yes Calcif Granuloma MWOA amt + prop DIF
28 F 24 Frontal
Throbbin
g 5 Visual Yes MWA prop DFI-12M
14 M 6 Parietal
Throbbin
g 3 Yes MWOA
Flunarazin
e DFI-6M+
32 F 24 Temporal
Throbbin
g 2 Sensory & Visual Yes MWA prop DIF
20 F 12 Temporal Pricking 8 Yes MWOA amt + prop DFI-12M
26 M 24 Frontal
Throbbin
g 6 Yes MWOA Amit DFI-6M+
17 M 6 Temporal
Throbbin
g 4 Yes MWOA amt + prop DIF
19 F 6 Temporal Burning 8 MWOA prop DIF
24 F 24 Temporal
Throbbin
g 7 Visual Yes Calcif Granuloma MWWOA amt + prop DIF
28 F 12 Temporal
Throbbin
g 9 Calcif Granuloma MWOA Amit DFI-6M+
15 F 6 Occipital
Throbbin
g 4 Yes MWOA amt + prop DFI-12M
26 F 24 Temporal Pricking 2 Visual Yes MWWOA amt + prop DIF
19 F 6 Temporal
Throbbin
g 4 Yes MWOA amt + prop DIF
30 F 24 Temporal Aching 11 MWOA amt + prop DFI-12M
25 M 12 Frontal
Throbbin
g 2 Visual Yes MWWOA amt + prop DIF
12 F 6 Occipital
Throbbin
g 3 Sensory Yes MWA-BM prop DIF
38 M 24 Temporal Diffuse 20 Yes CM amt + prop DIF
15 F 6 Temporal
Throbbin
g 1 Visual MWWOA prop DFI-12M
24 F 12 Frontal
Throbbin
g 4 Yes MWOA amt + prop DIF
28 F 24 Temporal Aching 2 Visual Yes MWWOA amt + prop DFI-12M
26 F 24 Temporal
Throbbin
g 4 Yes MWOA amt + prop DFI-12M
40 M 24 Temporal Pricking 8 Yes Calcif Granuloma MWOA Amit DFI-12M
40 F 6 Parietal
Throbbin
g 7 Yes PM
Flunarazin
e DFI-6M+
18 F 6 Temporal
Throbbin
g 9 Visual Yes MWWOA amt + prop DIF
14 F 24 Temporal
Throbbin
g 4 Visual Yes MWWOA amt + prop DFI-12M
26 F 12 Frontal Aching 4 MWOA amt + prop DIF
19 M 12 Temporal
Throbbin
g 8 Yes MWOA amt + prop DFI-12M
22 F 6 Temporal Burning 7 MWOA amt + prop DIF
20 F 6 Temporal Pricking 9 Yes MWOA amt + prop DIF
28 F 6 Occipital
Throbbin
g 4 Sensory Yes MWWOA
Flunarazin
e DFI-12M
13 M 24 Frontal
Throbbin
g 8 Yes MWOA amt + prop DIF
30 F 6 Occipital
Throbbin
g 7 Sensory Calcif Granuloma MWWOA
Flunarazin
e DFI-6M+
15 F 6 Temporal Pricking 9 Yes PM amt + prop DIF
19 M 24 Frontal Pricking 4 Visual Yes MWOA Amit DFI-6M+
27 F 12 Frontal
Throbbin
g 2 Yes Calcif Granuloma MWWOA amt + prop DIF
MWA – 
MIGRAINE WITH 
AURA
MWOA – 
MIGRAINE 
WITHOUT AURA
MWWOA – 
MIGRAINE WITH 
OR WITHOUT 
AURA
CM – CHRONIC 
MIGRAINE
PM – PROBABLE 
MIGRAINE
MTS –MIGRAINE 
TRIGERRED 
SEIZURES
MIGSTR– 
MIGRAINOUS 
STROKE 
MWA-BM 
BASILLAR 
MIGRAINE
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
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ABBREVIATIONS
12 Parietal Throbbing 5 Visual Yes MWWOA amt + prop DIF
6 Frontal Throbbing 14 Yes MWOA amt + prop DFI-12M
24 Temporal Pricking 3 Visual Yes Calcif Granuloma MWWOA prop DIF
6 Temporal Throbbing 9 Sensory & Visual Yes MWWOA amt + prop DFI-6M
24 Temporal Aching 10 Yes MWOA amt + prop DIF
12 Frontal Throbbing 12 PM amt + prop DFI-6M 
6 Occipital Throbbing 4 Yes MWOA prop DIF
24 Occipital Pricking 5 Sensory MWWOA Flunarazine DFI-6M+
6 Frontal Throbbing 12 Yes MWOA amt + prop DFI-12M
24 Frontal Throbbing 8 Yes MWOA amt + prop DIF
12 Temporal Burning 12 MWOA amt + prop DIF
6 Temporal Throbbing 7 Sensory Yes MWWOA amt + prop DFI-12M
24 Occipital Burning 2 Visual Yes MWWOA Flunarazine DFI-6M+
6 Temporal Aching 4 Yes MWOA amt + prop DIF
12 Frontal Throbbing 4 Yes MWOA prop DFI-12M
24 Parietal Throbbing 7 Yes Calcif Granuloma PM Amit DIF
24 Temporal Pricking 24 Sensory Yes CM amt + prop DFI-12M
MWA – MIGRAINE WITH AURA
MWOA – MIGRAINE WITHOUT 
AURA
MWWOA – MIGRAINE WITH OR 
WITHOUT AURA
CM – CHRONIC MIGRAINE
PM – PROBABLE MIGRAINE
MTS –MIGRAINE TRIGERRED 
SEIZURES
MIGSTR– MIGRAINOUS STROKE 
BM – BASILLAR MIGRAINE
DFI-6M+ - DISEASE FREE 
INTERVAL 6MONTHS -12 
MONTHS
DFI-6M - DISEASE FREE 
INTERVAL LESS THAN 6MONTHS
DFI-12M DISEASE FREE 
INTERVAL MORETHAN 12 
MONTHS
NR – NO RESPONSE
 
APPENDIX 2 – B : MASTER CHART – TENSION TYPE HEADACHE
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ABBREVIATIONS
35 F 3 TEMPORAL HEMI THROBBING 4 YES YES calcific granuloma IETTH Amitryptiline 10 DFI-6M+
29 F 8 OCCIPITAL HOLO BAND 3 YES IETTH Amitryptiline 10 DIF
48 M 16 FRONTAL HOLO PRICKING 10 YES calcific granuloma FETTH Amitryptiline 25 DFI-6M
34 M 4 TEMPORAL HOLO ACHE 16 YES YES CTTH Amitryptiline 50 DFI-12M
36 F 14 OCCIPITAL HOLO ACHE 3 YES PTTH Amitryptiline 25 DFI-6M+
43 F 7 FRONTAL HOLO BAND 11 YES calcific granuloma FETTH Amitryptiline 25 DIF
22 F 15 FRONTAL HOLO ACHE 12 YES calcific granuloma IETTH Amitryptiline 10 DIF
18 F 9 PARIETAL HEMI THROBBING 17 YES calcific granuloma CTTH Amitryptiline 50 DFI-6M
38 F 18 TEMPORAL HOLO ACHE 20 YES YES CTTH Amitryptiline 25 DFI-6M+
45 F 36 TEMPORAL HOLO BAND 9 YES IETTH Amitryptiline 10 NR
27 M 20 FRONTAL HOLO ACHE 20 YES Gliosis CTTH Amitryptiline 50 DFI-6M
53 F 5 OCCIPITAL HOLO ACHE 15 YES CTTH Amitryptiline 25 DIF
37 F 10 FRONTAL HOLO BAND 10 YES FETTH Amitryptiline 25 NR
28 F 24 FRONTAL HOLO BAND 5 YES calcific granuloma PTTH Amitryptiline 10 DIF
33 M 24 FRONTAL HOLO THROBBING 15 CTTH Amitryptiline 25 DFI-6M+
56 F 4 FRONTAL HOLO THROBBING 8 YES FETTH Amitryptiline 25 DFI-6M+
44 F 24 PARIETAL HOLO PRICKING 16 YES Gliosis CTTH Amitryptiline 50 DFI-12M
26 F 7 TEMPORAL HEMI ACHE 18 YES CTTH Amitryptiline 25 DIF
42 F 22 FRONTAL HOLO BAND 15 YES CTTH Amitryptiline 25 DIF
38 M 9 FRONTAL HOLO BAND 2 YES YES calcific granuloma PTTH Amitryptiline 25 DFI-6M+
29 M 3 FRONTAL HOLO BAND 20 CTTH Amitryptiline 50 DFI-6M
43 F 32 FRONTAL HOLO ACHE 17 YES CTTH Amitryptiline 25 DFI-6M+
38 F 20 OCCIPITAL HOLO PRICKING 3 YES calcific granuloma IETTH Amitryptiline 10 DFI-6M
25 F 7 TEMPORAL HOLO ACHE 27 YES CTTH Amitryptiline 50 DFI-12M
44 F 18 TEMPORAL HOLO BAND 22 YES CTTH Amitryptiline 25 DIF
47 F 24 FRONTAL HOLO ACHE 10 calcific granuloma FETTH Amitryptiline 25 DFI-6M
42 F 13 FRONTAL HOLO THROBBING 24 YES CTTH Amitryptiline 25 DFI-6M+
36 F 6 FRONTAL HOLO ACHE 4 YES YES PTTH Amitryptiline 10 DIF
45 M 24 PARIETAL HOLO PRICKING 2 YES Gliosis IETTH Amitryptiline 10 DFI-6M
45 F 8 FRONTAL HEMI ACHE 16 YES CTTH Amitryptiline 25 DFI-6M+
17 F 24 FRONTAL HOLO BAND 7 calcific granuloma FETTH Amitryptiline 25 DIF
39 F 18 FRONTAL HOLO BAND 15 YES calcific granuloma CTTH Amitryptiline 50 DFI-6M
26 M 10 TEMPORAL HOLO ACHE 17 YES YES CTTH Amitryptiline 25 DIF
44 F 24 FRONTAL HOLO PRICKING 19 CTTH Amitryptiline 25 DFI-6M
39 M 11 OCCIPITAL HOLO THROBBING 21 YES calcific granuloma CTTH Amitryptiline 25 NR
IETTH – 
INFREQUENT 
EPISODIC TTH
FETTH
FREQUENT 
EPISODIC TTH
CTTH – 
CHRONIC TTH
PTTH – 
PROBABLE TTH
DIF – 
DECREASED 
INTENSITY AND 
FREQUENCY
DFI-6M+
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
 
APPENDIX 2 – C : MASTER CHART – TRIGEMINAL AUTONOMIC CEPHALAGIAS
SE
X
AG
E
 O
F 
O
N
SE
T
D
U
R
AT
IO
N
 IN
 H
R
S
LO
C
AT
IO
N
C
H
AR
AC
TE
R
AS
SO
C
IA
TI
O
N
TR
IG
G
ER
FA
M
 H
C
TS
C
AN
 - 
BR
AI
N
D
IA
G
N
O
SI
S
PR
O
PH
YL
AX
D
os
e 
in
 m
g
R
ES
PO
N
S
E
M 39 11 FT ACHE AUTONOMIC FR + - NORMAL CCH Amitryptiline 25 DFI-12M
M 32 6 FT ACHE AUTONOMIC FR + ALCOHOL - NORMAL ECH Amitryptiline 50 DFI-12M
36 5MIN FT PRICK AUTONOMIC FR + SUNLIGHT - NORMAL SUNCT Carb + prop 50 DFI-12M
M 22 6 P THROBBING AUTONOMIC FR + - NORMAL EPHC Propranolol 80 DFI-12M
M 35 8 FT ACHE AUTONOMIC FR + ALCOHOL - NORMAL ECH Amitryptiline 50 DFI-6M+
M 49 6 FT ACHE AUTONOMIC FR + ALCOHOL - NORMAL CCH Propranolol 120 DFI-12M
M 37 3 FT ACHE AUTONOMIC FR + - NORMAL CPHC Amitryptiline 50 DFI-12M
30 6 FT ACHE AUTONOMIC FR + LACK OF SLEEP - NORMAL ECH Amitryptiline 25 DFI-12M
M 27 5MIN FT ACHE AUTONOMIC FR + - NORMAL SUNCT Carb +Prop 80 DFI-12M
M 35 12 P ACHE AUTONOMIC FR + - NORMAL CPHC Amitryptiline 50 DFI-12M
M 38 3 FT THROBBING AUTONOMIC FR + LACK OF SLEEP - NORMAL EPHC Amitryptiline 50 DFI-12M
ABBREVIATIONS
CCH – CHRONIC 
CLUSTER HEADACHE
ECH –EPISODIC 
CLUSTER HEADACHE
EPHC – EPOSODIC 
PAROXYSMAL 
HEMICRANIA
CPHC – CHRONIC 
PAROXYSMAL 
HEMICRANIA 
DFI-6M+ - DISEASE 
FREE INTERVAL 
6MONTHS -12 MONTHS
DFI-12M DISEASE FREE 
INTERVAL MORETHAN 
12 MONTHS
 
APPENDIX 2 – D : MASTER CHART – TENSION VASCULAR HEADACHE
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ABBREVIATIONS
AMITR
Y
PTILIN
E
PROPRO
NOLOL
1 33 F 7 Band Like 6 Yes TTH TVH 25 120 DFI-12M
2 42 F 14 Throbbing 20 Yes Migraine TVH 25 100 DFI-6M+
3 44 F 13 Pricking 4 Calcif Granuloma Migraine TVH 25 80 DFI-6M
4 36 M 12 Band Like 3 Yes Migraine TVH 25 100 DFI-12M
5 32 F 24 Band Like 12 Yes TTH TVH 50 80 DFI-6M+
6 40 F 18 Aching 16 Migraine TVH 25 120 DFI-6M+
7 48 M 14 Diffuse 4 Migraine TVH 25 80 DFI-6M+
8 52 M 14 Diffuse 6 Migraine TVH 25 80 DFI-6M+
9 33 M 4 Throbbing 5 Yes Migraine TVH 25 80 DFI-6M+
10 55 F 12 Aching 8 Yes Migraine TVH 25 80 DFI-6M+
11 47 F 12 Band Like 4 Yes Migraine TVH 25 100 DFI-12M
12 33 M 19 Diffuse 2 TTH TVH 25 80 DFI-12M
13 37 M 18 Diffuse 6 Yes Migraine TVH 25 80 DFI-6M
14 32 F 36 Throbbing 2 Yes Migraine TVH 25 100 DFI-6M+
15 43 F 20 Aching 20 Migraine TVH 50 100 DFI-6M+
16 38 M 24 Aching 8 Yes Migraine TVH 25 100 DFI-6M+
17 47 F 18 Band Like 6 Yes Migraine TVH 25 80 DFI-6M
18 54 M 15 Band Like 4 TTH TVH
Medication 
Overuse 25 100 DFI-12M
19 50 F 15 Diffuse 2 Yes Calcif Granuloma Migraine TVH 25 80 DFI-12M
20 31 F 28 Throbbing 6 Yes Migraine TVH 25 80 DFI-6M
21 44 M 14 Band Like 18 Migraine TVH 50 100 DFI-12M
22 39 M 5 Aching 8 Migraine TVH 25 80 DFI-12M
23 36 F 24 Throbbing 2 Yes Migraine TVH 25 80 DFI-6M
24 32 F 24 Band Like 4 TTH TVH 25 80 DFI-6M
25 37 F 24 Diffuse 6 Yes Migraine TVH 25 80 DFI-6M+
26 40 M 12 Diffuse 6 Gliosis Migraine TVH 25 120 DFI-6M
27 45 F 36 Band Like 2 Yes TTH TVH 25 80 DFI-6M+
28 51 F 24 Aching 3 Yes Migraine TVH 50 80 DFI-6M
29 37 F 15 Aching 4 Migraine TVH 25 80 DFI-12M
30 35 F 12 Band Like 5 Yes TTH TVH
Medication 
Overuse 25 120 DFI-12M
31 40 M 12 Diffuse 2 Yes TTH TVH 25 80 DFI-6M
32 35 F 20 Throbbing 6 Yes Calcif Granuloma Migraine TVH 25 100 DFI-6M
33 42 F 24 Diffuse 8 Migraine TVH 25 120 DFI-6M+
34 33 M 30 Diffuse 10 Yes Migraine TVH 50 100 DFI-6M
35 37 F 7 Band Like 12 Yes TTH TVH 50 100 DFI-6M+
TVH - TENSION 
VASCULAR 
HEADACHE 
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
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ABBREVIATIONS
AMITR
Y
PTILIN
E
PROPRO
NOLOL
36 M 36 Throbbing 4 Yes Migraine
TV
H 25 80 DFI-6M
54 F 24 Diffuse 8 TTH
TV
H 50 80 DFI-6M+
36 F 9 Band Like 2 Yes Migraine
TV
H 25 80 DFI-6M+
33 M 22 Band Like 22 Yes Migraine
TV
H 25 120 DFI-6M
33 M 24 Aching 4 Migraine
TV
H 25 80 DFI-12M
42 F 24 Throbbing 8 Yes Migraine
TV
H 25 80 DFI-12M
44 F 14 Aching 5 Migraine
TV
H 25 100 DFI-12M
44 M 24 Diffuse 4 Yes TTH
TV
H 25 80 DFI-6M
36 F 24 Diffuse 11 Migraine
TV
H 25 100 DFI-6M
42 F 12 Band Like 12 Yes Migraine
TV
H 25 100 DFI-12M
40 F 12 Aching 3 Gliosis Migraine
TV
H 25 80 DFI-6M
54 F 14 Throbbing 6 Migraine
TV
H 25 80 DFI-6M
50 F 4 Diffuse 7 Yes Migraine
TV
H 25 80 DFI-6M+
31 F 6 Diffuse 2 Migraine
TV
H 25 80 DFI-6M
44 F 36 Band Like 3 Yes TTH
TV
H 50 100 DFI-6M+
49 M 14 Diffuse 5 Migraine
TV
H 50 80 DFI-6M
36 F 15 Band Like 19 Yes Migraine
TV
H 25 120 DFI-12M
32 F 12 Band Like 7 Yes TTH
TV
H 25 80 DFI-12M
37 F 24 Throbbing 5 Migraine
TV
H 25 80 DFI-6M
40 F 12 Band Like 4 Yes Migraine
TV
H 25 80 DFI-12M
45 F 14 Aching 10 Yes Migraine
TV
H 25 100 DFI-12M
52 M 24 Band Like 8 Yes TTH
TV
H 25 80 DFI-6M+
43 F 30 Diffuse 3 Migraine
TV
H 25 80 DFI-6M+
47 F 24 Diffuse 4 Yes Migraine
TV
H 25 100 DFI-6M+
35 M 5 Aching 2 Yes Migraine
TV
H 25 80 DFI-12M
40 F 36 Throbbing 3 Yes Calcif Granuloma Migraine
TV
H 25 120 DFI-12M
35 F 24 Band Like 19 Yes TTH
TV
H
Medication Overuse
25 80 DFI-12M
42 F 24 Band Like 5 Migraine
TV
H 25 80 DFI-6M+
33 M 30 Aching 8 Yes Migraine
TV
H 25 80 DFI-6M+
37 F 24 Diffuse 11 Yes Migraine
TV
H 25 80 DFI-12M
36 F 30 Diffuse 2 Yes Migraine
TV
H 25 120 DFI-12M
42 F 24 Aching 3 Migraine
TV
H 25 80 DFI-6M
46 F 12 Band Like 20 Yes Migraine
TV
H 25 80 DFI-12M
33 F 18 Band Like 18 Yes TTH
TV
H 25 80 DFI-12M
33 F 15 Band Like 3 Yes Migraine
TV
H 25 80 DFI-6M
TVH - TENSION 
VASCULAR 
HEADACHE 
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
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ABBREVIATIONS
AMITRY
PTILINE
PROPRO
NOLOL
71 42 F 24 Diffuse 8 Migraine TVH 50 80 DFI-6M+
72 34 F 24 Throbbing 2 Migraine TVH 25 80 DFI-6M+
73 44 F 24 Aching 4 Yes Migraine TVH 25 80 DFI-6M+
74 36 F 24 Diffuse 15 Yes Migraine TVH 25 120 DFI-6M
75 32 F 14 Diffuse 3 Yes Migraine TVH 25 80 DFI-6M+
76 33 F 15 Diffuse 5 Yes Migraine TVH 25 80 DFI-6M+
77 36 F 12 Diffuse 11 Yes Migraine TVH 25 80 DFI-6M+
78 41 F 24 Aching 4 Migraine TVH 25 100 DFI-6M
TVH - TENSION 
VASCULAR 
HEADACHE 
DFI-6M+ - 
DISEASE FREE 
INTERVAL 
6MONTHS -12 
MONTHS
DFI-6M - 
DISEASE FREE 
INTERVAL LESS 
THAN 6MONTHS
DFI-12M 
DISEASE FREE 
INTERVAL 
MORETHAN 12 
MONTHS
NR – NO 
RESPONSE
